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 Abstract 
 
Alastair K.O. Denniston, Academic Unit of Ophthalmology, School of Infection and 
Immunity, College of Medical and Dental Sciences, University of Birmingham 
 
A thesis submitted to The University of Birmingham for the degree of 
DOCTOR OF PHILOSOPHY 
 
The ocular microenvironment is immunosuppressive in animal models of antigen 
presenting cell function. My hypothesis was that in humans the normal ocular 
microenvironment maintains an immature dendritic cell (DC) phenotype, whereas in 
intraocular inflammation (uveitis) this regulation fails, permitting full DC maturation 
leading to the production and recruitment of pathogenic effector T cells to the eye. 
Using an in vitro model of DC function, I observed that non-inflammatory aqueous 
humour (AqH) inhibited DC maturation, with reduced MHC and CD86 expression, 
and reduced capacity to induce proliferation of allogeneic T cells, an effect which was 
cortisol and TGFβ2 dependent. In contrast, exposure to uveitis AqH generated a 
distinct DC profile with IFNγ dependent elevation of MHC class I, but reduced MHC 
class II and CD86 expression and impaired induction of T cell proliferation. Exposure 
to uveitis AqH from patients on topical glucocorticoid treatment caused additional 
suppression of CD86. 
Characterisation of ex vivo myeloid DC from patients with uveitis supported the 
findings of the in vitro model, with AqH-derived myeloid DC showing elevated 
MHC, but reduced CD86 expression. 
In summary human AqH is shown to be a powerful inhibitor of DC maturation, 
retaining this regulatory role during uveitis. 
 To Anna, and the many like her 
 
 
 
Two weeks ago Anna could see ...  
But today, Anna is in trouble. Her own immune system has turned against her. White blood 
cells known as leucocytes have infiltrated most of the major structures of the eye. There are 
so many that I cannot see in much more than Anna can see out. At the back of the eye, the 
critical light-sensitive retina resembles the victim of a microscopic paint-ball competition. 
Clusters of leucocytes choke the retinal vessels and spill over into the surrounding tissues. 
The immune system is running riot. 
Most of the time our eyes live in their own protected little world. They travel in the "quiet 
coach" of the human body in which the most dramatic thing that should ever happen is a 
change in the view. It is a civilised place, in which even the immune system is on low 
volume. Most of our research underlines the ways that the immune system is kept in check 
within the eye. Inflammation inside the eye should not happen. But sometimes, as with 
Anna, the eye's immune system ramps up the volume, releasing the destructive 
inflammatory process of uveitis. 
Most uveitis is unexplained. We are good at describing it, reasonable at classifying it, 
moderate at treating it and, as yet, terrible at understanding it. In our research we probably 
get closest to what is going on through taking precious fluid samples from the front of the 
inflamed eye. 
Detailed study has allowed us to start building an accurate picture of the types of white 
blood cells involved during an attack of uveitis. We only have snapshots, but from these 
images we are steadily working backwards towards the key events that kick this whole 
process off. Uveitis should not happen. But it does, and it can blind people. 
I want to know why uveitis happens. I want to know because Anna is sitting in front of me 
in the clinic, and we've been filling in the forms that will officially register her blind. I 
want to know because she can't go back to her job. I want to know because the best 
treatments we had weren't good enough. And I want to know so that, next time, I have 
something more to offer. 
 
From ‘Blind Ignorance‟ by Alastair Denniston, MRC Max Perutz Science Writing 
Competition  
Reproduced from the Guardian (on-line edition) at 
http://www.guardian.co.uk/education/2009/sep/04/blindness-uveitis-max-perutz-prize 
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Chapter One General Introduction 1 
1 GENERAL INTRODUCTION 
1.1 The hypothesis and its context 
 
The primary role of the eye is to facilitate vision. Integral to this function is a 
transparent visual axis permitting light to pass through cornea, aqueous humour, lens 
and vitreous to reach the retinal photoreceptor layer which performs the remarkable 
feat of transducing light to nerve impulses.  
 
In order to maintain this clear visual axis, the eye is one of a number of structures that 
has a relatively protected relationship with the immune system, known as immune 
privilege (Medawar, 1948; Kaplan and Niederkorn, 2007). Thus by a number of 
different strategies it achieves the balance of permitting the immune responses 
required for protective immunity, and at the same time restricting these responses to 
prevent significant pathological damage which might obstruct vision (Streilein, 
2003b; Streilein, 2003a). 
 
However potentially blinding intraocular inflammation (known as uveitis) does still 
occur. This can be due to intraocular infection, but most uveitis is non-infective and is 
thought to be an autoimmune (or at least an autoinflammatory) phenomenon. There is 
clear evidence from both human and animal work that activated T cells are involved 
in the pathogenesis of uveitis (Muhaya et al., 1999). It is proposed that, as in other 
organ systems, these T cells have been activated by mature dendritic cells (DC), 
typically within the draining lymphoid tissue(Guermonprez et al., 2002; Steinman, 
1991). The site of DC maturation is not known, but is most likely to occur in the eye 
with trafficking of mature dendritic cells (mDC) to the draining lymphoid tissue 
Chapter One General Introduction 2 
(Streilein, 2003a; Streilein, 2003b). Alternative and quite possibly coexisting 
mechanisms include the drainage of soluble antigen (accompanied by inflammatory 
cytokines and other molecules from the ocular microenvironment) to the lymphoid 
tissue with processing, maturation and presentation by a resident lymphoid DC or 
local antigen presentation within the eye by resident ocular DC to incoming CD4+ T 
cells (Camelo et al., 2006; Camelo et al., 2004b; Dullforce et al., 2004).  
 
My central hypothesis is that the normal resting ocular microenvironment 
maintains a relatively immature DC phenotype which generates anergic or 
regulatory T cells, whereas in intraocular inflammation (uveitis) this regulation 
breaks down permitting full DC maturation resulting in production and 
recruitment of pathogenic effector T cells to the eye.  
 
 
 
Figure 1.1 Schematic representation of the hypothesis.  
My hypothesis is that the normal resting ocular microenvironment maintains a 
relatively immature DC phenotype which generates anergic or regulatory T cells. In 
contrast in uveitis I propose that this regulation breaks down resulting in full DC 
maturation and inducing an effective adaptive immune response with T cell 
proliferation and recruitment to the eye. 
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In the following introduction, I outline the immunological context of this hypothesis 
in more detail. I will consider the dendritic cell first within the framework of the 
normal immune system, second within the unique microenvironment of the normal 
eye and finally within the dysfunctional microenvironment of the uveitic eye.  
 
1.2 The dendritic cell and its role in immunity 
 
The immune system is a remarkable series of inter-related defence mechanisms which 
protect the host from danger, whether external (invasion by pathogens) or internal 
(neoplasia). The immune system can be broadly divided into innate and acquired 
processes. Innate immunity provides an immediate line of defence, and is of sufficient 
efficacy to deal with the majority of potential pathogens encountered in peripheral 
tissue.  The target requirements of innate immunity are either non-specific or of broad 
specificity to ensure defence against a wide-range of pathogens. Key components of 
the innate system include the barrier itself (surface epithelium), specialised leucocytes 
(macrophages, neutrophils, natural killer cells, mast cells, eosinophils, basophils), and 
secreted molecules (acute phase response proteins, complement, and interferons).  
 
In contrast, the processes of acquired immunity are highly specific, enabling a highly 
potent but customized response to almost any pathogen encountered. The acquired 
immune system also has „memory‟, whereby any further encounter with the same 
pathogen will generate a faster and amplified response. The key players of the 
acquired immune system are lymphocytes, either B cells (which secrete antigen-
specific antibody) or T cells (which may have a „cytotoxic‟ role to kill infected cells 
or a cytokine-producing/„helper‟ role). 
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DC are bone-marrow derived leucocytes that provide a crucial link between the innate 
and adaptive immune responses. They are highly specialised antigen-presenting cells 
(APC) that respond to the presence of pathogens and inflammation at peripheral tissue 
sites, migrating to secondary lymphoid organs where they present antigen to either 
naïve or memory T cells, leading to T cell proliferation and differentiation towards 
effector cells (Steinman, 1991; Reis e Sousa, 2004a; Reis e Sousa, 2006; Rossi and 
Young, 2005). It is the DC that provides the initial signals that determine both the 
magnitude and quality of the T cell response (and via T helper cells, the B cell 
response). The DC is thus central to the potent and pathogen-specific defence 
characteristic of the acquired immune response (Reis e Sousa, 2004a; Reis e Sousa, 
2006; Rossi and Young, 2005; Moser, 2003). 
 
1.3 The paradigm of DC function 
 
Our current understanding of antigen presentation is still largely based on studies on 
the Langerhans cell, a type of dendritic cell found in the epidermis.  
 
In 1985 Steinman and colleagues showed that freshly isolated Langerhans cells 
expressed high levels of MHC class II but were poor at stimulating T cell proliferation 
in a mixed lymphocyte reaction. In contrast after two days of culture they became 
much more potent at simulating T cell proliferation (Schuler and Steinman, 1985; 
Inaba et al., 1986), but lost the capacity to process antigen (Romani et al., 1989). 
Parallel behaviour was observed in vivo by Austyn and colleagues, who noted that 
Langerhans cells from skin transplants and explants emigrate to lymphoid tissues, 
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undergoing a phenotypic „maturation‟ in the process and losing the ability to process 
antigen (Larsen et al., 1990; Reis e Sousa et al., 1993). It was subsequently shown that 
„maturation‟ could be induced both in vitro by the addition of inflammatory cytokines 
(notably TNFα), LPS or CD40 ligation (Sallusto and Lanzavecchia, 1994; Winzler et 
al., 1997), and in vivo by the addition of LPS (Roake et al., 1995; De Smedt T. et al., 
1996). 
 
In the simplest form of the paradigm, DC resident in the tissues encounter and process 
antigen in the context of a „danger signal‟ such as LPS or TNFα, and „mature‟ in 
terms of their chemokine receptors (to enable migration to the draining lymph node) 
and costimulatory molecules (to induce efficient T cell proliferation). In recent years 
this paradigm has had to evolve. First, the simple linear concept of maturation has 
struggled to encompass the range of DC behaviour observed in vitro and in vivo, 
particularly with regard to DC-induction of tolerance. Second, more recent studies in 
the skin show that a subcutaneous injection of antigen actually gives rise to three 
waves of antigen arriving in the draining lymph node: (1) soluble antigen which is 
then internalized by interdigitating DC (at around 90mins); (2) antigen borne by 
dermal DC (at around 24h); and (3) antigen borne by Langerhans cells (at around 48h) 
(Sixt et al., 2005; Kissenpfennig et al., 2005).Third, it has become clear that in 
addition to the „migratory‟ DC of the paradigm, there are significant populations of 
non-migrating lymph node resident DC. Even within the Langerhans cell model, a 
number of studies have failed to show that the migrated cells directly induce T cell 
proliferation (Allan et al., 2003; Itano et al., 2003), and it now seems increasingly 
likely that there is transfer of antigen from migratory DC to lymph node resident DC 
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(such as the interdigitating DC) with subsequent antigen presentation by the resident 
DC (Carbone et al., 2004).  
 
1.4 Classification of DC 
1.4.1 Subsets of human DC  
 
There are two major subsets of DC that have been identified from human blood: 
conventional myeloid DC and plasmacytoid DC. Conventional myeloid DC have a 
classic dendritic morphology and can be further subdivided on the basis of their 
surface molecules The most common (0.6% of all PBMCs) are CD1a
+
 BDCA-
1(CD1c)
+
CD11c
high
 BDCA-3
low
 and are designated type-1 MyDC (Dzionek et al., 
2000). The lesser population (0.04% PBMC) are CD1a
-
 BDCA-1(CD1c)
-
CD11c
low
 
BDCA-3
high
 and are designated type-2 MyDC (Narbutt et al., 2004). Both populations 
are effective stimulators of T cells which may be enhanced by coculture with GM-
CSF. In contrast plasmacytoid DC (0.4% PBMC) have a rounder morphology, and are 
poor stimulators of T cells unless stimulated with IL-3 and CD40L. They are 
functionally distinguished by the ability to produce high levels of IFNα in response to 
virus. They are BDCA-2+BDCA-4+ but are CD1a
-
BDCA-1
-
CD11c
-
BDCA-3
-
 
(Kadowaki and Liu, 2002).   
 
Although most studies of human DC depend on blood DC, conventional myeloid DC 
have also been isolated from tonsil, thymus and spleen; plasmacytoid DC have also 
been isolated from the tonsil and bone marrow.  
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 Myeloid type-1 Myeloid type-2 Plasmacytoid 
CD1a ++ - - 
CD4 ++ ++ ++ 
CD11b + - - 
CD11c +++ ++ - 
CD40 + + - 
CD80 + + + 
CD86 + + - 
BDCA-1 ++ - - 
BDCA-2 - - ++ 
BDCA-3 - ++ - 
BDCA-4 - - ++ 
MHCII +++ +++ ++ 
 
Table 1.1   Circulating human DC and their expression of key surface molecules 
 
1.4.2 Subsets of murine DC 
 
Studies on murine DC have also shown a clear division between conventional DC and 
plasmacytoid DC (reviewed (Sato and Fujita, 2007)). In the mouse, conventional DC 
can be subdivided primarily on the basis of CD4 and CD8 expression into the 
following subtypes:  
CD4-CD8αhighCD205+CD11b-, CD4-CD8α-CD205-CD11b+, CD4+CD8α-CD205-
CD11b+, CD4-CD8αlowCD205highCD11b+ and CD4-CD8α-CD205+CD11b+ (Sato 
and Fujita, 2007). These subtypes show some degree of anatomical localisation: CD4-
CD8αhighCD205+CD11b- are found in the T cell areas of spleen and lymph nodes, 
CD4-CD8α-CD205-CD11b+ and CD4+CD8α-CD205-CD11b+ are found in the 
marginal zone of spleen and lymph nodes, CD4-CD8αlowCD205highCD11b+ are 
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found in skin draining lymph nodes and CD4-CD8α-CD205+CD11b+ in all lymph 
nodes.  The DC found in the spleen have been demonstrated to be capable of inducing 
Th1, Th2 and regulatory T cell responses. The other two subtypes are generally only 
found in the lymph nodes and are mature forms of DC which have migrated from the 
peripheral tissues (Sato and Fujita, 2007). Thus CD4-CD8αlow appear to be the 
mature form of Langerhans cells, whereas CD4-CD8α- represent the mature form of 
interdigitating tissue DC. Murine plasmacytoid DC are functionally similar to their 
human equivalents being distinguished by the ability to produce high levels of type-1 
IFN in response to virus (Asselin-Paturel et al., 2001). 
1.5 Anatomical localization 
 
Dendritic cells are found in both blood and tissue. In the blood, dendritic cells and 
dendritic cell precursor cells comprise around 1% of peripheral blood mononuclear 
cells. In the non-lymphoid tissues dendritic cells are found in the skin (epidermal 
Langerhans cells and dermal cells), most organs (including liver, kidney, heart), 
connective tissues and mucosa (notably gastrointestinal tract). In the lymphoid tissues 
interdigitating dendritic cells are found in both T cell areas of the paracortex and in 
the germinal centres(Sato and Fujita, 2007). The germinal centre also contains 
follicular dendritic cells which are stromal cells with a dendritic morphology which 
trap whole antigen in the form of immune complexes for extended periods, promoting 
B cell activation and selection (Batista and Harwood, 2009). They are not “true” 
dendritic cells and will not be discussed further in this thesis.  
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1.6 DC maturation and cell surface molecules 
 
It is clear that DC may exist in a number of states that are more or less immunogenic 
or tolerogenic. As outlined earlier, the paradigm of DC maturation is one of a 
unidirectional pathway with DC moving from an antigen sampling immature state to 
an antigen presenting mature state. Despite important caveats to this model, the 
concepts of “immature” and “mature” DC continue to be useful to describe states of 
DC phenotype and function. 
 
A number of stimuli have been shown to induce maturation of DC, notably 
inflammatory cytokines and/or ligands for pattern recognition receptors (PRR) (De 
Smedt T. et al., 1996; Roake et al., 1995; Sallusto and Lanzavecchia, 1994; Winzler et 
al., 1997), although CD40 ligation has also been shown to be effective in vitro 
(Sallusto and Lanzavecchia, 1994). In response the DC undergoes a number of 
changes in terms of its surface molecules, cytokine production, migratory capacity 
and ability to act on other cells which are discussed below (Lutz and Schuler, 2002; 
Reis e Sousa, 2006)(Figures 1.2 and 1.3). 
1.6.1 DC surface molecules 
 
The immature DC in peripheral tissue express low levels of MHC class I and II and 
lack costimulatory molecules such as CD80/86. They do however express pattern-
recognition receptors (PRR) such as Toll-like receptors (TLR)(Reis e Sousa, 2004b) 
which can recognise conserved pathogen associated molecular patterns (PAMPs), 
molecules such as DEC 205 which can facilitate phagocytosis (Bonifaz et al., 2002), 
and chemokine receptors such as CCR5 which serve to retain the iDC in the 
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peripheral tissue (Sallusto and Lanzavecchia, 1999). They also ingest large amounts 
of antigen indiscriminately by macropinocytosis (Sallusto et al., 1995). 
Maturation signals (cytokine or TLR ligand) induce the upregulation of key molecules 
on the DC. These molecules are involved in presenting antigen to T cells as part of 
“signal 1” via MHC class I and II (Janeway, Jr., 1989);  in contributing to T cell 
activation as part of  “signal 2”  via the costimulatory molecules CD80/CD86 
(Greenwald et al., 2005), 4-1BBL(Bertram et al., 2002), ICOSL (Greenwald et al., 
2005)  and OX40L (Chen et al., 1999) and adhesion molecules (eg ICAM-2, LFA-1, 
CD58); or in directing the migration of the DC to the draining lymph node (CCR7) 
(Sallusto and Lanzavecchia, 1999; Sallusto et al., 1998). Selected molecules are 
considered further in table 1.2 (reviewed (Jeras et al., 2005b)). 
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Figure 1.2 Outline of dendritic cell development  
Outline includes key surface molecules, cytokine production and function. 
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Figure 1.3 Summary diagram of significant molecules related to DC function 
which are considered further in this project.  
These include molecules involved in the interaction between DC and T cells, 
chemokine receptors and soluble factors. 
 
MHC II + 
peptide 
TCR 
CD28 
CD40 CD40L 
CD80/CD86 
   Signal 1 
 Signal 2 
Polarising factors  Signal 3 
CD1a 
CD11b 
CD11c 
CD275 
CD137L 
CCR5 
CCR7 
IL-12, IL-23, TGFβ, IL-6, IL-10, IL-1β, TNFα 
DCSIGN 
DC PROFILE 
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 Mo M iDC mDC Function 
CD1a +/- - + + Presentation of non-
peptide Ag to CD1 
restricted T cells 
 
CD1b +/-  + + Presentation of non-
peptide Ag to CD1 
restricted T cells 
 
CD11b + +/++ ++ ++ Assoc with 
CD18integrin β2; 
adhesion via 
ICAM1,2,3 
 
CD11c + ++ + ++ Assoc with 
CD18integrin β2; 
adhesion and CTL 
 
CD14 
 
++ ++ +/- +/- LPS/LPS Binding 
Protein receptor 
CD80 
 
- + - ++ Costimulation via 
CD28 
CD83 
 
-  - ++ Unknown but marker 
of mature DC 
CD86 
 
+ + + ++ Costimulation via 
CD28 
CDw137L 
(4-1BBL) 
- + +/- + Costimulation; 4-1BB 
on activated T/B 
CD209  
(DC-SIGN) 
- - + + Capture of Ag 
CD275 
(ICOSL) 
+ + +/- + Costimulation; ICOS 
on T cells (especially 
antigen experienced T 
cells vs CD28 ) 
 
PD-L1 - -/+ + ++ Upregulated by IFNγ;  
regulates T-cells via 
PD-1 
 
PD-L2 - -/+ - + Upregulated by IL-4; 
regulates T-cells via 
PD-1 
 
B7-H3 - - + + Upregulated by IFNγ; 
regulates T-cells via 
unknown receptor 
 
B7-H4 - - - + Regulates T cells via 
unknown receptor 
 
 
Table 1.2 Selected surface molecules relevant to the function of monocytes, 
macrophages and dendritic cells. 
Abbreviations: monocytes (Mo), macrophages (M), immature DC (iDC) and mature 
DC (mDC).  
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1.6.2 Pattern Recognition Receptors 
 
Pattern recognition receptors (PRR) are cell-surface molecules which recognise 
conserved pathogen-associated molecular patterns (PAMP). Toll like receptors are the 
archetypal PRR, recognising a range of PAMPs from viruses, bacteria, protozoa and 
fungi, and widely expressed by cells of the innate immune system. Of particular 
importance to monocyte derived DC are TLR3, TLR4 and TLR8 although they do 
also express TLR1, TLR2, TLR5, TLR6, and possibly TLR7 and TLR 10 (Mazzoni 
and Segal, 2004; Reis e Sousa, 2004b). Unlike monocyte-derived and myeloid DC, 
plasmacytoid DC do not express TLR4 (ligand LPS), but do express TLR9 (ligand 
CpG oligonucleotide), activation of which generates large amounts of IFNα (Krug et 
al., 2001). 
 
DC-SIGN is a C-type lectin found on DC which can also act as a pattern recognition 
receptor. It has been shown to recognise human herpes virus 8 and Mycobacterium 
tuberculosis. DC-SIGN expression is IL-4 dependent and inhibited by IFN, IFN 
and TGF(Granelli-Piperno et al., 2005; Relloso et al., 2002). Other C-type lectins 
which can act as PRR are dectin-1 (which can signal in response to β-glucan) and 
BDCA-2 (exact role still uncertain)(Reis e Sousa, 2004a). 
 
1.6.3 Molecules involved in ‘signal 1’ 
1.6.3.1 TCR/CD3 complex and CD4/8 
 
The T cell receptor (TCR) is a transmembrane disulphide-linked heterodimer 
containing immunoglobulin-like domains. The TCR recognises antigen in the form of 
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processed peptides bound to MHC molecules on the surface of the antigen presenting 
cell. Endogenously produced peptides (whether host or foreign from intracellular 
infection) are presented on class I MHC. Exogenous peptides are taken up by 
phagocytosis or macropinocytosis (Sallusto et al., 1995), and are processed and  
presented on either class II MHC, the usual pathway for exogenous peptides, or class I 
MHC; class I MHC presentation in this context is known as „cross presentation‟ and is 
important in enabling DC to induce naive CD8+ T cells to respond to exogenous 
antigen eg viral infections of parenchymal cells (Rock and Shen, 2005). 
 
TCR are antigen specific. When the TCR recognises their specific MHC-peptide 
complex on the APC, the TCR signals via the CD3 complex of tyrosine kinases 
(known as „signal 1‟)(Janeway, Jr., 1989). T cells also express the coreceptor 
molecules CD4 or CD8 (or rarely both) which bind at different sites on invariant parts 
of the MHC molecule; CD4 binds to class II MHC and CD8 to class I MHC. Binding 
of CD4 or CD8 leads to the activation of tyrosine kinases associated with their 
cytoplasmic domains that, via phosphorylation of the immunoreceptor tyrosine-based 
activation motifs (ITAMs) of the CD3 molecule, lower the threshold for activation of 
the TCR CD3 complex by about 100-fold. 
 
1.6.4 Molecules involved in ‘signal 2’ 
1.6.4.1 CD40L and CD40 
 
The engagement of the TCR with the MHC-peptide complex („signal 1‟) leads to 
upregulation of CD40L on the T cell which interacts with CD40 on the DC. This 
interaction, known as licensing (Fujii et al., 2004), increases the capacity of the DC to 
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activate the T cell by increasing formation of MHC–peptide complexes („signal 1‟),  
by increasing expression of costimulatory molecules such as CD80/86 („signal 2‟) and 
by the production of cytokines including IL-12 („signal 3‟). CD40 also influences DC 
survival, migration, and avoidance of suppression (Fujii et al., 2004). 
 
1.6.4.2 CD28 and CD80/86  
 
TCR engagement with the MHC-peptide complex is not sufficient on its own to 
induce an effector T cell response, and indeed may lead to a refractory state known as 
anergy unless accompanied by an appropriate costimulatory signal (Schwartz, 2003). 
The most important costimulatory signal is the CD28 interaction with CD80/86 which 
promotes the activation of T cell responses, with a predominant role during initial T 
cell activation. CD80 is not expressed at significant levels on immature DC but is 
upregulated in response to maturation stimuli. CD86 is already present at low levels 
on immature DC and is also upregulated on mature DC(Jeras et al., 2005b). Signalling 
via CD28 upregulates T cell production of IL-2 both by increasing transcription of the 
gene and by stabilising IL-2 mRNA  leading to autocrine stimulation and T-cell 
expansion(Lindstein et al., 1989). Signalling through CD28 can also upregulate 
distinct effector T cell cytokine responses characteristic of the distinct T cell subtypes, 
Th1 and Th2 (discussed later)(Fujii et al., 2004; Greenwald et al., 2005)  
1.6.4.3 Inducible costimulator (ICOS; CD278) and ICOSL (CD275)  
 
ICOS interaction with ICOSL synergizes with the CD28 interaction with CD80/86 to 
promote T cell activation but predominantly affects antigen-experienced (rather than 
naïve) T cells. ICOS does not upregulate IL-2 production (so does not lead to T cell 
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proliferation) but can upregulate Th1 and Th2 cytokines and via IL-10 production 
may have a role in generating regulatory T cells. ICOS also provides important T cell 
help to B cells for their differentiation and effector functions (Greenwald et al., 2005). 
1.6.4.4 4-1BB (CDw137) and 4-1BBL  
 
4-1BB is a costimulatory member of the TNFR family, expressed on activated CD4 
and CD8 T cells(Vinay et al., 2006). Its ligand, 4-1BBL, is expressed on activated 
APC, including dendritic cells. 4-1BB is upregulated on the T cell in response to TCR 
stimulation, but after CD28-mediated costimulation (Bertram et al., 2002). It is 
thought to augment T cell proliferation, cytokine production, and prevent activation-
induced cell death. Although it can induce IL-2 production in resting T cells, it is 
much less effective than CD28 (Wen et al., 2002). 
1.6.4.5 Inhibitory molecules 
 
CTLA-4 and PD-1 are CD28 family members which provide inhibitory signals that 
can attenuate T cell responses. Although CTLA4 predominates they have synergistic 
roles (Greenwald et al., 2005). Levels of the ligand for PD-1 (PD-1L) increase in 
primary culture murine RPE cells on exposure to IFNγ, and this is associated with 
inhibition of bystander T cell responses although this appeared to be Th1 (as opposed 
to Th17) selective (Sugita et al., 2009). 
 
1.6.5 Chemokine receptors 
 
Immature DC are usually resident in the peripheral tissue and so are appropriately 
placed to deal with pathogen entry. However they, like monocytes, may be recruited 
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from blood to sites of inflammation under the influence of the chemokine receptors 
CCR1, CCR2, CCR5 and CXCR1 responding to the chemokines CCL2, CCL3 (MIP-
1), CCL4 (MIP-1), CCL5 (RANTES) and CXCL8 (IL-8) (Sallusto et al., 1999). 
 
During maturation these chemoreceptors are downregulated or desensitised, whereas 
CCR7 and CXCR4 are upregulated. This leads to DC responsiveness to chemokines, 
CCL19 and CCL21 (for CCR7), and CCL12 (for CXCR4), which are constitutively 
expressed in the lymph nodes and T cell areas of the spleen. DC (from the afferent 
lymphatic vessels) and CCR7/CXCR4 expressing T cells (from the high endothelial 
venules) are thus directed to the appropriate compartments of the lymphoid tissue to 
facilitate efficient antigen presentation (Scandella et al., 2002).  
 
1.6.6 Cytokines and chemokines produced by DC 
 
In addition to cell-surface signals between DC and T cell, mature DC produce 
secreted molecules (cytokines and chemokines) with wide-ranging effects on the 
immune system. DC secretion of IL-1β (Gardella et al., 2001), TNFα (Telusma et al., 
2006) and IL-6 (Dodge et al., 2003) have broad pro-inflammatory functions including 
fever and endothelial activation. Most fundamentally, DC effectively launch the 
adaptive immune system by the activation of CD4+ and CD8+ T cells and the 
direction of their differentiation (discussed further below). Additionally secretion by 
mature DC of the chemokines CCL3, CCL4 and CCL5 recruit further monocytes and 
iDC (Sallusto et al., 1999; Scandella et al., 2002). The cytokines and chemokines 
considered further in this project are listed in tables 1.3 and 1.4. 
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Cytokine Producer Receptor Target Action 
 
IL-1β M, epithelial 
cells 
CD121a, 
CD121b 
T cell, 
M, 
Activation of T cells 
and M; Fever 
 
IL-1RA Mo, M, N , 
Hepatocytes 
CD121a  Competitive antagonist 
of IL-1 
 
IL-2 T cell IL-2R  T cell Proliferation 
 
IL-4 T cells, Mast cells CD124  B cell  
T cell 
B activation, IgE 
switch; T  Th2 
 
IL-6 T cells, M, DC, 
Endothelial cells 
CD126/CD130 T cell 
B cell 
T cell growth + 
differentiation 
B cell growth + 
differentiation 
Fever 
IL-8 (CXCL8) M CXCR1,2 N, B, T cell Chemotaxis 
 
IL-10 T cells (TH2), 
M, 
 T cells, M, DC, 
B cells 
TH1 inhibition 
Inhibits M activation   
Inhibits DC response to 
chemokines 
Increase MHCII on B 
cells 
 
IL-12 
 
M, DC IL-12R 
 
NK 
CD4+ T cell 
NK activation 
T  Th1 
 
IL-13 T cells IL-13R  B cell 
T cell 
M 
B growth and 
differentiation 
Inhibits M 
inflammatory cytokine 
production 
Inhibits Th1  
 
IL-15 Many IL-15R  T cell 
NK 
T Proliferation and 
CD8 memory T cell 
survival 
NK Proliferation 
 
IL-17A,F TH17 IL-17R Fibroblasts, 
endothelium, M 
Induce pro-
inflammatory cytokine 
production by other 
cells 
  
TNFα M, NK, T  cells TNFR-I, and –
II 
M, endothelial 
cells 
 
Endothelial activation 
 
GM-CSF M, T cells CD116 Mo 
 
Mo  DC, M, 
 
Table 1.3 Selected cytokines relevant to the function of DC and T cells. 
Abbreviations: macrophages (M), monocytes (Mo), neutrophils (N), dendritic cells 
(DC).  
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Chemokine Producer Receptor Target Action 
CCL2 
(MCP-1) 
Mo, M, 
Fibroblasts, 
Keratinocytes 
 
CCR2 Mo, B, T, Chemotaxis 
CCL3  
(MIP-1α) 
Mo, T cells 
Fibroblasts, Mast 
cells 
 
CCR1,5 Mo, M, iDC, 
NK, B, T (Th1 
>Th2),  
Chemotaxis 
CCL4 
 (MIP-1β) 
Mo, M, 
Neutrophils, 
endothelium 
 
CCR5 Mo, M, iDC, 
NK, B, T (Th1 
>Th2), 
Chemotaxis 
CCL5 
(RANTES) 
T cells, 
endothelium, 
platelets 
CCR1,3,5 Mo, M, DC, 
NK, B, E, T 
(memory > other; 
Th1 >Th2), 
 
Chemotaxis 
CXCL8 
(IL-8) 
Mo, M, 
fibroblasts, 
endothelium, 
keratinocytes 
 
CXCR1,2 N, B, T cell Chemotaxis 
CXCL9  
(Mig) 
Mo, DC, 
fibroblasts 
CXCR3 Activated T (Th1 
> Th2) 
 
Chemotaxis 
CXCL10  
(IP-10) 
Keratinocytes, 
Monocytes,  
T cells, 
fibroblasts, 
endothelium 
CXCR3 Activated T (Th1 
> Th2) 
Chemotaxis 
 
Table 1.4. Selected chemokines relevant to DC and T cells.  
Abbreviations: macrophages (M), monocytes (Mo), neutrophils (N), basophils 
(B), dendritic cells (DC), eosinophils (E), natural killer cells (NK).  
 
 
1.7 DC effects on T cell phenotype 
 
The DC interaction with the naive CD4+ T cell is central to most adaptive immune 
responses (Figure 1.4). The phenotype of the DC in terms of the surface molecules 
expressed and cytokines produced are the most important influence on the 
differentiation of the CD4+ T cell into Th1, Th2, Th17, and Treg T cell subtypes. 
Thus IL-12 and IL-18 production by mature DC, and DC stimulation of NK cells to 
produce IFNγ biases T cell differentiation to Th1 (Trinchieri, 2003). Similarly IL-6 
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and IL-23 production by DC may bias T cell differentiation down a Th17 pathway 
(Boniface et al., 2008). DC regulation of Th2 responses is less clear. It has been 
suggested that the Th2 may be the default pathway with predominantly negative 
regulation by DC via IL-12 inhibition of GATA-3 expression. These mature DC 
responses contrast with immature DC antigen presentation to T cells where there is 
minimal proliferative response and the resulting T cells are frequently anergic (as 
reviewed earlier) , or may develop regulatory function (discussed below). DC 
therefore have the ability to control the balance between tolerance, immunity and 
autoimmunity (Moser, 2003; Lutz and Schuler, 2002; Moser, 2003; Reis e Sousa, 
2006). 
 
 
 
Figure 1.4 Summary of CD4+ T cell lineages indicating the primary signals of 
differentiation, their transcription factors, cytokine profile and function. 
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1.8 DC and regulatory T cells 
 
In addition to the long-established mechanisms of anergy and deletion, it has become 
apparent that T cell function may be regulated by specific populations of T cells 
known as regulatory T cells. These appear to have an important role in the 
maintenance of peripheral tolerance and the prevention of autoimmune disease. 
Several types of “regulatory” T cell have been identified (Tarbell et al., 2004; 
Sakaguchi, 2005). Natural T regs develop in the thymus and are CD4+CD25+Foxp3+; 
CD25 being the high affinity IL-2 receptor, Foxp3 being a transcription 
factor(Sakaguchi, 2005). Their development may depend on DC. DC conditioned 
with thymic stromal lymphoprotein can stimulate the development of CD4+CD25+ T 
regs from CD4+CD25- thymocytes under human thymus culture conditions 
(Watanabe et al., 2005). To proliferate and to enhance their suppressive function the T 
regs require an antigen-specific signal from a DC, however their suppressive function 
is then relatively widespread, being capable in experimental models of blocking 
autoimmunity due to multiple antigens(Tarbell et al., 2006). Induced T regs are 
produced in the periphery in response to peripheral stimuli. These include IL-10-
secretors (sometimes called Tr1) and TGFβ-secretors (sometimes called Th3)(Tarbell 
et al., 2006; Kojo et al., 2005).  As with CD4+ T cell differentiation in general, it is 
the nature of the DC: T cell signal (and therefore the phenotype of the DC itself) that 
is primarily responsible for T cell differentiation into a regulatory or effector T cell 
(Lutz and Schuler, 2002; Reis e Sousa, 2006). 
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1.9 Immune privilege and the eye 
 
The immune system has evolved to protect the individual from a wide variety of 
pathogens, but alongside this protective immunity there is frequently significant non-
specific damage to the surrounding tissues. Although this can be tolerated in the 
majority of tissues, certain sites are more sensitive to these effects due to their limited 
capacity for self-renewal or the delicate physiology of the tissues. Immune responses 
in these sensitive tissues are highly specialised, with a reduction in the pathological 
damage caused by the immune response, conferring immune privilege to these 
sites(Streilein, 2003b; Streilein, 2003a). The eye (Figure 1.5) is the archetypal site of 
immune privilege and will be considered first, before reviewing other sites of immune 
privilege such as the brain, the pregnant uterus, the hamster cheek pouch, the hair 
follicle, and the testes. 
 
 In order to maintain a clear visual axis, the eye must allow immune responses 
required for protective immunity, and at the same time restrict these responses to 
prevent significant pathological damage. Many mechanisms have been suggested to 
contribute to the maintenance of immune privilege in the eye, both immunological 
and anatomical. Immunological mechanisms include: a complex network of 
immunosuppressive molecules in the ocular microenvironment (aqueous humour – 
AqH) (Taylor et al., 1992; Taylor, 2007; Cousins et al., 1991b), expression of FasL on 
ocular surfaces (pro-apoptotic signal notably against activated T cells) (Ferguson and 
Griffith, 2007), expression of atypical rather than typical class I MHC (inhibit NK 
cells, and not recognised by CD8+ cytotoxic T cells), and the phenomenon of anterior 
chamber associated immune deviation (ACAID)(Streilein, 2003b; Streilein, 2003a). 
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Anatomical mechanisms comprise a tightly regulated blood:ocular barrier and limited 
lymphatic drainage. 
 
 
 
 
Figure 1.5 Key structures of the eye.  
Extraocular and intraocular views showing key anatomical structures, including the 
uveal tract comprising iris, ciliary body and choroid. Illustration by Angela Luck; 
adapted with permission. 
 
 
 
1.9.1 Ocular immune privilege 
 
Evidence for the unusually protected status of the anterior segment of the eye 
stretches back to the observation by Van Dooremaal in 1873 that murine-to-canine 
skin grafts were tolerated when inserted into the anterior chamber of the dog eye. 
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Medawar, recognising that immunity was responsible for allograft rejection, regarded 
allograft tolerance by the eye and the brain as evidence that they were „immune 
privileged‟ (Medawar, 1948)(recently reviewed (Kaplan and Niederkorn, 2007)). 
Further investigation has highlighted the contribution of aqueous humour to ocular 
immune privilege, and its regulation of both afferent and efferent arms of the immune 
response. Whilst other immunological and anatomical mechanisms are undoubtedly 
also important in maintaining immune privilege, within the context of this thesis I will 
be primarily considering the role of aqueous humour and its influence on the ocular 
antigen presenting cell with specific regard to the dendritic cell. 
 
1.9.2 Aqueous humour 
 
Aqueous humour is a clear colourless plasma-like fluid produced by the ciliary body 
at around 2.5μl/min (in human). Its functions include structure (providing support to 
the anterior segment of the eye), nutrition (to the avascular lens and cornea), light 
transmission and immunoregulation. It differs biochemically from plasma by being 
high in ascorbate but lower in glucose and protein, unless there has been breakdown 
of the blood-ocular barrier. 
 
The earliest direct demonstration of the immunomodulatory effects of AqH was 
Kaplan‟s observation that injection of alloantigenic cells into the anterior chamber of 
the eye resulted in immune deviation in which there was antigen-specific suppression 
of classical Th1 immune responses (Kaplan et al., 1975). Subsequent studies by 
Streilein and colleagues refined this concept of Anterior Chamber Associated Immune 
Deviation (Kaplan and Streilein, 1977; Kaplan and Streilein, 2007; Streilein and 
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Niederkorn, 2007; Wilbanks et al., 1991; Wilbanks and Streilein, 1991; Wilbanks et 
al., 1992), one of the fundamental tenets of which was that the differentiation of 
ocular antigen presenting cells and their processing of antigen under the influence of 
aqueous humour results in a unique immunoregulatory phenotype (recently reviewed 
by Niederkorn (Niederkorn, 2007)).  Several investigators also observed that when 
APC and T cells are co-cultured in the presence of AqH or iris/ciliary body 
supernatants, proliferation is inhibited (Cousins et al., 1991a; Streilein and Bradley, 
1991). Whilst interesting, it should be noted that these experiments do not identify 
whether it is the afferent arm (ie the APC) or the efferent arm (the T cell) or both 
which are affected by AqH. More recently, however, Shen has shown that murine 
bone-marrow derived dendritic cells when cultured in vitro with rabbit AqH, are 
inhibited in their capacity to induce a mixed lymphocyte reaction (Shen et al., 2007).  
 
AqH was also found to modulate the efferent arm of the DTH response.  Benson and 
Niederkorn demonstrated local suppression of DTH responses to a highly 
immunogenic tumour (UV5C25) within the eye of BALB-c mice despite  persistence 
of systemic DTH responses (Benson and Niederkorn, 1991). As noted above, most 
studies on the effects of AqH on T cell proliferation are hard to interpret due to the 
exposure of both APC and responder T cell to the AqH. Important exceptions include 
AqH inhibition of T cell proliferation in the IL-2 dependent CTLL assay (Cousins et 
al., 1991a), and AqH inhibition of lymphocyte proliferation to  polyclonal mitogens 
and to growth hormones (Kaiser et al., 1989). 
  
Investigation into the mechanism by which AqH achieves its effects have identified 
the presence of a number of potential immunomodulatory molecules including TGFβ, 
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the neuropeptides αMSH, VIP, CGRP, somatostatin and the endogenous 
glucocorticoid, cortisol. 
 
1.9.3 Transforming Growth Factor β (TGF) 
 
TGFβ was the first significant immunomodulatory molecule to be identified in AqH 
(Cousins et al., 1991a; Wilbanks et al., 1992). TGF exists in three isoforms, TGF1-
3. Although mRNA for all three isoforms may be found in ocular cells, TGF2 is the 
only isoform to actually be expressed at sufficient levels to be recovered from healthy 
aqueous humour. (Cousins et al., 1991a; Pasquale et al., 1993) In healthy aqueous 
humour TGF2 levels are 1-10ng/ml, the vast majority being in its latent form 
(Knisely et al., 1991b). 
 
TGF2 has been shown to have a number of immunomodulatory properties on APC. 
In some of the early experiments into the phenomenon of ACAID, Wilbanks showed 
that conferral by AqH of ACAID-inducing properties on non-ocular macrophages was 
TGFβ-dependent (Wilbanks et al., 1992). TGF2-treated APC lose the ability to 
activate Th1 cells and induce delayed type hypersensitivity (DTH). These APC 
produce less IL-12 and have lower expression of various accessory molecules 
(Takeuchi et al., 1998; Tsunawaki et al., 1988). Recently Shen has shown that 
recombinant TGFβ2 recapitulated the inhibitory effects of rabbit AqH on murine 
bone-marrow derived DC, and that the effects of AqH were blocked by AqH-pre-
treatment with anti-TGFβ2 (Shen et al., 2007). TGF2 treatment of macrophages also 
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reduces their production of inflammatory cytokines and their ability to generate 
reactive oxygen species(Tsunawaki et al., 1988).  
 
TGFβ2 present in AqH has also been shown to be capable of modulating T cell 
proliferation directly. In an IL-2 dependent CTLL assay, Cousins et al showed that 
AqH inhibition of proliferation was completely reversed by the addition of anti-
TGFβ2 (Cousins et al., 1991a). TGFβ has been shown to inhibit proliferation of naive 
T cells by inhibiting IL-2 production via Smad3 (in contrast activated T cells are 
relatively insensitive (Cottrez and Groux, 2001)), and to inhibit the differentiation of 
Th1 and Th2 subtypes via T-bet/Stat4 and GATA-3/NF-AT respectively (recently 
reviewed by Li et al (Li et al., 2006)). Significantly TGFβ also induces FoxP3 
expression and the induction of CD4+CD25+ T regs from CD4+ CD25- naive T cells 
(Chen et al., 2004).  
 
1.9.4 α -Melanocyte Stimulating Hormone (MSH) 
 
MSH is a 1.6 kDa, 13-amino acid neuropeptide which is cleaved from the protein, 
pro-opiomelanocortin hormone (POMC). It is produced by a number of cell types 
including neurons, macrophages and keratinocytes. MSH is constitutively expressed 
in the healthy eye with aqueous humour levels of around 20pM (Taylor et al., 1992). 
DC respond to αMSH via the melanocortin receptor MC-1R, with downregulation of 
CD86 and CD40, inhibition of the production of IL-1, IL-2, IL-4,IL-6, IL-13, IFNγ 
and TNFα and increased secretion of IL-10 (reviewed  (Luger et al., 2003)). Similarly 
αMSH has been noted to suppress activated macrophages, reducing their expression 
of pro-inflammatory cytokines, reactive oxygen species and nitric oxide, whilst 
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increasing their production of IL-10, MSH and their expression of MSH receptors 
(Star et al., 1995). It has also been found to suppress the pro-inflammatory effects of 
LPS (Chiao et al., 1996), IL-1 (Watanabe et al., 1993) and TNF (Martin et al., 
1991). 
 
In addition to its effects on APC, MSH has a number of important effects on T cells. 
AqH and αMSH (at its ocular concentration) inhibit IFNγ production by antigen-
stimulated T cells; neutralization of the αMSH component of AqH reverses this 
inhibition. αMSH can also induce a regulatory phenotype in CD4+ T cells which may 
be augmented by TGF2. This has been demonstrated both in vitro and in the mouse 
model of experimental autoimmune uveitis  (Taylor et al., 1992). In addition in a 
model of local adoptive transfer of delayed type hypersensitivity (DTH) in which 
lymph node cells from immunized C57BL/6 are reintroduced after incubation with 
Mycobacterium tuberculosis antigen, the suppressive effects of AqH were found to be 
partially reversed by removal of the αMSH fraction (Taylor et al., 1994a). 
 
1.9.5 Vasoactive Intestinal Peptide (VIP) 
 
VIP is a 3.3 kDa, 28 amino acid neuropeptide produced by neurons, with variant 
forms also being produced by neutrophils and mast cells. It is present in the anterior 
chamber at 12 + 1 nM. VIP has been shown to inhibit mitogen-driven lymphocyte 
proliferation and function (Ottaway, 1988; Stanisz et al., 1986). Its effects on APC are 
not well defined. At its ocular concentration it has been shown to inhibit Ag-
stimulated lymph node cell proliferation and IFNγ production in vitro. Interestingly 
removal of VIP from the low molecular weight fraction of AqH did not neutralize the 
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effect of AqH on proliferation but did neutralize the suppression of IFNγ-production. 
In addition removal of VIP neutralized the suppression of local adoptive transfer of 
delayed type hypersensitivity (DTH) (Taylor et al., 1994b). Ferguson subsequently 
showed that VIP was essential for the induction of ACAID, that it was antagonised by 
substance P and that the presence of VIP was dependent on a normal diurnal rhythm 
of light exposure. 
 
1.9.6 Cortisol 
 
Cortisol (hydrocortisone) is one of a class of hormones known as „glucocorticoids‟, a 
group of steroid hormones produced in the cortex of the adrenal gland, and the 
functions of which include glucose metabolism. It has wide-ranging effects on many 
homeostatic processes including metabolism, fluid balance, the cardiovascular 
system, and the immune system. Cortisol is secreted according to a diurnal rhythm , 
peaking in the morning, but is secreted at increased levels in response to stress.  
 
Cortisol has been observed at biologically significant levels in human and rodent AqH 
with levels of 18.0 + 1.0 ng/ml (mean + SD) for human; cortisone (corticosterone) 
levels were significantly lower at 0.7 + 1.0ng/ml. These levels equate to 49.7nmol/l 
and 1.9nmol/l respectively (362.5Mol mass). Our own group has measured levels of 
cortisol of 4.8 + 0.38 nmol/l and cortisone of 1.9 + 0.13 nmol/l (mean + SEM) by RIA 
in patients attending for cataract surgery(Rauz et al., 2003). Other groups observed 
human hydrocortisone levels of between 2.5 and 17ng/ml (Weinstein et al., 1991; 
Rozsival et al., 1981). Interestingly  the binding protein Cortisol Binding Globulin 
(CBG) was not present at detectable levels (by radioimmunoassay) (Knisely et al., 
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1994). Thus it would appear that the vast majority of cortisol in AqH exists in free 
form, in contrast to the situation in serum where 80-90% is bound to CBG, 4-10% is 
bound to albumin and the remaining 6-10% is free cortisol.  
 
The effects of cortisol on the immune system are primarily mediated via the 
glucocorticoid receptor (GR). The availability of cortisol for a specific tissue or cell 
may also be modified by the actions of the enzyme 11β-hydroxysteroid 
dehydrogenase (11β-HSD) which catalyzes the cortisone-cortisol shuttle. 11β-HSD1 
catalyzes the generation of active cortisol from cortisone, whereas the isoform 11β-
HSD2 catalyzes the reverse process.  
 
Binding of glucocorticoid to the glucocorticoid receptor results in downstream 
inhibition of the transcription factors NF-κB and AP-1, and, via binding  to negative 
glucocorticoid response elements (GRE) in inhibition of the POMC gene (reviewed 
(Webster et al., 2002)). Cortisol has wide-ranging effects including the apoptosis of 
monocytes, inhibiting IL-1 (Lee et al., 1988), IL-6  and TNFα production (Steer et al., 
2000), inhibiting IL-12 production by DC and inducing a shift from Th1 to Th2 
(Freeman et al., 2005). The addition of cortisol at the levels found in AqH inhibited 
PHA/IL-1-stimulate murine thymocyte proliferation and CCL64 cell proliferation 
(Knisely et al., 1994).  
 
1.9.7 Extraocular sites of immune privilege 
 
Other sites of immune privilege include the brain, the pregnant uterus, the hamster 
cheek pouch, the hair follicle, and the testes. The advantage of immune privilege 
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varies from organ to organ. For the brain (like the eye) it reduces the chance of 
immune-mediated collateral damage in a structure with limited regenerative capacity 
and where minor anatomical damage can cause survival-compromising loss of 
function. The pregnant uterus, effectively a semiallogeneic graft, requires immune 
privilege to prevent rejection of the fetus. Finally, without the immune privilege of the 
cheek pouch, the hamster would not be able to store food for the prolonged periods 
necessary for its survival.  
 
Some of the mechanisms of immune privilege familiar to the ocular  immunologist, 
have also been observed in other immune privileged structures. Mechanisms of 
immune privilege shared by the eye, brain and feto-placental unit include the presence 
of immunomodulatory molecules such as TGFβ, αMSH, VIP, CGRP and 
somatostatin, expression of FasL, absence  of typical MHC class I molecules, and, 
more speculatively, brain and fetal equivalents to ACAID (recently reviewed by 
Niederkorn (Niederkorn, 2006)).  
 
1.10 Antigen presentation in the ocular context 
In contrast to the role of the Langerhans cell within the skin (reviewed earlier), the 
nature and role of the antigen presenting cells of the eye are much less well-defined. 
Some of the most fundamental questions of ocular immunology centre on the ocular 
APC: its nature (dendritic cell, macrophage or other), its function (stimulatory or 
regulatory) and its location/migratory behaviour (resident or migratory). I will first 
summarise the background to each of these questions, before reviewing our central 
hypothesis within this context. 
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1.10.1 The identification of the ocular APC 
 
The nature of the ocular APC-like cell has been a matter of some debate. In human 
cadaveric studies of 12 eyes Chang observed that a population of dendritiform stromal 
cells of the iris, ciliary body and choroid were HLADR+ TLR4+MD2+ but CD68-, 
and were therefore most typical of dendritic cells.(Chang et al., 2004) However the 
same cells appeared to express CD14, which whilst expressed at high levels in 
macrophages is also expressed on iDC. In an earlier cadaveric study of 34 human eyes 
Flugel observed similar CD45+HLADR+ dendritiform cells in the trabecular 
meshwork, around the intra- and episcleral vessels,  the stroma of the ciliary body  
and the iris, and, with increasing age of the patient,  in the “uveoscleral” pathway. In 
this paper co-authored with Streilein,  Flugel argued that the CD45+HLADR+ cells in 
the trabecular meshwork were migrating APC “in transit” which could go on to 
mediate ACAID(Flugel et al., 1992).  
 
In mouse and rat anterior uveal tissues both Knisely and McMenamin  observed 
networks of Class II MHC (Ia) + dendritiform cells which they identified as dendritic 
cells (Knisely et al., 1991a) (McMenamin et al., 1994). Further work in the rat 
showed that the pleomorphic or dendritiform DC express MHC II and/or OX62 
antigen (α2 E integrin) and have a half-life of around 3 days whereas the macrophage 
population are positive for CD163, are usually MHCII- and have a much longer half-
life (Steptoe et al., 1995).  
 
Meanwhile in the mouse Streilein and colleagues observed F4/80+ cells in the 
anterior uveal tissues which they identified as monocyte/macrophages. This was of 
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particular interest because they also showed that these F4/80+Class II MHC (1a)- 
cells when derived from either iris/ciliary body or from the peritoneal cavity could be 
loaded with antigen (in vivo or in vitro) and transferred intravenously or 
intracamerally (ie into the anterior chamber) to induce ACAID in a second 
animal.(Wilbanks et al., 1992; Wilbanks et al., 1991) (Wilbanks and Streilein, 1991). 
Although F4/80 is often considered as a marker of murine macrophages it may also 
label groups of dendritic cells such as the Langerhans cell group of DC(McMenamin 
et al., 1994; Camelo et al., 2003). Immunolabelling of murine iris and ciliary body by 
McMenamin suggested that 80% of the F4/80+ cells were also positive for the 
macrophage marker SER4 (and apparently similarly for CD11b). However 33% of the 
F4/80+ cells also expressed MHCII (Ia) which has been primarily described on the 
DC population. Two thirds of the class II(Ia) + cells also expressed specific DC 
markers such as CD11c (McMenamin, 1999). 
 
1.10.2 The function of the ocular APC 
 
Although there is general agreement over the existence of both a DC-like population 
and a macrophage-like population, there is considerable argument over two issues: 
first, their function – do they act as immunogenic APCs or do they have an 
immunoregulatory role?; second, their migration – do they act purely locally or do 
they migrate, and if so where to? Camelo and colleagues have hypothesised that the 
anterior uveal dendritic cells are the sentinel APC which migrate to the draining 
lymph node to induce naïve T cell proliferation and so generate the primary ocular 
immune response, whereas the macrophage may be involved in the secondary 
immune response by restimulating activated T cells (Camelo et al., 2003). 
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Previous studies by Williamson and Streilein found that single-cell suspensions and 
whole preparations of the iris/ciliary body not only failed to function as allogeneic 
APCs but actually suppressed the mixed lymphocyte reaction. Intraocular injection of 
IFNγ led to upregulation of MHCII on resident bone-marrow derived cells of the iris-
ciliary body and could abrogate these immunosuppressive properties, although the 
exact mechanism of this altered function is unclear (Streilein et al., 1992). In contrast 
Steptoe found that purified MHCII (Ia)+ED2- iris DC, but not MHCII-ED2+ 
macrophages, did have moderate allostimulatory capacity in the mixed leucocyte 
reaction assay and that this could be further enhanced by  the addition of GM-CSF 
(Steptoe et al., 2000). These authors suggested that the failure to observe 
allostimulation in other studies might be due to contamination with iris/ciliary body 
epithelial or stromal cells which are known to have a strong immunoregulatory effect, 
rather than being a feature of the iris DC themselves. 
 
1.10.3 The traffic of soluble antigen and of ocular antigen presenting cells  
 
In the absence of a well-developed system of draining lymphatics it is unclear where 
antigen presentation actually takes place. A number of explanations have been 
proposed which are not mutually exclusive and may indeed coexist. The three 
dominant models are discussed below. 
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1.10.3.1 Model 1: Antigen presentation occurs in the eye only 
 
The simplest solution, proposed by Chang and colleagues, is that the traffic of antigen 
or APC out of the eye is unnecessary. They propose that naïve T cells may be 
recruited directly to the uvea and that priming and activation could occur in the uvea 
itself (Chang et al., 2004). Although there is no direct evidence for this occurring 
within the eye, direct antigen presentation to naive and memory CD4+ T cells can 
occur in peripheral tissues. Although under normal circumstances, only primed CD4+ 
T cells would be recruited to the site of inflammation, it is possible that in the 
presence of generalised endothelial activation (such as in the presence of severe blood 
ocular barrier breakdown) naïve CD4+ T cells may also traffic through. 
 
1.10.3.2 Model 2: Ocular APC migrate from the eye and present antigen in the 
spleen 
 
In contrast the Anterior Chamber Associated Immune Deviation (ACAID) model 
postulates that antigen introduced to the anterior chamber is picked up by APC which 
follow the conventional outflow pathway of aqueous humour via the venous system to 
the spleen(Streilein, 2003b). In the context of ACAID antigen presentation occurs in 
the spleen triggering an immunoregulatory (rather than an effector) response 
(Streilein, 2003b) . This has similarities to venous induction of tolerance where 
antigen is directly injected into the vein resulting in the traffic of large quantities of 
antigen directly to the spleen, although most advocates of ACAID argue that it is a 
distinct tolerogenic mechanism (Niederkorn, 2007) .  
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1.10.3.3 Model 3: Soluble antigen migrates to the draining lymph node and is 
processed by resident DC 
 
Other investigators have noted that almost all antigen is carried in mainly soluble 
form and not by an ocular APC. They propose that soluble antigen leaves the eye by 
either the conventional route or the unconventional uveoscleral route, and may then 
be transported in the venous system or in the afferent lymphatics to the secondary 
lymphoid tissues (Camelo et al., 2006; Dullforce et al., 2004). Wilbanks and Streilein 
compared the subsequent distribution of intracameral, subconjunctival and 
intravenous injections of 125I labelled BSA. In contrast to intravenous administration, 
both intracameral and subconjunctival sites acted as antigen depots, with detection of 
antigen even 4 weeks later. However they noted that 95% of the injected antigen left 
the eye in soluble form ie without being processed by ocular antigen presenting cells 
(Wilbanks and Streilein, 1989). 
 
Egan et al found that both the peptide OVA 323-339 and the whole OVA protein 
when inoculated into the posterior chamber of the eye led to the expansion of OVA-
specific T cells in the ipsilateral submandibular lymph node by day 3. This effect is 
abrogated by enucleation of the eye at 30mins, 1h or 5h, but persists with  enucleation 
at 24h suggesting that the antigen (in whatever form) exits the eye between 5 and 24h 
(Egan et al., 1996). 
 
Becker and colleagues subsequently used intravital microscopy in the mouse to 
identify which ocular APC ingested ovalbumuin after intracameral administration.  
Fluorescent ovalbumin and/or fluorescent antibodies to MHC II, CD11b, CD11c and 
F4/80 were injected into the anterior chamber of healthy mice. They found that 
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ovalbumin was taken up by some cells with morphologic and surface molecules 
typical of macrophages and some more typical of dendritic cells. At 6h after injection 
most (95%) ovalbumin+ cells were CD11c+, 90% were F4/80+, around 60% were 
MHCII+, and around 15% were CD11b+. On colabelling only 10% of the CD11b+ 
cells were MHCII+, and only 10-20% of the MHCII+ cells were CD11b+. At 24h 
after injection only 24% of ovalbumin+ cells were CD11c+, and around 30% were 
MHCII+, whereas the proportion of CD11b+ cells had increased to 60% and F4/80+ 
cells had remained at 90%. They also found that at 24h most of the MHCII+ cells 
were positive for an antibody mix to CD80 and CD86. The authors suggest that this 
apparent shift from a typical dendritic cell phenotype (CD11c+ and/or MHCII+) to a 
more macrophage-like phenotype (CD11b+ and/or MHCII-) may reflect actual 
differentiation of the DC, emigration of the DC or death of the DC with ingestion by 
macrophages (Becker et al., 2003). 
 
The same group then compared the uptake of texas red labelled ovalbumin (TR-OVA) 
with the uptake of fluorescent 2μm latex beads after injection into the murine anterior 
chamber. Cells positive for TR-OVA but not for fluorescent beads  were observed in 
the submandibular lymph nodes from 6h onwards. The majority of the beads 
remained clumped in the angle of the eye, although a few could be found in the spleen 
at 24h post injection(Dullforce et al., 2004). Video microscopy showed that no bead-
containing APC from the iris showed directionally significant movement or left the 
iris at any time point (4h, 5h, 6h, 12h, 24h, 48h) even under the additional 
inflammatory stimulus of LPS (Dullforce et al., 2004). This contrasted with their 
parallel experiments in which intradermal injection of identical beads resulted in 
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bead-containing APC in the draining lymph nodes, so recapitulating the work of 
Randolph (Randolph et al., 1999). 
 
Using in vivo video microscopy in the rat Camelo found that 24h after intracameral 
injection of fluorescent-labelled dextran, antigen had been taken up by numerous cells 
of the iris, ciliary body, anterior suprachoroidal space and episcleral connective tissue. 
Confocal microscopy revealed that the majority of these cells were MHCII (Ia) -,  and 
bore typical macrophage markers ED1 (syn macrosialin;  stains most rat tissue 
macrophages, may also be on DC; homologue of CD68),  and ED3 (CD169, stains 
marginal zone and subcapsular sinus subsets of lymphoid macrophages); however 
there was also a population of cells which were positive for both ED2 (CD163;syn 
scavenger receptor B) usually found on monocytes/macrophages (particularly 
alternatively activated (M2) macrophages(Tiemessen et al., 2007)) as well as OX62+ 
(ie rat αE2  integrin) which is a typical DC marker (Camelo et al., 2003). 
 
The same group then attempted to identify which extraocular sites the fluorescent-
labelled dextran drained to. They observed dextran+ cells in the marginal zone of the 
spleen, in the subcapsular sinus of the ipsilateral submandibular, superficial cervical 
and deep cervical lymph nodes, and unexpectedly in the mesenteric lymph nodes. In 
some cases dextran+ cells were also found in the contralateral submandibular and 
superficial cervical  lymph nodes (Camelo et al., 2004a). In the spleen these dextran+ 
cells were CD1+, CD11b+, CD11c-, CD68+ (clone ED1), CD86low, CD163low 
(clone ED2), CD169+ (clone ED3),MHCII (Ia)+ (clone OX6), ED5- (marker of 
FDC), and in the lymph nodes were CD4+, CD8+, CD80+ and CD172a+ (OX41). 
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The authors argue that these phenotypes suggest that they are resident lymphoid 
macrophages, and do not represent migrated APC from the eye (Camelo et al., 2006). 
 
The work by Camelo (Camelo et al., 2003) suggesting that in the rat eye intracameral 
dextran is mostly taken up by macrophages contrasts with the work of 
Dullforce(Dullforce et al., 2004) (discussed earlier) suggesting that in the mouse eye 
intracameral ovalbumin was first taken up by DC and only later appeared in cells of a 
macrophage phenotype. These differences could reflect differences in the nature of 
the antigen, interspecies variation or issues of experimental design and technique. 
Camelo and colleagues attempted to address some of these issues by repeating their 
earlier work with dextran (a polysaccharide) using ovalbumin and BSA (both 
proteins). With all three antigens, antigen positive cells were observed within the iris, 
iridocorneal angle, pre-equatorial choroid and around limbal/episcleral vessels. 
Interestingly whereas with BSA and dextran (40-70kDa), antigen positive cells were 
found lining both the conventional and non-conventional pathways, with albumin 
antigen positive cells were found mainly along the conventional outflow pathway. At 
24h most of the antigen positive cells were of a similar phenotype regardless of the 
antigen used; specifically they were CD68+ (ED1), CD163+ (ED2), mostly MHCII- 
and occasionally CD169+ (ED3) suggestive of a macrophage phenotype. A few 
antigen positive MHCI++ dendriform cells were identified in the iris, trabecular 
meshwork, choroid and episclera, and these were proposed as possible DC.(Camelo et 
al., 2004b) It should be noted that the studies by Camelo did not involve examining 
the eye earlier than 24h post injection, and thus direct comparison with the Dullforce 
(Dullforce et al., 2004) study is not possible. 
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In a subsequent series of experiments with parallels to the Dullforce paper,  Camelo 
and colleagues injected cascade-blue-dextran into the AC of the right eye and FITC-
dextran into the AC of the left eye: significantly individual APC bearing both 
fluorochromes were identified. Similarly when CB-Dx was injected into the AC of the 
right eye and FITC-DX was injected into the tail vein, APC bearing both fluorescent 
antigens were identified in the marginal zone of the spleen. They also showed that the 
distribution to lymph nodes following intracameral injection was almost identical to 
that seen after subconjunctival injection; they argued that this suggests that the 
intracameral antigen that ends up in these sites also travels via the conjunctival 
lymphatics (Camelo et al., 2006). 
 
1.10.4 Summary of antigen presentation in the eye 
 
My central hypothesis is that the normal resting ocular microenvironment maintains a 
relatively immature DC phenotype which generates anergic or regulatory T cells, 
whereas in intraocular inflammation (uveitis) this regulation breaks down permitting 
full DC maturation resulting in production and recruitment of pathogenic effector T 
cells to the eye.  
 
In terms of the identity of the ocular APC, MHC class II+ cells have been identified in 
the mouse, rat and cadaveric human eye, mainly around the iris (Becker et al., 2003; 
McMenamin et al., 1994; Forrester et al., 1994). These can be divided into two groups 
according to whether they express typical dendritic cell or macrophage markers. The 
iris dendritic cells express low CD11c, CD80 and CD86 suggesting that they are 
relatively immature (McMenamin et al., 1994) . Although less abundant than 
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macrophage-like populations, there is now good evidence that DC are present within 
the anterior (and posterior) segment of the eye (Chang et al., 2004; Forrester et al., 
1994; Forrester et al., 1993; Forrester et al., 2005; McMenamin et al., 1994; 
McMenamin, 1999; McMenamin, 1997; McMenamin et al., 1992). 
 
In terms of function, indirect evidence for the role of dendritic cells in uveitis (or at 
least a form of ocular antigen presenting cell) comes from the presence during 
inflammation of recently primed, activated T cells (CD45RO+, CD69+) suggesting 
recent activation by professional APC(Muhaya et al., 1999) . Antigen injected into the 
AC is captured within 6-24h by macrophage and DC-like cells in the iris and 
subconjunctival tissue(Dullforce et al., 2004; Camelo et al., 2003), however it  
remains unclear whether antigen presentation is by these ocular DC themselves, or by 
resident DC of the lymphoid tissues which have imbibed soluble antigen or 
transferred antigen (from migratory DC). It is also uncertain whether antigen 
presentation takes place in the draining lymph nodes, the spleen (as per ACAID 
model) or indeed in the ocular tissue itself (as proposed by Chang). 
 
In the light of my hypothesis and the limits of our current knowledge (summarised 
above), one of the challenges of this thesis was therefore to develop an in vitro model 
of DC function that would reflect DC behaviour in both the resting ocular 
microenvironment and under inflammatory conditions and would enable us to assay 
its capacity to induce T cell responses both of naive cells, and of memory cells. 
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1.11 Uveitis 
1.11.1 The clinical problem of uveitis 
 
Uveitis comprises a group of diseases characterised by intraocular inflammation, 
which by its very existence challenges the paradigm of ocular immune privilege. 
Many cases resolve rapidly, but a significant number of patients develop persistent 
disease, with damage to ocular structures resulting in severe visual impairment. It is 
currently unclear whether the development of uveitis reflects a failure of immune 
privilege or whether these mechanisms are overwhelmed and conversely whether 
disease resolution represents a re-establishment of the normal mechanisms of immune 
privilege function.   
 
Although uveitis per se is a term correctly used to describe inflammation of the uveal 
tract (iris, ciliary body and choroid; Figure 1.5) alone, the term has come to include a 
large group of diverse diseases affecting also the retina, optic nerve and vitreous(Bora 
and Kaplan, 2007; Forrester, 2007). It predominantly affects people of working age, 
peaking  in the 20 – 50 year age group, with an annual incidence of 14 – 50 per 
100,000(Durrani et al., 2004).  Whilst there is some variation in prevalence across the 
globe, in the developed world it is the 5
th
 commonest cause of visual loss  accounting 
for 10 – 15% of total blindness and up to 20% of legal blindness(Durrani et al., 2004).  
 
Uveitis can be a devastating sight-threatening condition. The main causes of reduced 
vision are cystoid macular oedema and secondary cataract. Other vision threatening 
complications include secondary glaucoma, band keratopathy, vitreous opacities, 
optic neuropathy, retinal scars and phthisis (involution of the eye). Depending on the 
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primary site and extent of inflammation it may be described as anterior, intermediate, 
posterior or panuveitis (Table 1.5), each of which have their own constellation of 
typical clinical features (Table 1.6)((Jabs et al., 2005; Bora and Kaplan, 2007; 
Forrester, 2007).  
 
 
 
 
Type Primary site of 
inflammation 
Includes 
Anterior uveitis Anterior chamber Iritis 
Iridocyclitis 
Anterior cyclitis 
Intermediate uveitis Vitreous Pars planitis 
Posterior cyclitis 
Hyalitis 
Posterior uveitis Retina or choroid Focal, multifocal or 
diffuse choroiditis 
Chorioretinitis 
Retinochoroiditis 
Retinitis 
Neuroretinitis 
Pan uveitis Anterior chamber, vitreous 
and retina or choroid 
 
 
Table 1.5 Anatomical classification of uveitis 
The Standardization of Uveitis Nomenclature (SUN) anatomical classification of 
uveitis (2005)(Jabs et al., 2005)  
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Type Common symptoms Common signs 
Anterior uveitis  If acute: pain, redness 
If chronic: usually 
asymptomatic  
Ciliary injection 
AC cells 
AC flare 
Keratic precipitates 
Posterior synechiae 
Intermediate uveitis „Floaters‟ 
Reduced vision 
May be asymptomatic 
Vitreous cells 
Exudation at the ora 
serrata 
Posterior uveitis Reduced vision 
„Floaters‟ 
Macular oedema 
Retinal or choroidal 
infiltrates/oedema 
Retinal haemorrhages 
Periphlebitis or arteritis 
Panuveitis Any of the above 
 
Any of the above 
 
Table 1.6 Common clinical features observed in anterior, intermediate, posterior 
and panuveitis 
Clinical presentation varies according to the primary site of intraocular inflammation 
(Bora and Kaplan, 2007; Forrester, 2007). 
 
 
One of the challenges of inflammatory disease is to score activity and so permit 
monitoring of disease and assessment of any intervention. Anterior segment 
involvement is scored using the SUN grading score for anterior chamber cells and 
flare(Jabs et al., 2005). For AC cells this involves scoring the number of AC cells in a 
1.0 x 1.0mm beam as follows: <1 cells, score 0; 1-5 cells, score 0.5+; 6-15 cells, score 
1+, 16-25 cells, score 2+, 26-50 cells, score 3+, >50 cells, score 4+. For AC flare the 
grading is similarly from 0 to 4, and is based on the increasing visibility of the beam 
within the normally transparent AqH, the loss of clarity of the intraocular structures 
and the visibility of fibrin (Jabs et al., 2005). 
 
In the majority of patients the cause of the intraocular inflammation is unknown 
(Table 1.7). Infectious agents, such as Toxoplasma gondii, and the herpes viruses are 
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well-recognised causes, but, particularly amongst industrialized nations, only account 
for a minority of disease. Of the non-infectious cases, some are part of a systemic 
disease process, such as sarcoidosis, Behçet‟s disease, multiple sclerosis and the 
HLA-B27 related group of diseases, but in most cases the pathogenesis is not 
understood.  It is thought that many of these „idiopathic‟ cases have an autoimmune 
aetiology(Bora and Kaplan, 2007; Forrester, 2007). They share similarities (and 
indeed are often associated) with established autoimmune conditions; they also 
respond to immunosuppresives drugs, such as glucocorticoids (Curnow et al., 2004; 
Curnow et al., 2005; Muhaya et al., 1999; Becker et al., 2002). 
 
 
Group Subgroup 
 
Infectious Bacterial 
Viral 
Fungal  
Parasitic 
Others 
Non-infectious Known systemic association 
No known systemic association 
Masquerade Neoplastic 
Non-neoplastic 
 
Table 1.7 Clinical classification of uveitis 
The clinical classification of uveitis (infectious/non-infectious/masquerade) has been 
described by the International Uveitis Study Group, 2008)(Deschenes et al., 2008) 
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1.11.2 Treatment of uveitis 
 
In common with most other inflammatory diseases, uveitis responds well to treatment 
with glucocorticoids (Oksala, 1960; Dick et al., 1997; Gaudio, 2004). In most anterior 
uveitis topical synthetic glucocorticoids are sufficient: typically dexamethasone 0.1% 
or prednisolone 1%. In more severe episodes of uveitis or where uveitis is not 
confined to the anterior part of the eye systemic glucocorticoids are usually 
given(Oksala, 1960; Dick et al., 1997; Gaudio, 2004). Where prolonged 
immunosuppresssion is required (or where systemic glucocorticoids at an acceptable 
dose are insufficient to control disease) alternative agents are used in addition or 
instead of glucocorticoids. Such agents include cyclosporine (Dick et al., 1997; 
Murphy et al., 2005), tacrolimus (Murphy et al., 2005), methotrexate (Gangaputra et 
al., 2009), azathioprine(Pasadhika et al., 2009), mycophenolate mofetil (Kilmartin and 
Dick, 1999; Teoh et al., 2008), cyclophosphamide (Rosenbaum, 1994), anti-TNF 
therapies (Murphy et al., 2004; Mushtaq et al., 2007; Suhler et al., 2009),  IFNα 
(Deuter et al., 2009) and other „biological‟ therapies(Sen et al., 2009). All of these 
agents, like glucocorticoids, have significant potential side-effects (Okada, 2005; 
Gaudio, 2004; Dick et al., 1997) (Table 1.7, 1.8).  Within the field of uveitis there is a 
dearth of large scale high quality randomised controlled trials to direct the appropriate 
use of these agents. Although there is a general reliance on glucocorticoids first-line, 
the selection of supplementary or alternative immunosuppressants (and their dosing 
regimen) still tends to be led more by personal experience, retrospective studies or by 
extrapolation from other diseases than from randomised controlled trials specific to 
uveitis. Fortunately this situation is beginning to improve with the development of 
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consensus guidelines (Jabs et al., 2000) and a move to prospective studies (Sen et al., 
2009; Suhler et al., 2009). 
 
Experimental therapies currently under investigation for use in uveitis include T reg 
infusion and tolerogenic DC vaccination, both of which have shown to be effective in 
EAU (Jiang et al., 2003). Other targets which have shown promise in animal models 
include IL-17, CD44(Xu et al., 2002; Reis e Sousa et al., 1999), chemokines (such as 
MIP-1α)(Crane et al., 2003), and adhesion molecules (such as ICAM-1) (Uchio et al., 
1994; Xu et al., 2003).  
 
 Part of this project was to investigate how glucocorticoid treatment may alter the 
effect of the ocular microenvironment on DC, by studying the effect on DC both of 
AqH from patients with uveitis pre or post-commencement of treatment and of the 
therapy itself . 
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Drug Mechanism Side-effects (selected) 
Glucocorticoid 
Prednisolone 
Methylprednisolone 
Dexamethasone 
Inhibits NF-κB and AP-1 Glucose intolerance/diabetes 
mellitus 
Weight gain 
Osteoporosis 
Adrenal suppression  
Cataracts 
Antimetabolites 
Azathioprine Inhibits purine metabolism Bone marrow suppression 
Gastro-intestinal (GI) upset 
Secondary malignancies 
Alopecia 
Methotrexate Inhibits dihydrofolate 
reductase  
Hepatotoxicity 
Bone marrow suppression 
GI upset 
Mycophenolic acid Inhibits purine metabolism Bone marrow suppression 
GI upset 
Secondary malignancies 
Leflunomide Inhibits pyrimidine synthesis Bone marrow suppression 
Hepatotoxicity 
Calcineurin inhibitors 
Ciclosporin Inhibits calcineurin/NF-AT 
transcription factor  reduce 
IL-2 + other cytokines 
Nephrotoxicity 
Hypertension 
Hepatotoxicity 
Gingival hyperplasia 
Hypertrichosis 
Tacrolimus Inhibits calcineurin/NF-AT 
transcription factor  reduce 
IL-2 + other cytokines 
Nephrotoxicity 
Hypertension 
Neurotoxicity 
Hepatotoxicity 
Voclosporin Inhibits calcineurin/NF-AT 
transcription factor  reduce 
IL-2 + other cytokines 
Nephrotoxicity 
Hypertension 
Cytotoxics 
Cyclophosphamide Alkylating agent: DNA cross-
linking blocks cell replication 
Bone marrow suppression 
Haemorrhagic cystitis 
GI upset 
Sterility 
 
Table 1.8 Conventional anti-immunosuppressive drugs used in uveitis, their chief 
mode of action and selected important side-effects 
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Drug Mechanism Side-effects (selected) 
TNF inhibitors 
Adalimumab Anti-TNF: fully human 
monoclonal antibody against 
TNF 
TB and Hep B reactivation 
Severe infections 
Etanercept Anti-TNF: Fc fusion protein 
which binds extracellular 
TNF- 
Hypersensitivity reactions 
TB and Hep B reactivation 
Severe infections 
Inflixamab Anti-TNF: chimeric 
monoclonal antibody against 
TNF- 
Human antichimeric antibodies 
serum sickness 
TB and Hep B reactivation 
Anaphylaxis 
Severe infections 
Interleukin receptor antagonists 
Anakinra Anti-IL1R: recombinant 
version of IL1 receptor 
antagonist (IL1RA) 
Injection-site reaction 
Neutropenia 
Severe infections (especially in 
asthma) 
Daclizumab Anti-IL2R: humanized 
monoclonal antibody against 
the IL2 receptor 
Hypersensitivity reactions 
Hypertension 
Severe infections 
Anti- B cell 
Rituximab Anti-CD20: chimeric 
monoclonal antibody against 
CD20 (B-cells) 
Severe infusion reactions(inc 
dyspnoea, hypoxia, 
bronchospasm) 
Cytokine release syndrome 
Cardiac dysfunction (inc arrest, 
hypotension, angina, 
arrhythmias) 
TB reactivation 
PML 
Interferons 
Interferon-2 Antiviral and anti-tumour:  
decreases NK cell activity 
Leukopenia 
Depression 
TB reactivation 
Flu-like symptoms 
Nephrotoxicity 
Hepatotoxicity 
 
Table 1.9 Biological therapies currently used in uveitis, their chief mode of action 
and selected important side-effects.  
A number of emerging biological therapies (such as anti-IL-17 therapies) are also 
currently under consideration. 
 
Chapter One General Introduction 51 
1.11.3 The initiation of uveitis 
 
The processes leading to the initiation of non-infective uveitis are still unclear. With 
regard to the most common group, acute anterior uveitis (AAU), there is good 
evidence for both a genetic and environmental component. Genetic factors include a 
strong association with HLA-B27. In the West the prevalence of HLA-B27 is < 10% 
in the general population but around 50% in those presenting with AAU(Brewerton et 
al., 1973a; Ehlers et al., 1974). Conversely being HLA-B27+ is estimated to carry 
around a twenty five-fold relative risk of AAU (vs non-carriers) (Brewerton et al., 
1973a; Ehlers et al., 1974). It is not clear whether the HLA-B27 association for AAU 
(and spondylarthropathies such as ankylosing spondylitis) is directly due to the 
molecule itself (eg via inappropriate recognition of self antigen on the HLA-B27 
molecule) or whether it is due to the presence of neighbouring genes existing in 
linkage disequilibrium with HLA-B27. Candidates include MHC I chain-related gene 
A (MICA; MICA A4 is associated with AAU (Goto et al., 1998); MICA*009 with 
Behcet‟s disease (Mizuki et al., 2007)) and TNF(Kaijzel et al., 1999).  
 
Despite its high relative risk of AAU, being positive for HLA-B27 only carries a 
lifetime incidence of around 1% (Linssen et al., 1991) raising the possibility of a 
significant environmental contribution. Most attention has focused on the presence in 
a proportion of AAU of recent gram negative bacterial infection, particularly Yersinia 
and Salmonella(Saari and Kauranen, 1980; Saari et al., 1980b; Saari et al., 1980a). 
The role of Gram negative bacteria is reasonably well established in other HLA-B27 
diseases (notably in reactive arthritis)(Liu et al., 2001) and thus a natural target in 
AAU. Interestingly both mice and rats transgenic for HLA-B27 only develop an 
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Ankylosing Spondylitis-like inflammatory disease when exposed to non-sterile 
conditions.   
 
In the eye the expression of TLR-4 and its associated LPS receptor complex is limited 
to DC-like APC found in perivascular and sub-epithelial locations where they can 
potentially respond to either intraocular or blood-borne LPS (from Gram negative 
bacteria); indeed this is used to induce a hyperacute anterior uveitis in the model 
endotoxin-induced uveitis (EIU)(Rosenbaum et al., 1980). It is proposed that the 
precipitating event in acute anterior uveitis may be an inappropriate TLR-4-mediated 
response within the eye, driven by either LPS or endogenous TLR-4 ligands. The self 
perpetuating autoimmune cycle may become established once LPS acts as an adjuvant 
for hypothetical self-antigens leading  to full APC maturation and breakdown of 
peripheral tolerance. Additionally in the presence of inflammation and tissue damage 
endogenous TLR-4 ligands are generated which may reinforce the TLR-4 response 
(Chang et al., 2004). Alternative animal models of anterior uveitis include collagen-
induced anterior uveitis (CAU) induced by a type I collagen fragment (Bora et al., 
2004)and experimental melanin induced uveitis induced by choroid derived melanin-
associated antigen (Chan et al., 1994)(Figure 1.10). 
 
The situation with regard to intermediate and posterior uveitis is even more complex. 
First it is a matter of debate as to whether the various clinical entities are different 
diseases or part of the spectrum of a single pathological process. Evidence for the 
former view comes from the clinical, prognostic, and genetic differences between 
some types of uveitis, for example, pars planitis (a form of intermediate uveitis with 
good prognosis) and the strongly HLA-A29 associated bird-shot retinochoroidopathy 
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(a form of posterior uveitis with poor prognosis). The interesting possibility that these 
are artificial groupings to describe a spectrum of inflammatory response has been 
recently reviewed by Forrester (Forrester, 2007) who points out that in animal models 
(summarised in table 1.10) the induction of autoimmune intraocular inflammation by 
ocular antigens can lead to a spectrum of disease with strong similarities to the range 
of human uveitis. 
 
Animal models such as experimental autoimmune uveitis (the most widely used 
model of posterior uveitis; recently reviewed (Kerr et al., 2008)) have demonstrated 
the capacity of ocular antigens (notably retinal-S antigen and interphotoreceptor 
retinoid binding protein) to induce uveitis when immunised with an adjuvant (usually 
a Mycobacteria tuberculosis extract such as Complete Freund‟s Adjuvant)(Table 
1.10). Modifications of this model (species, genetic background, immune status) 
result in variations in clinical phenotype which can be used to mimic acute 
monophasic, acute recurrent, and chronic disease. Traditionally regarded as a Th1 
disease, it has become increasingly apparent that Th17 cells may also play a critical 
role(Peng et al., 2007). This switch in paradigm (similar to that which has occurred 
with Experimental Autoimmune Encephalomyelitis (EAE)(Chen et al., 2006)) 
explains why switching off IFNγ alone does not cure EAU(Raveney et al., 2008), and 
why the presence of IL-6 (in the constitutively TGFβ2 rich ocular microenvironment) 
may be so central to the development of EAU and possibly human uveitis (Peng et al., 
2007; Amadi-Obi et al., 2007). Despite this recent change in focus it should be noted 
that EAU can also be induced in IL-17 knock-out mice, and thus it seems that both 
pathways have a pathogenic role to play (Luger et al., 2008). 
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More recently spontaneous models have been developed which, it is argued, better 
model the spontaneous nature of human disease. These models include spontaneous 
uveoretinitis in nu/nu mice after thymic reconstitution at 4wks of age (Ichikawa et al., 
1991), bird-shot retinopathy-like uveitis in mice made transgenic for HLA-A29 
(Szpak et al., 2001),  or the introduction of a foreign antigen (eg Hen egg lysozyme 
(HEL)) under an ocular promoter (eg the αcrystallin promoter) with either the 
adoptive transfer of specific T cells or crossing onto a mouse transgenic for the 
specific TCR (eg anti-HEL)(Zhang et al., 2003; Lambe et al., 2007).  
 
Model Antigen Adjuvant Animal 
Experimental 
autoimmune uveitis 
(EAU) 
 
Retinal S-Ag or 
IRBP (bovine) 
CFA Mouse or rat 
Endotoxin-induced 
uveitis (EIU) 
 
LPS (systemic or 
intravitreal) 
As for Antigen Mouse or rat 
Mycobacterium 
tuberculosis 
adjuvant-induced 
uveitis (MTU) 
 
Mycobacterium 
tuberculosis 
adjuvant 
(intravitreal) 
As for Antigen Mouse 
Experimental 
melanin induced 
uveitis (EMIU) 
 
Melanin (bovine) Hunter‟s adjuvant Rat 
Experimental 
Autoimmune 
Encephalomyelitis 
(EAE) 
Myelin basic 
protein 
CFA Rat 
Collagen-induced 
autoimmune uveitis 
(CAU) 
Type I Collagen 
(bovine) 
CFA 
Pertussis toxin 
Rat 
 
Table 1.10 Outline of commonly used animal models of uveitis, their antigens 
and adjuvants. 
Abbreviations: IRBP = interphotoreceptor retinoid binding protein; CFA = complete 
Freund‟s adjuvant  
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In human uveitis evidence for the role of autoantigens is less complete. De Smet 
noted  lymphocyte stimulation responses to peptide determinants of retinal S antigen 
in a range of uveitis conditions, being most frequent in uveitis associated with 
Behcet‟s disease or sarcoidosis (de Smet et al., 1990; de Smet et al., 2001).  Attempts 
to identify responding T cells in the peripheral blood of uveitis patients are extremely 
challenging but have suggested a higher rate of responding cells in uveitis patients vs 
controls (0-400/10
7
 cells vs 0-4/10
7
 cells)(de Smet et al., 1998), and, at least in 
Behcet‟s patients a thirty-fold expansion of the retinal S-Ag specific T cell pool after 
an episode of intraocular inflammation (de Smet and Dayan, 2000).  No difference in 
serum levels of anti-retinal S Ag or anti-IRBP have been observed between patients 
and controls (Chan et al., 1985; Doekes et al., 1987).  
 
1.11.4 Immune privilege and inflammation 
 
Does AqH still have immunosuppressive properties in the presence of inflammation? 
In the murine model of experimental autoimmune uveitis, Ohta observed that blood 
ocular barrier breakdown is associated with increased levels of IL-6 and loss of the 
capacity to suppress anti-CD3 driven T cell proliferation at the onset of disease (day 
11 after inoculation with IRBP). However at day 17 when disease was progressively 
severe AqH recovered the ability to suppress anti-CD3 driven T cell proliferation 
associated with a fall in IL-6 and in the presence of TGFβ-1 (from blood) and TGFβ-2 
(from the eye)(Ohta et al., 2000a). Subsequently using the model of endotoxin 
induced uveitis the same group found that 6 to 24 hours after LPS injection AqH lost 
its capacity to suppress T-cell activation associated with an increase in IL-6 measured 
in the AqH and high levels of IL-6 mRNA in the iris/ciliary body tissue. 
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Neutralization by the addition of IL-6 specific antibodies to inflamed AqH led to 
recovery of its capacity to suppress T-cell activation. Similarly CD3-induced T cell 
proliferation suppressed by exogenous TGFβ2 (at 0.5 or 5 ng/ml) could be overcome 
by the addition of IL-6 (at 1 or 10ng/ml). Additionally they noted that the induction of 
antigen-specific anterior chamber–associated immune deviation (ACAID) in normal 
mice was prevented by the addition of IL-6 into the anterior chamber (Ohta et al., 
2000b). Conversely using a different model based on the injection of LPS into the 
vitreous cavity of BALB/c mice, Mo and colleagues found that even at the peak of 
intraocular inflammation (9h) these eyes would both permit the proliferation of 
allogeneic tumour cells and support ACAID, and their AqH would still strongly 
inhibit T cell activation.(Mo and Streilein, 2007)  
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1.12 Objectives 
 
In this thesis, I set out to achieve the following:  
 To develop an in vitro model of DC differentiation, maturation and function 
that would best reflect the microenvironment of the human eye.  
 To study the effects of non-inflammatory AqH (or its significant components) 
on DC phenotype and function.  
 To compare the effects of non-inflammatory AqH with AqH from patients 
with uveitis.  
 To consider the effects of treatment on the ocular microenvironment as 
reflected by the effects of AqH from patients on or off treatment at the time of 
sampling.  
 To establish whether DC can be identified in aqueous humour from uveitis 
patients, and to characterize their phenotype.  
 To identify the mechanisms within the eye that regulate DC maturation under 
both non-inflammatory conditions and during uveitis. 
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2 MATERIALS AND METHODS 
2.1 List of reagents 
2.1.1 Media and solutions 
 
All Sigma-Aldrich, Irvine, UK unless otherwise specified. 
RPMI medium RPMI (Roswell Park Memorial Institute) 1640  
L-glutamine (1.64mM), benzylpenicillin (40U/ml), 
streptomycin (0.4mg/ml) and HEPES buffer (10mM) 
RPMI/ITS+3  RPMI medium with 1% ITS+3 liquid media supplement;  
ITS+3 liquid media supplement contains 1.0 mg/ml insulin 
from bovine pancreas, 0.55 mg/ml human transferrin 
(substantially iron-free), 0.5 μg/ml sodium selenite, 470 μg/ml 
linoleic acid, 470 μg/ml oleic acid and 50 mg/ml bovine serum 
albumin (equivalent to 2 moles each of linoleic acid and oleic 
acid per mole of albumin). 
RPMI/ITS+3/NEAA/Na pyruvate         
RPMI medium with 1% ITS+3 liquid media supplement, 1% 
Nonessential amino acids, 1% Sodium pyruvate 
Non-essential amino acid solution (100x) stock solution 
contains 0.89g/l L-alanine, 1.5g/l L-asparagine, 1.33g/l L-
aspartic acid, 1.47 g/l glutamic acid, 0.75 g/l glycine, 1.15 g/l L-
proline and 1.05 g/l L-serine. 
Sodium pyruvate stock solution contains 100mM sodium 
pyruvate solution. 
RPMI/1% BSA RPMI medium with 1% bovine serum albumin (BSA) 
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RPMI/10% HS RPMI medium with 10% pooled human AB+male serum (HS; 
HD Supplies, Aylesbury,UK)  
RPMI/10% FCS RPMI medium with 10% pooled fetal calf serum (Biosera, 
Ringmer, UK) 
PBS Phosphate buffered saline contains 8g/l NaCl, 0.2g/l KCl, 1.15 
g/l Na2HPO4, 0.2g/l KH2PO4 in distilled H2O; prepared as 1 
PBS tablet per 100ml  distilled H2O (tablets supplied by Oxoid, 
Basingstoke, UK) 
MACS buffer  Phosphate buffered saline (PBS) with 0.5%BSA, 2mM 
ethylenediamine tetra-acetic acid (EDTA) 
2.1.2 Cytokines and prostaglandins 
 
Recombinant human IL-4 (Immunotools, Friesoythe, Germany) 
Recombinant human GM-CSF (Immunotools) 
Recombinant human IL-1β  (Peprotech, London, UK) 
Recombinant human IL-6  (Immunotools) 
Recombinant human TNFα (Peprotech)  
Recombinant human PGE2 (Sigma-Aldrich). 
Recombinant human TGFβ1  (R & D Systems, Abingdon, UK) 
Recombinant human TGFβ2  (Peprotech)  
Recombinant human TGFβ3 (R & D Systems) 
Recombinant human αMSH (Bachem, Weil am Rhein, Germany) 
Recombinant human VIP  (Bachem) 
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2.1.3 Antibodies 
Target Conjugate Species Isotype Clone Company Cat No Dilution 
 
CD1a PB Mouse IgG1 HI149 Biolegend 300117/8 1in 50 
 
CD1c 
(BDCA-1) 
APC Mouse IgG2a AD5-8E7 Miltenyi 130-090-903 1in 10 
 
CD4 
 
PECy5 Mouse IgG2a 53.5 Caltag MHCD0406 1 in 50 
CD11b 
  
APCCy7 Mouse IgG1 ICRF44 
(44) 
BD Pharmingen 557754 1 in 40 
CD11c 
 
PECy7 Mouse IgG1 3.9 Biolegend 301607 1 in 10 
CD14  
 
FITC Mouse IgG1 MEM-18 Immunotools 21270143 1 in 20 
CD14 
 
APCCy7 Mouse IgG2b MφP9 BD Pharmingen 557831 1 in 20 
CD16 
 
FITC Mouse IgG1 LNK16 Immunotools 21279163 1 in 10 
CD19 
 
FITC Mouse IgG1 LT19 Immunotools 21270193 1 in 10 
CD40  
 
PECy5 Mouse IgG1 5C3 BD Pharmingen 555590 1 in 5 
CD45RA 
 
PETR Mouse IgG1 2H4LDH 
11LDB9 
Beckman Coulter PN IM2711 1 in 80 
CD45RO 
 
FITC Mouse IgG2a UCHL1 Dako F0800 1 in 20 
CD56 
 
FITC Mouse IgG2a MEM-188 Immunotools 21270563 1 in 10 
CD80 
 
FITC Mouse IgG1 2D10 Biolegend 
 
305206 
 
1 in 10 
 
CD80 
 
PE Mouse IgG1 L307.4 BD Pharmingen 557227 1 in 20 
CD80 
 
Biotin Mouse IgM BB1 BD 
Pharmingen 
555682 
 
1 in 50 
 
CD83 
 
PE Mouse IgG1 HB15 Serotec MCA1582PE 1 in 10 
CD86 
 
PECy5 Mouse IgG1 2331 
FUN-1 
BD Pharmingen 555659 1 in 20 
CDw137L  
(4-1BBL) 
PE Mouse IgG1 5F4 Biolegend 311503/4 1 in 10 
CD209 
(DCSIGN) 
FITC Mouse IgG2b DCN46 BD Pharmingen 551264 1 in 5 
CD275 
(ICOSL) 
Biotin Mouse IgG2b 2D3 Biolegend 
 
309405/6 
 
1 in 50 
 
CD303 
(BDCA-2) 
FITC Mouse IgG1 AC144 Miltenyi 130-090-510 1in 10 
 
CCR5 
(CD195) 
PECy7 Mouse IgG2a 2D7 / 
CCR5 
BD Pharmingen 557752 1 in 10 
CCR7 
 
FITC Mouse IgG2a 150503 R+D FAB197F 1 in10 
 
Table 2.1 List of primary antibodies used for flow cytometry (against surface 
molecules other than MHC).  Abbreviation used Allophycocyanin (APC), 
Cyanine 5 (Cy5), Cyanine 7 (Cy7) Fluorescein isothiocyanate (FITC), Pacific blue 
(PB), Phycoerythrin (PE), Phycoerythrin Texas Red (PETR) 
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Target Conjugate Species Isotype Clone Company Cat No Dilution 
 
HLA- 
A,B,C 
PB Mouse IgG2a W6/32 Biolegend 311417/8 1 in 50   
HLA-DR 
 
FITC Mouse IgG2a L243 BD Pharmingen 347400 1 in 20 
HLA-DR 
 
PE Mouse IgG2a 
 
L243 BD Pharmingen 347401 1 in 50 
HLA-DR 
 
PETR Mouse IgG1 Immu-357 Beckman 
Coulter 
PN IM3636 1 in 20 
 
Table 2.2 List of primary antibodies used for flow cytometry (against MHC) 
 
 
 
 
 
 
 
Target Conjugate Species Isotype Clone Company Cat No Dilution 
 
Biotin  Qdot 525  
 
Mouse N/A N/A Invitrogen Q10141MP 1 in 50 
Biotin Qdot 605  
 
Mouse N/A N/A Invitrogen Q10101MP 1 in 50 
 
Table 2.3 List of streptavidin-conjugated secondary antibodies used for flow 
cytometry  
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Target Conjugate Species Isotype Clone Company Cat No Dilution 
 
Irrelevant FITC 
 
Mouse IgG1 203 Immunotools 21335023 1 in 20 
Irrelevant PE 
 
Mouse IgG1 203 Immunotools 21335014 1 in 10 
Irrelevant PETR  
 
Mouse IgG2b MOPC-195 Caltag MG2b17 S 1 in 40 
Irrelevant PECy5 
 
Mouse IgG2a UPC-10 Immunotools 21335025 1 in 20 
Irrelevant PECy7 
 
Mouse IgG2a 5.205 Caltag MG2a12 S 1 in 10 
Irrelevant PB 
 
Mouse IgG2a 5.205 Caltag Mg2a 28 S 1 in 10 
Irrelevant APC Cy7 
 
Mouse IgG1 MOPC-21  BD 
Pharmingen 
557873 1 in 20 
Irrelevant Biotin 
 
Mouse IgG1 DAK-GO1 Dako X0945 1 in 10 
 
Table 2.4 List of isotype control antibodies used for flow cytometry  
 
 
 
 
 
 
 
Target Conjugate Species Isotype Clone Company Cat No Dilution 
 
FoxP3 PE 
 
Rat IgG1 eBR2a eBioscience 12-4321-73 1 in 5 
Irrelevant PE 
 
Rat IgG1 PCH101 eBioscience 12-4776-73 1 in 5 
 
Table 2.5 List of antibodies used for flow cytometry against intracellular targets 
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2.1.4 Other reagents 
 
Ficoll-Paque Plus (GE Healthcare Biosciences, Amersham, UK) 
MACS CD14-microbeads (Miltenyi Biotec, Surrey, UK) 
MACS Naïve CD4+ T cell isolation microbeads (Miltenyi Biotec) 
MACS Memory CD4+ T cell isolation microbeads (Miltenyi Biotec) 
MACS CD8+ T cell isolation microbeads (Miltenyi Biotec) 
MACS Myeloid Dendritic Cell isolation microbeads (Miltenyi Biotec) 
Carboxyfluorescein diacetate, succinimidyl ester (CFSE) (Invitrogen) 
Cortisol (> 98% HPLC Hydrocortisone; Sigma-Aldrich) 
RU486 (Mifepristone; Sigma-Aldrich) 
SB431542 hydrate (Sigma-Aldrich) 
Flow Check Fluorospheres (Beckman Coulter Inc) 
Counting beads (CALTAG/Invitrogen, Paisley, UK) 
Propidium iodide (Sigma-Aldrich) 
 
2.1.5 Other consumables 
 
96-well suspension culture plates sterile U bottom with lid (Greiner Bio-one Ltd, 
Stonehouse, UK) 
96-well adherent culture plates sterile flat bottom with lid (Sarstedt, Leicester, UK) 
24-well adherent culture plates sterile flat bottom with lid  
Tissue culture flasks for adherent cells (25cm
2
 surface area size) (Sarstedt) 
96-well multiscreen-MIC transmigration plates (Millipore, Watford, UK) 
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2.2  Aqueous humour samples 
 
Ethical approval for the collection of AqH and matched peripheral blood from 
patients either with uveitis (cases) or cataract (controls) had previously been obtained 
in 1996 from West Birmingham Local Research Ethics Committee. I oversaw the 
successful renewal of both our ethical application (Dudley Local Research Ethics 
Committee) and our research and development applications, including writing the 
new patient information sheets and consent forms (see Appendix). 
 
A team of ophthalmologists at the Birmingham and Midland Eye Centre led by 
Professor P.I. Murray regularly undertake AqH sampling both from patients with 
uveitis (for clinical and research purposes) and from patients attending for cataract 
surgery (for research purposes). Under the previous and current ethical application we 
have been able to collect between 20-80 uveitis AqH samples each year. As part of 
this team, and as the named contact for reporting accrual of patients to the United 
Kingdom Clinical Research Network (UKCRN) I oversaw the recruitment of 188 
uveitis patients (of whom 182 had successful sampling of peripheral blood and 87 of 
aqueous humour).  
 
Clinical data recorded comprised anatomical type of uveitis (Table 1.5), aetiology 
(where known), whether unilateral or bilateral, duration of current episode, duration 
of disease, current medical treatment (if any) and anterior chamber cellular activity 
(as per Standardization of Uveitis Nomenclature 2005 classification (Jabs et al., 
2005)). Anterior chamber flare was not recorded at the outset of the study, but has 
since been added to the minimum data set. AqH sampling from patients with active 
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uveitis was performed at the slit lamp following a previously published 
protocol(Cheung et al., 2004) and with typical sampling volumes of 40-100μl. The 
procedure was only carried out by the following trained personnel: Prof P.I.Murray, 
Mr I.J.Khan, Mr J.Abbott, Mr P.Tomlins, Miss K.Oswal and myself. 
 
Patients attending for routine cataract surgery provided the group of non-
inflammatory control AqH samples. AqH sampling from the control group was 
performed in theatre at the start of their cataract surgery, using a 1ml syringe with a 
27 gauge needle via either the main incision or a paracentesis port prior to any other 
manipulation of the anterior chamber, obtaining samples of 50-100μl. Working with 
Professor P.I. Murray and Miss S. Rauz we recruited 311 cataract patients (of whom 
all 311 had uncomplicated sampling of aqueous humour) (Figure 2.1). There were no 
significant adverse events following peripheral blood or aqueous humour sampling in 
either the uveitis or the control group. 
 
Each sample was centrifuged (300g, 5mins, 20˚C), before aspirating the supernatant 
for freezing at -80ºC in aliquots. Detailed demographic data including classification of 
uveitis (anatomical and clinical, and specific uveitis syndromes), and therapy (where 
relevant) was documented. The cells were resuspended in 100μl of RPMI/10% heat 
inactivated fetal calf serum (HIFCS) prior to staining for analysis by flow cytometry. 
 
During the period 1/11/06 to 1/9/09 (the period during which we were specifically 
recruiting for this project) we recruited 188 patients with uveitis with a mean + SD 
age of 52yrs 9mths + 17yrs 4mths. Of these 107 had anterior uveitis, two intermediate 
uveitis, four posterior uveitis and 54 panuveitis. Of this group of 188 patients, 87 
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underwent sampling of AqH (Figure 2.1). The clinical features of the group who 
underwent AqH sampling are set out in Table 2.6. 
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Figure 2.1 Flow-chart highlighting the recruitment of uveitis patients, cataract 
patients and healthy donors, and the utilization of samples as part of this study 
(UKCRN4654).  
Note that all DC culture experiments were based on monocyte-derived DC or myeloid 
DC from healthy controls. Non-inflammatory „control‟ AqH was taken at the time of 
surgery from patients without uveitis attending for routine cataract extraction.  
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Parameter 
 
Aqueous humour samples 
Number recruited 
 
87 
Age 
(Mean + SD) 
49.3 +16 yrs 
Anatomical classification Anterior 
Intermediate 
Posterior 
Panuveitis 
 
72 /82 
0  
0  
10 /82 
 
Eyes affected Unilateral 
Bilateral 
 
68 /78 
10 /78 
  
Course Acute (first episode) 
Recurrent 
Chronic 
 
17 /82 
64 /82 
1   /82 
 
Aetiology  Idiopathic 
HLA-B27 or related disease 
Fuchs Heterochromic Uveitis 
Viral (Herpes family) 
Vogt-Koyanagi-Harada disease 
52 /82 
18 /82 
7  / 82 
2  / 82 
1  / 82 
 
Duration of episode  
(Mean + SD) 
5.9 + 4.9 days  
Treatment Nil 
Topical corticosteroid 
Oral corticosteroid 
Intravenous corticosteroid 
 
49 /77 
24 /77 
2   /77 
2   /77 
 
Activity (cells) 0    
1+  
2+  
3+  
4+  
 
6   /82 
20 /82 
24 /82 
29 /82 
3   /82 
 
 
Table 2.6 Demographic and clinical features of patients with uveitis undergoing 
AqH sampling during the course of this study.  
All data (including duration of episode and treatment) was recorded at the time of the 
sampling and therefore does not reflect subsequent disease course. Anterior chamber 
cellular activity was graded as per Standardization of Uveitis Nomenclature 2005 
classification criteria(Jabs et al., 2005). 
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2.3  Purification of cells 
2.3.1 Purification of peripheral blood mononuclear cell fraction from whole 
blood 
 
Heparinised peripheral blood samples were obtained from healthy donors (recruited 
from amongst work colleagues). Informed consent was taken in accordance with the 
Human Tissue Act 2004. Peripheral blood was diluted 1:1 with “RPMI medium” 
comprising RPMI (Roswell Park Memorial Institute) 1640 supplemented with L-
glutamine (1.64mM), benzylpenicillin (40U/ml), streptomycin (0.4mg/ml) and 
HEPES buffer (10mM)(all Sigma-Aldrich). Diluted blood was layered on 8ml Ficoll-
Paque Plus (GE Healthcare Biosciences) in 25ml universal tubes and centrifuged at 
300g, 20°C, 30 mins, without brake. The peripheral blood mononuclear cell layer was 
transferred to fresh universal tubes and washed four times in RPMI medium with 
centrifugation of 300g at 20°C for 8mins each time. 
The yield of peripheral blood mononuclear cells (PBMC) was calculated by use of the 
Improved Neubauer haemocytometer (Weber Scientific) as described by the 
manufacturer. The range of yield was 5 x 10
5
 – 1.5 x 106 per ml of peripheral blood. 
 
2.3.2 Purification of monocytes (CD14+) 
 
Monocytes were then isolated using MACS CD14-microbeads (Miltenyi Biotec) as 
described by the manufacturer. MACS Microbeads are superparamagnetic particles 
precoated with a specific antibody (here monoclonal anti-CD14) to enable positive or 
negative selection of cell populations when passed over a MACS column placed 
within a strong magnetic field. PBMC were incubated for 15mins at 4°C with 20µl 
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beads/10
7
 cells and 80μl MACS buffer /107 cells. MACS buffer was filter-sterilized 
and consisted of phosphate buffered saline (PBS; Oxoid limited), 0.5% bovine serum 
albumin of 98% purity (BSA; Sigma-Aldrich) and 2mM ethylenediamine tetra-acetic 
acid, (EDTA; Sigma-Aldrich). The cells were then washed once with MACS buffer 
(centrifugation of 300g, 4°C , 8 mins), the supernatant pipetted off to a dry pellet, and 
cells resuspended in 500μl MACS buffer/108 cells.  An LS MACS separation column 
was prepared by a single rinse with 3ml MACS buffer and placed on a QuadroMACS 
separator magnet. The resuspended cells were passed over the column, and the 
negative fraction eluted with a series of three x 3ml MACS buffer washes. The 
column was then removed from the magnet and the CD14-microbead positive fraction 
eluted with 5ml MACS buffer and firm column pressure from the plunger. 
 
The yield of monocytes was calculated by use of the haemocytometer. The range of 
yield was 5 x 10
4
 – 1.5 x 105 per ml of peripheral blood. These populations were 
highly enriched with purity of >95% as determined by percentage of cells expressing 
CD14 analysed by flow cytometry (Figure 2.2).  
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Figure 2.2 Selection of CD14+ monocytes by CD14-microbeads 
CD14+ monocytes were isolated by MACS CD14-microbeads as described in the 
text, and purity checked by flow cytometry with staining for CD14. (A) Scatter plots 
show distinctive high forward scatter (FS) vs side scatter (SS) of monocytes compared 
to predominant lymphocyte population in peripheral blood mononuclear cell (PBMC) 
fraction. (B) Gating on region 1 (R1) for all cells (ie excluding debris) shows the 
purified fraction (filled-in area) to be 98% positive for CD14+ expression. 
Background staining was measured by an isotype control (broken line). 
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2.3.3 Purification of myeloid dendritic cells (BDCA-1+) 
 
Myeloid dendritic cells were also isolated using MACS technology in a two-stage 
process involving the depletion of CD19+ B cells prior to the positive selection of 
BDCA-1+ cells; the depletion step is required due to BDCA-1 also being present on a 
subset of B cells. PBMC were incubated for 15mins at 4°C with 200μl MACS buffer 
/10
8
 cells, 100µl CD19 beads/10
8
 cells, 100µl FcR blocking reagent/10
8
 cells, and 
100μl BDCA-1-Biotin antibody /108 cells.  The cells were then washed once with 
MACS buffer (centrifugation of 300g, 4°C, 8 mins ), before being resuspended in 
500μl/108 cells MACS buffer and passed over a prepared  LD MACS depletion 
column (single preparatory rinse with 2ml MACS buffer) placed on a QuadroMACS 
separator magnet. The B cell-depleted fraction was then eluted with a series of two x 
1ml MACS buffer washes. The B-cell depleted fraction was then washed again with 
MACS buffer (centrifugation of 300g, 4°C ), before being resuspended in 400μl 
MACS buffer /10
8
 cells and 100μl anti-biotin beads/108 cells and incubated for 
15mins at 4°C. The cells were then washed once more with MACS buffer 
(centrifugation of 300g, 4°C , 8 mins), the supernatant pipetted off to a dry pellet, and 
cells resuspended in 500μl MACS buffer/108 cells before being passed over an MS 
MACS separation column placed on a MiniMACS separator magnet. Having prepared 
the MS column (by a single rinse with 500μl MACS buffer), the negative fraction was 
washed through with a series of three x 500μl MACS buffer. The column was then 
removed from the magnet and the BDCA-1-microbead positive fraction eluted with 
1ml MACS buffer and firm column pressure from the plunger. To improve purity, 
elution was performed directly into a second prepared MS column, the negative 
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fraction was again eluted (three x 500μl MACS buffer) before final collection of the 
BDCA-1-microbead positive fraction by the addition of 1ml MACS buffer and firm 
column pressure from the plunger. 
 
The yield of myeloid DC was calculated by use of the haemocytometer. The range of 
yield was 2 x 10
3
 – 5 x 103 per ml of peripheral blood. These populations were highly 
enriched with purity of >80% as determined by percentage of cells being          
BDCA-1+CD19- as analysed by flow cytometry (Figure 2.3).  
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Figure 2.3 Selection of BDCA-1+ myeloid DC by microbeads  
BDCA-1+  myeloid DC were isolated by MACS myeloid DC isolation kit as 
described in the text, and purity checked by flow cytometry with staining for BDCA-
1, CD14 and CD19. Scatter plots show distinctive intermediate forward scatter (FS) 
and side scatter (SS) when compared to monocytes or lymphocytes. CD19+ B cells 
(including those expressing BDCA-1) are successfully depleted, enabling enrichment 
of the BDCA-1+ CD19- myeloid DC to 80% purity.  
 
Chapter Two Materials and Methods 75 
2.3.4 Purification of naive (CD45RA+) CD4+ T cells, memory (CD45RO+) 
CD4+ T cells and CD8+ T cells 
 
Naive and memory CD4+ and CD8+ T cell subsets were isolated using MACS 
Isolations kits. This involved the depletion of non-CD4+ cells and memory T cells 
(for purification of naive CD4+ T cells), the depletion of non-CD4+ cells and naive T 
cells (for purification of memory CD4+ T cells) or the depletion of all non-CD8+ T 
cells (for purification of CD8+ T cells). In the CD4+ T cell isolation kits antibiotin-
microbeads are used after first labelling the PBMC fraction with a cocktail of biotin-
conjugated antibodies against CD8, CD14,CD16, CD36, CD56, CD123, TCRγδ, 
glycophorin A and either CD45RO (if isolating naive CD4+ T cells) or CD45RA (if 
isolating memory CD4+ T cells). The CD8+ T cell isolation kit is identical but 
comprises a cocktail of biotin-conjugated antibodies against CD4, CD15, CD16, 
CD19, CD34, CD36, CD56, CD123, TCRγδ, and glycophorin A. 
 
PBMC were incubated for 10mins at 4°C with 10µl biotin-antibody cocktail/10
7
 cells 
and 40μl MACS buffer /107 cells. A further 30µl MACS buffer/107 cells and 20μl 
anti-biotin microbeads /10
7
 cells were then added. The cells were then washed once 
with MACS buffer (centrifugation of 300g, 4°C , 8 mins), the supernatant pipetted off 
to a dry pellet, and cells resuspended in 500μl MACS buffer/108 cells before being 
passed over a prepared LS MACS separation column placed on a QuadroMACS 
separator magnet. The negative fraction (containing the population of interest) was 
eluted with a series of three x 3ml MACS buffer washes.  
 
The yield of CD4+ or CD8+T cells was calculated by use of the haemocytometer. The 
range of yield was 2 x 10
5
 – 4 x 105 per ml of peripheral blood for naive CD4+ T 
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cells, 5 x 10
4
 – 2 x 105 per ml of peripheral blood for memory CD4+ T cells and 5 x 
10
4
 – 5 x 105 per ml of peripheral blood for CD8+ T cells. These populations were 
enriched with purity of >90% as determined on flow cytometry by percentage of cells 
being CD4+ CD45RA+ (for naive CD4+ T cells) and CD4+CD45RO+ (for memory 
CD4+ T cells). For both the naive and memory CD4+ populations, the contaminating 
population (comprising 3-6%) were CD4- cells, and were distributed evenly between 
positive and negative fractions with regard to the CD45 splice variant of interest. For 
CD8+ T cells purity was >80% (Figure 2.4). 
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Figure 2.4 Selection of T cell subsets by microbeads  
Naive CD4+, memory CD4+ and CD8+ T cell subsets were isolated by MACS 
isolation kits as described in the text. Purity was checked by flow cytometry with 
staining for (A) CD4 and CD45RA, (B) CD4 and CD45RO or (C) CD8 as 
appropriate. Untouched naive CD4+ and memory CD4+ T cells could be isolated to 
>94% purity; untouched CD8+ T cells could be isolated to >80% purity).  
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2.4 Cell culture 
2.4.1 Standard culture conditions 
Human monocyte-derived DC were generated using well-established 
protocols(Sallusto and Lanzavecchia, 1994) . The standard culture conditions are 
described below. Variations from this protocol necessitated by experimental design 
are indicated in the text. Monocytes were resuspended in RPMI/10% pooled human 
AB+male serum (10%HS; HD Supplies, Aylesbury, UK) at 2ml medium/10
6
 cells 
supplemented with recombinant human IL-4 (500U/ml) and GM-CSF 
(1000U/ml)(both Immunotools, Friesoythe, Germany). These suspensions were 
placed in T25 flasks (Sarstedt, Leicester, UK) at 2.5 x 10
6
 cells/flask and cultured at 
37°C with 5% CO2.  At day 3, 2ml medium was removed and 2.5ml fresh medium (ie 
RPMI/10%HS) with IL-4 (final concentration 500U/ml) and GM-CSF (final 
concentration 1000U/ml) was added. At day 6 immature DC (iDC) were harvested by 
shaking the flask gently and collecting (and counting) non-adherent cells.  
 
2.4.2 Pooled human serum vs serum-free culture conditions 
 
To test the effect of alternative serum-free media on the differentiation and activation 
of DC the following serum-free media were used: RPMI/ITS+3, 
RPMI/ITS+3/NEAA/Na pyruvate, RPMI/1%BSA. These were compared to standard 
RPMI/10% pooled human serum. 
Cultures were carried out in 96 well flat-bottomed plates (Sarstedt) with initial counts 
of 50,000 cells in 100μl medium supplemented with IL-4 and GM-CSF (at standard 
concentration) per well  at 37°C with 5% CO2. At day 3, 25μl medium was removed 
and 50μl fresh medium with IL-4 and GM-CSF (standard concentrations) was added. 
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At day 6 immature DC (iDC) were harvested, and both number and surface 
expression of  HLA-DR, CD80 and CD86 were measured by flow cytometry. 
 
2.4.3 Pooled human serum vs alternative sera culture conditions 
 
To test the effect of alternative serum-free media on the differentiation and activation 
of DC the following media were used: RPMI/10%HS, RPMI/10% heat inactivated 
pooled human serum (HIHS), RPMI/10% fetal calf serum (FCS) and RPMI/10% heat 
inactivated fetal calf serum (HIFCS). Heat inactivation comprised being heated to 
56°C for 1 hour in a water bath. 
Cultures were carried out in 96 well flat-bottomed plates with initial counts of 50,000 
cells in 100μl medium supplemented with IL-4 and GM-CSF (at standard 
concentration) per well  at 37°C with 5% CO2. At day 3, 25μl medium was removed 
and 50μl fresh medium with IL-4 and GM-CSF (standard concentrations) was added. 
At day 6 immature DC (iDC) were harvested, and both number and surface 
expression of  HLADR, CD80 and CD86 were measured by flow cytometry. 
 
2.4.4 Pooled human serum vs autologous human serum culture conditions 
 
Cultures were carried out under standard conditions but with the addition of RPMI 
supplemented with either 10% pooled human serum or autologous serum 
supplemented with IL-4 and GM-CSF (standard concentrations). Cultures were 
carried out in T25 flasks, fed at day 3 and harvested at day 6 as per standard. 
Autologous serum was prepared by placing 10ml heparinised blood on ice for 10mins, 
before centrifuging at 500g, 4°C, 10mins and keeping the supernatant. Surface 
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expression of  HLADR, CD80 and CD86 was analysed as previously by flow 
cytometry. 
 
2.5 DC maturation 
 
Immature DC were cultured for a further 2d, under serum-free conditions, to induce 
maturation and/or modulation of their function. The standard culture conditions are 
described below. Any variations from this protocol necessitated by experimental 
design are indicated in the text. 
 
2.5.1 Standard maturation conditions 
 
At day 6 harvested DC were resuspended at 10
6
/ml in serum-free medium 
(RPMI/ITS+3/NEAA/Na pyruvate), and 500μl of DC suspension were added to each 
well of a 24 well plate (Sarstedt). To these wells were added either 500μl of the same 
serum-free medium alone or 500μl of a cocktail of the following inflammatory 
cytokines: IL-1β (final concentration 1μg/ml; Peprotech, London, UK), IL-6 (final 
concentration 200ng/ml; Immunotools), TNFα (final concentration 10ng/ml; 
Peprotech) and PGE2 (final concentration 1μg/ml; Sigma-Aldrich). 
 
2.5.2 Studies on the effect of non-inflammatory AqH 
 
Since the volume of individual samples of AqH is a limiting factor, these experiments 
were carried out in smaller total volumes (80μl/well). Cultures of DC (monocyte-
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derived or myeloid) were carried out in two matched 96 well round-bottomed plates 
(Greiner). After 2d plate 1 was harvested for analysis of surface molecule expression 
by flow cytometry, whilst plate 2 was used for the allogeneic proliferation assays. 
Experiments investigating the effects of non-inflammatory AqH were conducted 
using pooled samples of non-inflammatory AqH unless otherwise specified in the 
text. It was felt that under non-inflammatory conditions the properties of AqH from 
healthy individuals were likely to show sufficiently little variation, that pooling AqH 
would not mask its effects. In addition pooling of AqH was necessary to provide 
sufficient identical AqH within a single experiment to permit two plates (one for 
surface staining and one for allogeneic proliferation assay) of triplicate cultures of DC 
in the presence or absence of inflammatory cytokines with or without glucocorticoid 
blockade (or combined glucocorticoid and TGFβ blockade), an experimental design 
which requires 1920µl human AqH per experiment pooled from around 40 patients.  
 
At day 6 DC cultured under standard conditions were harvested, counted (by 
haemocytometer) and resuspended at 5x10
5 
cells/ml in serum-free medium 
(RPMI/ITS+3/NEAA/Na pyruvate). 20µl of DC suspension (ie 10
4
 cells) was added 
to each well of a 96 well plate (Greiner) with 20µl of medium or 20µl cytokine 
cocktail described previously:  IL-1β (final concentration 1μg/ml; Peprotech), IL-6 
(final concentration 200ng/ml; Immunotools), TNFα (final concentration 10ng/ml; 
Peprotech) and PGE2 (final concentration 1μg/ml; Sigma-Aldrich). AqH was added at 
50% final concentration (ie 40µl per well) in all experiments. Plates were cultured for 
2d at 37°C with 5% CO2. 
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2.5.3 Studies on the effect of uveitis AqH 
 
For experiments involving uveitis AqH, I opted not to pool specimens as I was 
concerned that the wide variation of clinical disease might be reflected in a diversity 
of properties of AqH which would be obscured if pooled.  In these experiments 
comparison is therefore between the effects of medium alone, individual uveitis AqH 
samples and individual non-inflammatory AqH samples; each AqH group comprised 
at least six individual samples. Due to the volumes of AqH available this meant that 
each sample could only be tested once (ie replicates were not possible). For studies of 
surface molecule staining these cultures were carried out as described previously but 
using Terasaki plates (vWR International, Lutterworth, UK) in a total volume of 20µl. 
For allogeneic proliferation assays, DC were cultured in  96 well plates (Greiner) as 
described previously.  
 
2.5.4 Studies on the effect of TGFβ and its inhibition 
 
To compare the effects of TGFβ isoforms, 20µl of DC suspension (as above, ie 104 
cells) was added to each well of a 96 well plate (Greiner) with 20µl of medium or 
20µl inflammatory cytokine cocktail as described previously. TGFβ isoforms were 
then added at a final concentration of 10ng/ml. TGFβ1 (R & D systems, UK), TGFβ2 
(Peprotech) and TGFβ3 (R+D sytems) were compared. All experiments were carried 
out  in a total volume of 80µl serum-free medium (RPMI/ITS+3/NEAA/Na pyruvate) 
and at 37°C with 5% CO2.  
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To investigate the dose-response effect of TGFβ2, experiments were carried out as 
above but with TGFβ2 being added at a final concentration of 0.1, 1, 10 or 100ng/ml. 
 
Inhibition of TGFβ  was achieved with the synthetic molecule SB431542 which is a 
potent and selective inhibitor of TGFβ receptor type I kinases, specifically the Activin 
receptor-Like Kinases (ALK) -4, -5 and -7 which signal via phosphorylation of the 
transcription factors Smad-2 and Smad-3. In all experiments requiring TGFβ 
blockade, SB431542 was added at a final concentration of 10
-7
M. 
 
2.5.5 Studies on the effect of cortisol  and its inhibition 
 
To study the effect of cortisol, 20µl of DC suspension (as above, ie 10
4
 cells) was 
added to each well of a 96 well plate (Greiner) with either 20µl of medium or 20µl 
inflammatory cytokine cocktail as described previously. Cortisol was then added at a 
final concentration 10
-9
, 10
-8
, 10
-7
, 10
-6
 and 10
-5
M.  All experiments were carried out  
in a total volume of 80µl serum-free medium (RPMI/ITS+3/NEAA/Na pyruvate) at 
37°C with 5% CO2.  
 
Inhibition of cortisol or other glucocorticoids (eg dexamethasone)  was achieved with 
the synthetic molecule RU486 (also known as mifepristone) which is a potent  
inhibitor of both the glucocorticoid receptor and the progesterone receptor. In all 
experiments requiring glucocorticoid blockade RU486 was added at a final 
concentration of 10
-7
M. 
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2.6 Transmigration studies 
 
Ninety-six well transmigration plates (Millipore (UK), Watford, UK) were used to 
determine DC migration to the chemokines CCL-19 (MIP-3β) and CCL5 (RANTES).  
Monocyte-derived DC were harvested at day 6 and placed into fresh serum-free 
medium culture for 48h under the conditions of interest (as described previously), but 
at a higher cell density of 8x10
4
cells/80µl medium  in each well. After 48h DC were 
harvested, washed and resuspended in fresh serum-free medium at 8x10
4
 cells/200µl. 
150µl of  serum-free medium containing  0, 1, 10 or 100ng/ml of either CCL-19 
(MIP-3β) and CCL5 (RANTES) was placed into the lower chambers of the 96 well 
transmigration plate. DC were placed in the top wells at 2x10
4
 cells in 50µl of serum-
free medium., and the plate was incubated at 37ºC for 3h. The plate was then 
disassembled and the cells in each chamber harvested and added to FACS tubes 
containing 195µl of PBS/2%BSA and 5µl of counting beads, and counted by flow 
cytometry. 
 
2.7 Carboxyfluorescein diacetate, sucinnimidyl ester (CFSE) labelling of 
T cells 
 
The population of interest (either naive CD4+ T cells, memory CD4+ T cells or CD8+ 
T cells) was labelled with carboxyfluorescein diacetate, sucinnimidyl ester (CFSE; 
Invitrogen) as follows. The cells were kept in a universal tube and were washed twice 
with 10ml sterile PBS, before being resuspended in PBS at 50ul/10
6
 cells. 2.5µl of 
10M CFSE was added to 5ml of sterile PBS to give a 5uM solution. This was added 
at a 1:1 ratio to the cell suspension to give a final CFSE concentration of 2.5uM, and 
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incubated for 10min at room temperature with periodic shaking. At 10mins an equal 
volume of RPMI/10%HIFCS was added. After 1further minute the cells were washed 
once with PBS once and twice with RPMI/10%HIFCS. The cells were resuspended in 
RPMI/10%HIFCS at 10
6
/ml and incubated overnight in a 24 well plate at 2ml/well. 
 
2.8 Allogeneic proliferation assay 
 
At day 8 of DC culture the CFSE labelled naïve CD4+ T cells were harvested, and 
washed twice in RPMI/10%HIFCS. They were counted by haemocytometer, and 
resuspended in RPMI/10%HIFCS at 10
6
/ml. 
 
One of the 96 well plates containing the DC cultures was spun down (300g, 4mins, 
21°C) and washed with 100µl RPMI/10%HIFCS three times under tissue culture 
conditions. This was achieved by performing the washes in the hood including 
flicking off the supernatant onto paper towels, and lightly dabbing the plate on further 
IMS-soaked paper towels. The DC were then resuspended in 100µl of 
RPMI/10%HIFCS and 100µl of the naïve CD4+ T cell suspension was added ie 10
5
 
CD4+ T cells/well. Three wells containing T cells alone (10
5
 in 200µl 
RPMI/10%HIFCS) were also set up. At day 4 of proliferation assay the cells were 
harvested and proliferation was measured by flow cytometry.  
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2.9 Multiplex bead immunoassay 
 
Culture supernatants which had been stored at -80ºC were analysed by multiplex bead 
immunoassay (Luminex), a technique which permits the analysis of up to 100 
analytes in a single sample of 50μl. I used a Human Cytokine 25-plex Antibody Kit  
(Biosource, Nivelles, Belgium) which assays the following analytes: IL-1β, IL-1RA, 
IL-2, IL-2R, IL-4, IL-5, IL-6, IL-7, IL-8, IL-10, IL-12, IL-13, IL-15, IL-17, TNFα, 
IFNα, IFNγ, GM-CSF, CCL2 (MCP-1), CCL3(MIP-1α), CCL4 (MIP-1β), CCL5 
(RANTES), CXCL9 (MIG), CXCL10 (IP-10) and  Eotaxin. 
The following solutions were prepared: wash solution (PBS/0.05% Tween 20), assay 
buffer (PBS/0.05% Tween 20/1%BSA), standard solution (lyophilised concentrate 
rehydrated with assay buffer as per data sheet), bead solution (vortex and sonicate, 
dilute tenfold in assay buffer, protect from light), biotinylated detector antibody 
solution (vortex, tenfold dilution in assay buffer), streptavidin-RPE solution (vortex, 
tenfold dilution in assay buffer). The standard curve, blanks and samples were all 
initially prepared in a 96 well flexiplate to allow rapid transfer to the luminex plate. 
100µl of standard solution was placed in the first well of the standard curve and 75µl 
of assay buffer in wells 2 – 10. Serial transfer of 25µl from wells 1 – 8 gave the 1 in 4 
dilutions of the standard curve. Wells 9 and 10 were left with assay buffer only as 
“blanks”. The samples were placed in wells 11 onwards.  
 
The luminex filter plate was hydrated with wash solution 200ul/well and allowed to 
stand for a minimum of 30s, before aspirating via the vacuum manifold. 25µl bead 
solution was added to each well followed by 200µl wash solution. After 30s this was 
aspirated using the vacuum manifold. 25µl of assay buffer was then added to each 
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well prior to transferring 50µl from each well of the 96 well flexiplate to its 
corresponding well in the luminex plate. The plate was sealed and incubated for 2 
hours on an orbital shaker.  
 
The fluid was then aspirated via the vacuum manifold and washed twice by adding 
200µl wash buffer and again aspirating via the vacuum manifold. 100µl of 
biotinylated detector antibody was added to each well, the plate sealed and incubated 
for a further 1 hour on the orbital shaker. The fluid was then aspirated via the vacuum 
manifold and washed twice by adding 200µl wash buffer and again aspirating via the 
vacuum manifold. 100µl of streptavidin-RPE solution was added to each well. The 
plate was sealed and incubated for 30mins on an orbital shaker. The fluid was then 
aspirated via the vacuum manifold and washed three times by adding 200µl wash 
buffer and again aspirating via the vacuum manifold. The wells were then 
resuspended in 100µl of assay buffer and run on the luminometer (Luminex). 
  
Analysis was performed using StarStation 2 software (Applied Cytometry Systems, 
Sheffield, UK). The standard curve was adjusted to be five parameter weighted with 
the reciprocal of y fit. Upper and lower limits of sensitivity were defined by excluding 
any regions where the curve plateaued.  
 
2.10 Cortisol Enzyme-linked Immunosorbant Assay 
 
A high sensitivity cortisol acetylcholinesterase competitive EIA assay (Cayman,  US) 
was used to determine the concentration of free cortisol in human AqH and serum. 
EIA buffer, wash buffer, standard, cortisol tracer and cortisol antiserum were prepared 
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as per manufacturer‟s instructions. Human AqH was diluted 25-fold prior to testing. 
50µl aliquots of the following were added to the plate: the standard curve comprising 
standard and seven serial 1 in 2 dilutions, and the samples. Additional wells comprise 
a Blank well (Blk), Total Activity (TA) well, Non-Specific Binding (NSB) well, and 
Maximum Binding well (B0). 50µl of cortisol tracer was then added to all wells 
except the Total Activity and Blank wells, and 50µl of cortisol antiserum was added 
to all wells except Total Activity, Non-Specific Binding and Blank wells. The plate 
was the covered and incubated for 12-18h  at 4ºC. The plate was then washed five 
times with wash buffer before adding 200µl of Ellman‟s reagent (reconstituted on the 
day as per manufacturer‟s instructions) to all wells and 5µl of cortisol tracer to the 
Total Activity well. The plate was again covered and put on an orbital shaker for 120-
240mins before being read with a multiwall plate reader (Anthos HT III, Anthos 
labtec Instruments, Salzburg, Austria). 
 
As the ELISA is a competitive assay, absorbance values are proportional to 
concentration of competitive bound cortisol tracer (and inversely proportional to 
concentration of cortisol). Standard curves were plotted using a 4-parameter logistic 
equation fitted to the logarithmic transformation of the standard concentrations vs the 
percentage cortisol bound. 
 
2.11 Flow cytometry 
 
All flow cytometry was performed using either a Beckman Coulter Epics XL bench-
top flow cytometer (Beckman Coulter Inc, Fullerton, CA) or a Dako Cyan ADP High 
Performance flow cytometer (Dako, Colorado, US). Calibration was checked on a 
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daily basis with Flow Check Fluorospheres (Beckman Coulter Inc). Isotype controls 
were used to determine the level of background non-specific binding. For all multi-
colour cytometry compensation was performed using cells stained with each 
fluorochrome conjugated-antibody singly. This adjusts for false positives arising from 
detection of other fluorochromes due to spectral overlap. The level of median 
fluorescence intensity (MFI) was used to distinguish between high and low levels of 
expression. 
 
2.11.1 Analysis of DC differentiation  
 
At day 6 of DC differentiation the plate was centrifuged (300g, 4mins, 4°C), 
supernatant discarded and the plate was lightly vortexed. The cells were then labelled 
with anti-HLA-DR FITC, -CD80 PE and –CD86 PECy5 (or the matched irrelevants) 
made up to optimal concentrations in PBS/2%BSA and to a total volume of 50μl/well 
(see table 2.1).  They were then incubated for 20mins at 4°C. 
 
The cells were then washed with 100µl PBS/2%BSA, centrifuged at 300g, 4mins, 
4°C, the supernatant discarded and cells resuspended in 100μl PBS/2%BSA. The cell 
suspension was then transferred to flow cytometry tubes containing 180µl 
PBS/2%BSA and 20μl counting beads (CALTAG/Invitrogen, Paisley, UK). Flow 
cytometry was performed on the Beckman Coulter Epics XL bench-top flow 
cytometer. 
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2.11.2 Analysis of DC maturation 
 
 After 2d culture the 96 well plate containing the DC cultures for surface staining (ie 
plate 1)  was spun down (300g, 4mins, 4°C) and the supernatants removed and kept 
(frozen down at -80°C). The plate was then spun down again, any remaining 
supernatant discarded and the cells labelled as described earlier. Unless otherwise 
specified in the text, the standard panel was anti-CCR7 FITC, HLA-DR PE, CD86 
PECy5, CCR5 PECy7 and  MHCI PB. After 20mins at 4º the cells were washed with 
100μl PBS/2%BSA (300g, 4mins, 4°C), the supernatant discarded and cells 
resuspended in 100μl PBS/2%BSA. The cell suspension was then transferred to flow 
cytometry tubes containing 180μl PBS/2%BSA and 20μl counting beads and 100μl of 
40μg/ml propidium iodide (Sigma-Aldrich) which acts as a dead cell exclusion dye. 
Flow cytometry was performed on the Dako Cyan ADP High Performance flow 
cytometer (Dako Colorado). 
 
2.11.3 Analysis of  T cell proliferation 
 
After 4 days of culture the 96 well plate of DC: T cell cocultures was centrifuged 
(300g, 4mins, 21°C) and 100μl supernatant harvested and kept (frozen down at -
80°C). The cells were then spun down again, any remaining supernatant discarded 
and the cells were resuspended in 100μl PBS/2%BSA before being transferred to flow 
cytometry tubes containing 180μl PBS/2%BSA, 20μl counting beads and 100μl 
propidium iodide (Sigma-Aldrich) which acts as a dead cell exclusion dye. Flow 
cytometry was performed on the Dako Cyan ADP High Performance flow cytometer 
(Dako Colorado). When only part of the sample is run the actual numbers of cells in 
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the original sample can be calculated from the number of counting beads counted 
using the following equation:  
Total live cells = total PI negative cells counted/(total beads counted/total beads 
added).  
Undivided cells have the highest concentration of CFSE (and therefore highest signal) 
and this halves with successive generations of proliferated cells. The number of 
proliferated cells can therefore be calculated from the percentage of live cells to the 
left of the first peak (ie of highest signal). 
 
2.11.4 Analysis of FoxP3 expression of CD4+ T cells 
 
To assess FoxP3 expression in dividing cells, intracellular staining was performed as 
follows. At day 4 (or timepoint specified in the text) DC:T cell co-cultures were 
harvested, and each well divided in two to enable comparison of FoxP3 staining vs 
isotype for each well.  Cells were washed twice in 100µl PBS/0.5%BSA (300g, 4ºC) 
before being resuspended in 100µl of fix buffer (eBioscience; made up as per 
manufacturer‟s instructions) and incubated for 30mins at 4ºC. The plate was then 
washed once in 150µl PBS/0.5%BSA and twice in 150µl permeabilisation buffer 
(eBioscience; made up as per manufacturer‟s instructions).  1µ rat serum and 30µl of 
permeabilisation buffer was then added to each well and the plate was incubated for 
15mins at 4ºC. Anti-human FoxP3 antibody (or isotype control) was then added  to 
each well and the plate was incubated for a further 30 mins at 4ºC. After two further 
washes in 150µl permeabilisation buffer, the cells were resuspended in 100µl 
PBS/0.5%BSA, and transferred to FACS tubes containing 140µl PBS/0.5%BSA and 
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10µl counting beads. Flow cytometry was performed as previously with the important 
exception that propidium iodide was not used concurrently. 
 
 
2.12 Statistical tests 
 
The Kolmogorov-Smirnov test was used to test for normality of distribution. For 
normally distributed data, parametric tests were used as follows: Student‟s t-test 
(paired or nonpaired as appropriate) to determine significant differences between two 
conditions and one-way ANOVA for comparison of three or more conditions with 
Bonferroni‟s post hoc test for selected conditions. For non-normally distributed data, 
nonparametric tests were used: Mann−Whitney U test to determine significant 
differences between nonpaired groups, Wilcoxon−matched pairs analysis for paired 
samples and Kruskal-Wallis for comparison of three or more conditions with Dunn‟s 
post-hoc test for selected conditions. Correlation was tested by use of the Pearson 
correlation coefficient (for normal data) or the Spearman rank test (for non-normal 
data). The minimal level of confidence at which the results were judged significant 
was p < 0.05. 
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3 THE DEVELOPMENT OF AN IN VITRO MODEL TO 
STUDY DENDRITIC CELL FUNCTION IN THE 
OCULAR MICROENVIRONMENT 
 
3.1 Introduction 
 
In vivo, the anterior segment of the eye is a unique physiological niche in which 
tightly- regulated homeostatic and immunological mechanisms minimise the 
perturbations in the ocular microenvironment. Under resting non-inflammatory 
conditions, the blood-ocular barrier ensures that the aqueous humour which bathes the 
tissues of the ocular anterior segment is a distinctive serum-free environment. During 
uveitis, blood-ocular barrier break-down and local generation of inflammatory 
mediators cause significant changes in this environment with elevations in a number 
of key inflammatory cytokines such as IL-6, IL-8, CCL2 (MCP-1), and IFNγ 
accompanied by a fall in the regulatory molecule, TGFβ2 (Curnow et al., 2005). 
Dendritic cells present in the anterior segment of the eye have been difficult to 
characterise but appear to have a distinct, immature phenotype, possibly reflecting 
their exposure to this unique immunosuppressive environment (Forrester et al., 1994; 
Camelo et al., 2003; Chang et al., 2004). 
 
The aim of this body of work was to establish an in vitro model of ocular dendritic 
cell function in which human DC could be cultured and exposed to AqH or its 
constituents under serum-free conditions. Achieving this would require: (1) 
generating pure populations of homogeneous human dendritic cells either by 
differentiation from precursors, or by direct isolation; (2) establishing a serum-free 
environment in which the effects of AqH could be studied; (3) ensuring that the 
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dendritic cells would tolerate these serum-free conditions and function normally in 
terms of cytokine production, chemotaxis and induction of T cell responses.  
 
Monocyte-derived dendritic cells are the most widely studied in vitro model of human 
DC function, having the advantages over direct isolation of myeloid DC of being (1) 
reasonably abundant (ie easily generated from circulating monocytes which comprise 
around 10% of peripheral blood mononuclear cells),  (2) available at high purity and 
(3) of known experience (ie naive). In vitro generation of monocyte-derived dendritic 
cells is commonly carried out in serum-supplemented media (Jeras et al., 2005a) . Our 
group has  previously used 10% pooled human AB+ male serum supplementation of 
RPMI as standard for all our DC cultures, but I wished to investigate whether I could 
generate DC under serum-free conditions (as reported elsewhere (Bender et al., 1996; 
Royer et al., 2006)) and whether supplementation with other types of sera, notably 
Fetal Calf Serum (FCS) – which is often used as standard by other investigators 
(Sallusto and Lanzavecchia, 1994; Jeras et al., 2005b) – would alter DC 
differentiation and activation. Serum-free differentiation of monocyte-derived DC has 
received increasing attention mainly due to the use of these DC in clinical trials 
(Cerundolo et al., 2004).  
 
One of the conditions of my proposed  in vitro model of ocular dendritic cell function, 
was that the effects of AqH on DC should be studied under serum-free conditions, 
primarily so as to better reflect the environment of the anterior segment and 
secondarily to avoid the effects of AqH being obscured by the effects of serum. It was 
therefore important to characterise the behaviour of DC on being transferred to a 
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serum-free environment and to ensure that they demonstrated normal DC function 
under these conditions. 
  
The culture of cells in human AqH in vitro raises a number of challenges of 
miniaturisation. Even when used at 50% rather than 100% the volumes of AqH that 
can be safely obtained (usually 50 – 100μl) place severe constraints on the total 
volume (and therefore the number of cells) that can be used in each culture. It was 
therefore necessary to establish whether DC could still undergo normal maturation in 
total culture volumes of 100μl. It was also important to characterise the baseline 
phenotype of these DC in some detail (surface molecules, cytokine production, 
migration, induction of T cell responses)  before moving on to consider the effects of 
aqueous humour.  
 
More recently it has become possible to isolate and study in vitro significant numbers 
of circulating myeloid dendritic cells. Although there are still a number of 
disadvantages to their use, notably lower yields and lower purities than with 
monocyte-derived DC, myeloid DC are of interest as being a true ex vivo DC, which 
avoids the criticism levelled at the monocyte-derived DC that it is an in vitro 
generated cell type which happens to resemble the paradigm of DC behaviour. I 
therefore investigated the phenotype and function of myeloid DC as compared to 
monocyte-derived DC  in my in vitro model of dendritic cell maturation. 
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3.2 The role of serum on the differentiation of monocyte derived 
dendritic cells in vitro 
 
As outlined above monocyte-derived DC are most commonly differentiated in FCS 
(Sallusto and Lanzavecchia, 1994; Jeras et al., 2005b), but emerging DC-based 
immunotherapies have led to interest in the generation of DC under serum-free 
conditions. Additionally whilst FCS is reported to provide good yields of monocyte-
derived DC, it is likely that it is a less good model than human serum (HS) of the 
environment in which human DC differentiate in vivo. I therefore investigated the role 
of serum-supplementation and its alternatives in the differentiation of monocyte-
derived dendritic cells in vitro. 
 
3.2.1 Differentiation in serum-supplemented rather than serum-free medium 
improves yield and dendritic cell profile 
 
In order to determine whether DC differentiation could be supported in the absence of 
serum, CD14+ bead-purified monocytes from healthy volunteers were cultured in 96 
well plates in either standard conditions (RPMI/10% HS) or a serum-free alternative: 
(1) RPMI with 1% ITS+3, (2) RPMI with 1% ITS+3, 1% NEAA and 1% Na 
pyruvate, or (3) RPMI with 1%BSA. After six days of culture, cells were harvested, 
and cell number and surface expression of class II MHC (specifically HLA-DR) and 
the key costimulatory molecules CD80 and CD86 were measured by flow cytometry. 
 
The number of DC harvested per culture was lower in all serum-free conditions than 
standard RPMI/10% human serum (Figure 3.1A,B). Compared to the low yield with 
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RPMI/ITS+3 or RPMI/1%BSA, mean cell recovery was two-fold higher with 
RPMI/ITS+3/NEAA/Na pyruvate and four-fold higher with RPMI/10% human 
serum.  DC cultured in serum-free conditions were more heterogeneous and had 
significantly lower expression of HLA-DR and CD86 than DC cultured under 
standard conditions (Figure 3.1A,C).  
 
3.2.2  Differentiation of dendritic cells is affected by serum type (human or 
fetal calf serum) with reciprocal changes in CD80 and CD86 
 
Having established that serum-supplementation during differentiation improved the 
yield and profile of the DC generated, I compared the effect of standard pooled 
human serum (HS) with fetal calf serum (FCS), heat-inactivated HS (HIHS), or heat-
inactivated FCS (HIFCS) under the same culture conditions. Yield of DC at day 6 was 
comparable in all serum-supplemented conditions. There was a trend towards a higher 
cell recovery with FCS, but this was not statistically significant (Figure 3.2).  
 
DC cultured in any of the four serum-supplemented media had comparable expression 
of  HLADR, but differed significantly in terms of the level of costimulatory molecules 
(Figure 3.2B) . Supplementation with FCS or HIFCS resulted in significantly higher 
expression of CD80 with an MFI that was higher than with HS supplementation by a 
factor of 3.1 and 2.6 respectively. Conversely supplementation with FCS or HIFCS 
resulted in significantly lower expression of CD86 with an MFI that was four-fold 
lower than with HS supplementation. Heat inactivation of the serum, whether for HS 
or FCS, did not significantly alter HLA-DR, CD80 or CD86. 
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The reciprocal effects of HS and FCS on CD80 and CD86 were then investigated by 
culturing DC in varying concentrations of each serum individually and in combination 
(Figure 3.3). FCS induced CD80 to near maximal levels (twice baseline levels) from 
2.5% FCS supplementation, but was completely suppressed by the presence of even 
low levels of human serum (2.5%). Conversely CD86 expression was near maximal 
from 2.5% HS supplementation upwards, but was only partially suppressed by 
increasing concentrations of FCS (cf titration curve of HS alone). 
 
3.2.3  Dendritic cell differentiation in human serum is not affected by the 
serum being autologous or pooled 
 
Subsequently it was considered whether the donor-to-donor variation in yield and 
differentiation which occurs even under standard conditions might be partly due to 
individual “compatibility” with the pooled human serum. I hypothesized that the use 
of autologous human serum might therefore lead to more consistent results. In these 
experiments DC were cultured under standard conditions in T25 flasks with media 
supplemented with either autologous or pooled human serum (Figure 3.4). 
  
The use of autologous vs standard pooled HS did not affect DC cultures in terms of 
yield or levels of  HLA-DR, CD80 or CD86 (Figure 3.4). DC yields were 26 +14 % 
for autologous and 23 +13% (mean +SD) for standard pooled serum conditions.  
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3.3 The effect of inflammatory cytokines on the maturation of 
monocyte-derived dendritic cells in vitro 
The previous experiments established (1) the suitability of pooled human serum for 
the differentiation of DC from monocytes in my model system, and (2) the potential 
advantages over serum-free or FCS based media.  The subsequent experiments were 
directed towards establishing a successful in vitro model of DC maturation. To 
establish a model in which the putative effects of AqH on DC maturation could be 
investigated, it was important to first assess whether normal DC maturation could 
occur under serum-free conditions. In vivo, dendritic cell maturation may be driven by 
the milieu of inflammatory cytokines and/or by TLR stimulation (Reis e Sousa 2004). 
I had previously observed that under standard serum-supplemented conditions 
cytokine-driven maturation of DC was  more effective than TLR stimulation alone, as 
measured by upregulation of HLA-DR, CD80, CD83, CD86 and CCR7 (Curnow 
personal communication). 
 
 Monocyte-derived DC which had differentiated under standard serum-supplemented 
conditions until day 6, were washed and then cultured for a further 48h with or 
without inflammatory cytokines (IL-1β, IL-6, TNFα, PGE2)  under either serum-
supplemented (RPMI/10%HS) or serum-free (RPMI/1%ITS+3/1%NEAA/1%Na 
pyruvate) conditions (Figure 3.5). Serum supplementation was associated with higher 
yields of dendritic cells under non-inflammatory conditions with a 1.6 fold increase in 
cell recovery for iDC (p < 0.01). Under both serum-free and serum-supplemented 
conditions, the pro-inflammatory cytokines caused similar DC maturation in terms of 
upregulation of HLA-DR, CD80 and CD86. The absence of serum was not associated  
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with any significant difference in the levels of CD80 or CD86, but was associated 
with 20-30% higher levels of HLA-DR.  
 
3.3.1 Inflammatory cytokines can induce a surface phenotype characteristic of 
dendritic cell maturation under serum-free conditions 
 
Having established that under my defined serum-free conditions, monocyte-derived 
DC could respond appropriately to an inflammatory stimulus by upregulating 
HLADR, CD80 and CD86, these „serum-free‟ immature DC (iDC) and mature DC 
(mDC) were analysed in more detail  in terms of their surface phenotype and function. 
In addition to the  upregulation of class II MHC, and the costimulatory molecules 
CD80 and CD86,  the pro-inflammatory cytokine cocktail caused upregulation of 
CD40, and of the accessory costimulatory molecule ICOSL, but not of the accessory 
molecule 4-1BBL; there was also reciprocal downregulation of CCR5 and 
upregulation of CCR7 consistent with the published literature (Figure 3.6)(Greenwald 
et al., 2005; Scandella et al., 2002). 
 
3.3.2 DC maturation under serum-free conditions alters DC chemotactic 
function 
 
In order to test whether this characteristic change in surface phenotype towards a 
mature DC phenotype was accompanied by a change in DC behaviour, DC function 
was tested in three key areas: migration to chemokines, cytokine production and 
induction of T cell proliferation. 
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Ninety-six well plates with transwell inserts were used to assess DC migration to a 
range of concentrations of either CCL5 (RANTES; ligand for CCR5 expressed on 
iDC) or CCL19 (ligand for CCR7 expressed on mDC). Monocyte-derived dendritic 
cells which had differentiated under standard serum-supplemented conditions until 
day 6, were washed and then cultured for a further 48h with or without inflammatory 
cytokines (IL-1β, IL-6, TNFα, PGE2)  under serum-free conditions 
(RPMI/1%ITS+3/1%NEAA/1%Na pyruvate). They were then harvested and placed in 
fresh serum-free medium in the top chambers of the 96-well insert, with serum-free 
medium or 1 -100ng/ml chemokine placed in the bottom chamber. After three hours 
of culture both chambers were harvested and cell number was counted by flow 
cytometry (Figure 3.7). iDC showed directional responses to CCL5 (18% 
transmigration to 100ng/ml vs 1.5% baseline) but not to CCL19, consistent with their 
high expression of CCR5 and low CCR7. In contrast, mDC had high levels of 
transmigration to CCL19 (77% to 100ng/ml CCL19 vs 11% baseline), consistent with 
their high CCR7 and low CCR5 status.  In preliminary experiments DC migration was 
also tested using twenty-four well transwell plates and modified Dunn chambers but 
these had poor intra-experimental reproducibility when using the low DC numbers 
required for proposed AqH-culture experiments, and so were discarded in favour of 
the 96 well transwell plates.  
 
3.3.3 DC maturation under serum-free conditions alters cytokine profile 
 
Under standard conditions, DC maturation is associated with alteration of the profile 
of cytokine production. To assess whether this change in cytokine profile occurred 
under serum-free conditions, I analysed DC culture supernatants by multiplex bead  
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immunoassay. Monocyte-derived dendritic cells which had differentiated under 
standard serum-supplemented conditions until day 6, were washed and then cultured 
for a further 48h with or without inflammatory cytokines (IL-1β, IL-6, TNFα, PGE2)  
under serum-free conditions (RPMI/1%ITS/1%NEAA/1%Na pyruvate). Supernatants 
were then harvested and cytokine levels for IL-1β, IL-1RA, IL-2, IL-2R, IL-4, IL-5, 
IL-6, IL-7, IL-8, IL-10, IL-12, IL-13, IL-15, IL-17, TNFα, IFNα, IFNγ, GM-CSF, 
CCL2 (MCP-1), CCL3(MIP-1α), CCL4 (MIP-1β), CCL5 (RANTES), CXCL9 (MIG), 
CXCL10 (IP-10) and  Eotaxin were measured by multiplex bead immunoassay. 
 
DC maturation under serum-free conditions was associated with increased production 
of the Th1-inducing cytokine IL-12, the chemokine IL-8 and the inhibitory molecule 
soluble IL-2R (Figure 3.8). There were also trends towards increases in CCL3 (MIP-
1α), CCL4 (MIP-1β) and CCL5 (RANTES) but these did not reach conventional 
levels of statistical significance. The following were not elevated above baseline 
(limit of detection shown in parentheses): IL-4 (< 8pg/ml), IL-5 (< 0.5pg/ml), IL-7 (< 
5pg/ml), IL-13 (< 1pg/ml), IL-15 (< 1pg/ml), IL-17 (< 15pg/ml), IFNα (< 10pg/ml), 
IFNγ (< 2.5pg/ml), CXCL9 (< 60pg/ml), CXCL10 (< 30pg/ml), Eotaxin (< 1pg/ml); 
since IL-1β, IL-6 and TNFα were added to the mDC cultures these were excluded 
from the analysis. 
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3.3.4 DC maturation under serum-free conditions increases DC capacity to 
induce T cell proliferation 
 
The function of DC matured under serum-free conditions was then assayed in terms 
of their capacity to induce proliferation of CFSE labelled naïve CD45RA+CD4+ T 
cells using an allogeneic proliferation assay. The naive CD4+ compartment was of 
particular interest as representing the situation at the lymph node where it is proposed 
that a peripheral tissue-educated DC will present antigen to a naive T cell. CFSE 
labelled naïve CD45RA+CD4+ T cells were cultured for 4 days with or without 
monocyte-derived dendritic cells (either iDC or inflammatory cytokine-stimulated 
mDC).  Number of proliferated cells in the cultures were estimated from the number 
of total live cells with submaximal CFSE (ie gate R2) which represent divided cells 
(Figure 3.9). Absolute cell numbers were estimated by the simultaneous use of 
„counting beads‟, a known number of which had been added to each sample.  mDC 
were observed to induce greater proliferation of naïve CD4+ T cells than iDC 
(p=0.001), and both iDC and mDC induced greater proliferation than unstimulated T 
cell cultures (p<0.05 and p < 0.001 respectively).  
 
We also wished to assess whether there were significant differences in how the naive 
and memory compartments responded to DC in my model. CFSE labelled naïve 
(CD45RA+) or memory (CD45RO+) CD4+ T cells were cultured for 4 days with or 
without monocyte-derived dendritic cells as described previously. Memory CD4+ T 
cells showed a similar pattern of responses to naive CD4+ T cells, with mDC 
inducing higher levels of proliferation than iDC, and both inducing higher 
proliferation than T cells alone (mDC:T > iDC:T > T cells alone; Figure 3.10). There  
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was however a difference in the magnitude of the response to mDC with mDC-
induced proliferation of naive CD4+ T cells being significantly higher than for 
memory CD4+ T cells (p < 0.001); absolute levels of proliferation for T cells cultured 
alone or with iDC were not significantly different between naive and memory 
compartments. 
 
3.3.5 Cytokine production by DC-stimulated naive CD4+ T cells reflects their 
levels of proliferation 
 
The interaction of the naïve CD4+ T cell with its activating dendritic cell is thought to 
be the primary factor governing T cell differentiation and eventual phenotype (Th1, 
Th2, Th17, etc). I therefore wished to investigate whether serum-free culture 
conditions resulted in DC which skewed T cell differentiation towards one particular 
phenotype (eg Th1, Th2 or Th17). 
 
Naïve CD45RA+CD4+ T cells were cultured for 4 days with or without monocyte-
derived dendritic cells (either iDC or inflammatory cytokine-stimulated mDC). 
Supernatants were then harvested and cytokine levels for IL-2, IL-5, IL-10, IL-
12p40/p70, IL-13, IL-17, and IFNγ were measured by multiplex bead immunoassay 
(Figure 3.11). IL-2 levels were significantly higher in mDC stimulated cultures than 
iDC, associated with the increased levels of proliferation in these cultures. Indeed all 
cytokines considered showed a trend towards increasing levels in mDC rather than 
iDC stimulated cultures. Of interest the Th1-inducing cytokine IL-12 was elevated in 
mDC vs iDC: T cell co-cultures (mirroring the elevated IL-12 from mDC vs iDC 
cultures; Figure 3.8), but this did not translate into statistically significant higher  
Chapter Three Results 115 
Fig 3.11 
Chapter Three Results 116 
levels of IFNγ. Th2 cytokines IL-5 and IL-13 showed a non-significant trend to 
increase in the mDC vs iDC T cell cocultures; IL-17 levels were only just detectable 
for iDC:T cell co-cultures (16pg/ml) and remained low. 
 
3.3.6 Elevated FoxP3 expression in naive CD4+ T cells is sustained at higher 
levels in iDC vs mDC: T cell co-cultures 
 
We next wished to determine whether the state of DC maturation would differentially 
affect T cell expression of FoxP3, reflecting both the transient elevation seen with 
activation and the sustained FoxP3 elevation of regulatory T cells (reviewed Ziegler 
(Ziegler, 2006)). CFSE labelled naïve CD4+ T cells were cultured with iDC or mDC 
in an allogeneic proliferation assay as described previously. At various timepoints 
(d1, d2, d4, d8), the T cells were harvested and stained for intracellular FoxP3 (Figure 
3.12). In the presence of DC (but not T cells alone) a FoxP3
hi
 population of undivided 
cells could be identified from day 1. This population increased both in number and in 
FoxP3 expression from days 2 to 4 before subsiding either partially (for iDC) or 
completely (for mDC) to baseline (ie to the same levels as for T cells alone) at day 8. 
Divided cells were initially high for FoxP3 (day4) with FoxP3 levels dropping by 
day8 to medium (iDC) or low (mDC) levels. Further investigation confirmed these 
differences between iDC and mDC-stimulated cultures at day 8 (Figure 3.13) with 
significantly higher MFI in both divided (R11) and undivided (R10 + R12) iDC-
stimulated CD4+ T cells. 
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3.4 The effect of inflammatory cytokines on circulating myeloid 
dendritic cells in vitro 
 
Having used monocyte-derived DC to establish the in vitro model of dendritic cell 
maturation described above, I wished to establish whether myeloid DC would respond 
to inflammatory cytokines under similar serum-free conditions.   I therefore 
investigated both the phenotype and function of myeloid DC in my in vitro model of 
dendritic cell maturation. 
 
3.4.1 Myeloid DC upregulate MHC and costimulatory molecules in response 
to inflammatory cytokines 
 
Myeloid DC were bead-purified from the blood of healthy donors using a two-stage 
magnetic separation involving (1) the removal of BDCA-1+ B-cells by an anti-CD19 
depletion step and (2) the positive selection of BDCA-1+ myeloid DC via BDCA-1 
biotin followed by anti-biotin microbeads. Myeloid DC were then cultured for 48h in 
serum-free conditions with or without the addition of inflammatory cytokines (IL-1β, 
IL-6, TNFα, PGE2). The cells were then harvested and the expression of a range of 
key surface molecules was analysed by flow cytometry (Figure 3.14).  
 
The addition of inflammatory cytokines to myeloid DC culture led to changes similar 
to those seen with monocyte-derived DC, with increased expression of MHC, the 
costimulatory molecules CD80 and CD86, and the marker of maturation  CD83. 
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3.4.2 Inflammatory cytokines increase myeloid DC capacity to induce 
proliferation of CD4+ T cells  
 
Myeloid DC were cultured as before in the presence or absence of the inflammatory 
cytokine cocktail (IL-1β, IL-6, TNFα, PGE2), and tested for their capacity to induce 
proliferation of CFSE labelled naïve CD4+ T cells using an allogeneic proliferation 
assay. Monocyte-derived DC were included in this experiment by way of comparison. 
 
Number of proliferated cells in the myeloid DC:T co-cultures were compared to T 
cells alone (Figure 3.15), and to monocyte-derived DC:T cell cocultures. For both 
monocyte-derived and myeloid DC, exposure to inflammatory cytokines (ie mDC) 
increased their capacity to induce proliferation of naïve CD4+ T cells vs unstimulated 
(ie iDC). There were no significant differences in myeloid or monocyte-derived DC 
capacity to induce T cell proliferation (iDC or mDC). 
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3.5 Discussion 
 
The aim of the series of experiments described in this chapter was to establish an in 
vitro model of dendritic cell differentiation, maturation and function which could be 
used to investigate the effects of the ocular microenvironment, specifically human 
AqH and its components, on dendritic cells. 
  
The importance of establishing a reliable in vitro model of DC function in the eye is 
underlined by the limitations of our current understanding of the nature and function 
of antigen presenting cells within the eye. MHC class II+ cells with dendritic cell or 
macrophage markers have been identified in the mouse, rat and human eye, but the 
extent and nature of their role in antigen presentation is unclear. It has been shown 
that MHC class II+ cells from the anterior segment of the rat eye can function 
effectively as antigen presenting cells (Steptoe et al., 1995), however neither dendritic 
cells nor macrophages have been observed to leave the eye, leading to the suggestion 
that antigen escapes in soluble form(Camelo et al., 2006; Dullforce et al., 2004). 
Indeed these APC could not be induced to migrate even after stimulation with LPS or 
anti-CD40 (Dullforce et al., 2004). Additionally the iris dendritic cells that have been 
identified express low CD11c, CD80 and CD86 (Steptoe et al., 1995)  suggesting that 
they are relatively immature. We, like others, have hypothesized that it is the presence 
of immunosuppressive molecules in the anterior segment such as TGFβ and αMSH 
that inhibit maturation and at least partially repress migration of DC. 
 
It is not possible to do functional studies on these ocular APC themselves due to the 
issues of isolating sufficient numbers in humans. In non-inflamed conditions they will 
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be resident in tissues bathed in aqueous humour rather than circulating in the aqueous 
humour, requiring  biopsy of ocular tissue; such biopsies are scarce, would yield very 
low numbers of DC, and the tissue would usually be pathological. In uveitis (see 
chapter 5) I propose that the cellular infiltrate into the anterior chamber may well 
contain DC or at least DC-like APC, but not in sufficient numbers to perform any 
functional experiments. Even relatively large samples of AqH (150ul) taken from 
patients with severe uveitis may yield only 10 000 cells in total, the majority of which 
may be lymphocytes. 
 
In my in vitro model of dendritic cell differentiation, maturation and antigen 
presentation, I am attempting to mimic the conditions that may lead to the generation 
of a functional ocular APC. In this model, peripheral blood monocytes are induced to 
differentiate to iDC in serum, recapitulating the differentiation of DC from monocytes 
in the peripheral blood thought to occur in vivo. Then, as would be anticipated to 
occur in the anterior segment, immature DC in this in vitro model are exposed to 
serum-free conditions where they are bathed in AqH, either non-inflammatory AqH 
(see chapter 4) or uveitis AqH (see chapter 5). In this environment they may also be 
subjected to inflammatory stimuli (in my model a cocktail of maturation cytokines 
IL1, IL6, TNFα, and PGE2). When modelling functional antigen presentation I co-
culture with either allogeneic naive CD4+ T cells (to try to reflect the situation at the 
draining lymph node early on in inflammation) or allogeneic memory CD4+ T cells 
(to mimic re-stimulation).   
 
It should be recognised that alternative models are possible and, whilst not the subject 
of this thesis, may well be worthy of further investigation. For example, one could test 
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the effect of AqH on monocytes in order to model the potential differentiation of 
monocytes to DC within the eye. Similarly it could be argued that to model 
restimulation of T cells by DC within the eye one should conduct the DC: T cell co-
cultures (not just the DC cultures) within AqH; this would not, however, distinguish 
between the effects of AqH on the DC and on the T cell. 
 
As a result of the series of experiments described in this chapter, I have adopted the 
monocyte-derived dendritic cell as the model dendritic cell for the in vitro studies on 
AqH. As outlined earlier these are widely used for modelling dendritic cell function, 
since monocytes are available in reasonable numbers (around 1x10
5
 /ml peripheral 
blood), and generate pure cultures of homogeneous DC of known history. In all the 
experiments described in this thesis I have used bead purification by positive selection 
(CD14+ microbead kit from Miltenyi Biotec) which in my hands gives 
CD14+monocyte purities of >99%. Alternative methods of monocyte isolation 
include isolation by adherence, differential centrifugation, Flow Assisted Cytometric 
Sorting (FACS) or alternative magnetic bead methods (either positive or negative 
selection).  In my preliminary experiments I tested the adherence technique of 
isolation but found that the culture purities (70-90% CD14+) were not sufficiently 
high and gave lower yields, as has been observed by a number of other investigators 
(Thurner et al., 1999; Pickl et al., 1996). Differential centrifugation alone (Royer et 
al., 2006; Lehner et al., 2005)  is also no longer commonly used due to low purities of 
cultures obtained (70-90%).  
 
In contrast FACS techniques permit extremely pure cultures, but there is concern that 
the shear stresses on the cells and prolonged exposure to FACS buffer during sorting 
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adversely affect the health and viability of the cultures. Conversely negative selection 
bead-based techniques provide healthy cultures of untouched cells but at a cost of 
lower purity than positive selection techniques, whether these be bead-based or 
FACS. Isolation of monocytes by positive selection on CD14+ microbeads has thus 
become standard practice, whilst recognising that there is a theoretical possibility that 
ligating CD14 may modify function or induce partial activation.  It should be noted 
also that only CD14+ monocytes will be selected by these positive selection 
techniques (ie excluding the CD14loCD16+ subset), although this is likely to promote 
the homogeneity of the final cultures.  
 
In order to differentiate dendritic cells from these multipotent CD14+ monoctyes I 
cultured them in IL-4 and GM-CSF as first described by Sallusto and colleagues in 
1994, and which has since become standard practice (Sallusto and Lanzavecchia, 
1994; Jeras et al., 2005b). Most DC differentiation, like these early protocols, is 
carried out in FCS supplemented media, which, as described here, was found to give 
higher yields than other sera or serum-free alternatives (Figure 3.1).  In addition to 
affecting the yield, I found, like others that the use of serum-free media often leads to 
more adherent and heterogeneous populations, with striking variations in the level of 
expression of a number of key molecules such as CD86 (Figure 3.1)(Scandella et al., 
2002; Bender et al., 1996; Thurner et al., 1999).  
 
We also observed that both CD80 and CD86 were affected by whether HS or FCS 
was used as the serum supplement. Thus HS supplementation was associated with 
high CD86 and low CD80 whereas FCS was associated with low CD86 and high 
CD80. A number of other investigators have reported similar findings. Pietschmann 
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and colleagues found that monocyte-derived DC differentiating in 1% human plasma 
had lower levels of CD80 and higher levels of CD83 and CD86 than FCS 
supplemented cultures(Pietschmann et al., 2000).  Similarly Lehner and colleagues 
reported low CD80 in HS supplemented media(Lehner et al., 2005) and both 
Scandella(Scandella et al., 2002) and Royer (Royer et al., 2006) reported low CD86 
expression in FCS-differentiated DC, although in both cases the comparison was to 
serum free AIM-V ((Lehner et al., 2005), (Scandella et al., 2002), (Royer et al., 
2006)) or X-VIVO ((Royer et al., 2006)) media.   Another interesting difference 
between FCS-grown DC and some other media is the level of CD1a expression 
observed. Whereas monocyte-derived DC are often described as being CD1a
hi
 this is 
almost exclusively found with DC generated in FCS or some serum-free 
media(Sallusto and Lanzavecchia, 1994; Lehner et al., 2005). In contrast I, like others, 
found that DC grown under HS-or HP-supplemented conditions are CD1a
lo
 (Lehner et 
al., 2005) (Pietschmann et al., 2000; Duperrier et al., 2000). 
 
It is yet not known which molecules are of primary importance in the development of 
the CD80/CD86 profile of in vitro generated DC. Although the differences in the 
effects of HS, FCS and other media on these molecules have been noted by a number 
of investigators it does not appear to have been given serious study. My experiments 
showed that the key factors responsible are not inactivated by heat (1 hour at 56˚C in 
a water bath), and that there appears to be both (1)  one or more factors in FCS and 
HS which promote CD80 and CD86 respectively, and (2) one or more inhibitory 
factors which reciprocally inhibit CD86 and CD80 expression (Figure 3.2,3). Further 
study of these phenomena though interesting was not a priority for this project, and 
thus these experiments were not carried further.  
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One of my fundamental concerns when selecting a technique for generating DC was 
whether there would be sufficient yields for the complex AqH-based experiments 
planned. Under standard conditions (ie with 10% human serum, IL-4, GM-CSF  in 
T25 flasks) the (mean + SD) yield was 23(+15) % with significant donor-to-donor 
variability. These compare reasonably with other investigators (Bender et al., 1996), 
who, as here, report higher yield with (1) the use of bead purification vs adherence 
technique and (2) the use of FCS rather than other media. Despite the potential 
advantages of a higher yield with FCS, HS supplementation was chosen in this thesis 
as being likely to better reflect the in vivo environment that a differentiating dendritic 
cell is exposed to. 
 
An alternative method of generating in vitro dendritic cells is the use of human 
CD34+ cells, initially derived from cord blood, differentiated in the presence of GM-
CSF and TNFα (Caux et al., 1992). The main disadvantage of deriving DC from 
CD34+ cells is that only 0.1% PBMC are CD34+.  A similarly interesting but 
impractical technique for generating DC in vitro is the placement of PBMC on an 
unstimulated HUVEC monolayer, which results in selective transmigration of CD14+ 
cells within 1 hour (90% purity) and then reverse transmigration of some of these 
cells which have differentiated into a DC phenotype over the next 2 days(Randolph et 
al., 1998).  
 
More recently it has become possible to isolate myeloid dendritic cells (MyDC) 
directly from peripheral blood mononuclear cells by bead-purification or by FACS. 
Since even the predominant BDCA-1+ population of myeloid DC are only present at 
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around 0.6% of PBMC, yield is around ten-fold lower than achieved with 
differentiation from monocytes (3x10
5
 vs 2x10
6
 per 100ml blood); additionally the 
purity is significantly lower (75-85% vs 99% for monocyte-derived DC cultures). 
Despite these disadvantages, myeloid DC are a true ex vivo DC and therefore are an 
important comparator when considering whether any effects observed in monocyte-
derived DC in vitro are likely to be translatable to the in vivo situation (Piccioli et al., 
2007). 
 
In vivo DC maturation occurs in the presence of an inflammatory stimulus such as 
local infection. The signal to the DC will therefore usually comprise pro-
inflammatory cytokines with or without TLR stimulation. Similarly in vitro DC 
maturation is usually induced by recombinant human cytokines (eg TNFα, IL1β, IL6, 
PGE2) and/or TLR ligands (eg LPS), although direct CD40 stimulation with CD40L 
may also be used (Sallusto and Lanzavecchia, 1994).  Given that most uveitis is not 
infectious I elected to use a pure cytokine driven pro-inflammatory stimulus, however 
it should be recognised that some „non-infective‟ uveitis is associated with recent 
systemic gram negative bacterial infection (specifically Yersinia and 
Salmonella)(Saari and Kauranen, 1980; Saari et al., 1980b; Saari et al., 1980a). Indeed 
it has been hypothesised that the precipitating event in acute anterior uveitis may be 
an inappropriate TLR-4 response either by LPS or by endogenous TLR4-ligands 
(Chang et al., 2004). Previously I have also used ligands for TLR1-9 as the maturation 
stimulus but have found that they were all less effective at inducing maturation than a 
standard cytokine cocktail of IL1β, IL6, TNFα and PGE2; the additional effect of LPS 
combined with this cytokine cocktail was also relatively minor. Moreover LPS, which 
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was the most effective of the TLR ligands, showed considerable variation in effect 
depending on the monocyte donor.  
 
Our standard cocktail of cytokines to induce maturation of DC (IL1β, IL6, TNFα and 
PGE2) is in widespread usage(Jeras et al., 2005b), although alternative regimens 
include TNFα alone (Sallusto and Lanzavecchia, 1994), TNFα with IL-1β and IL-6, 
and TNFα with IL-1β and IFNγ(Jeras et al., 2005b). The predominant reason for 
including PGE2 is that it significantly upregulates CCR7 (Scandella et al., 2002) 
important for its in vivo function of homing to lymph nodes;). Although some 
investigators have found that PGE2 treated DC skew T cells to a Th2 phenotype 
(Jonuleit et al., 1997; Kalinski et al., 1998), I did not find the inclusion of PGE2 to 
significantly bias  to Th1 or Th2 subtypes. Conversely DC maturation by TNFα, IL-
1β and IFNγ results in DC which are strongly polarising towards a Th1 
phenotype(Mailliard et al., 2003; Mailliard et al., 2004). 
 
A major uncertainty at the outset of this project was whether the serum-free 
conditions required by my model would prevent the normal DC maturation seen under 
standard conditions. Although slightly more heterogeneous than cultures grown under 
serum-supplemented conditions, DC matured in this serum-free model showed a 
normal mature phenotype in terms of surface molecules, cytokine behaviour, 
chemotactic behaviour, and  induction of T cell responses.  Typical surface molecule 
changes included upregulation of class II MHC, CD40, the costimulatory molecules 
CD80, CD86 and the accessory costimulatory molecule CD275 (ICOSL) consistent 
with published work(Jeras et al., 2005b; Scandella et al., 2002; Greenwald et al., 
2005). I also found strong evidence of functional maturation in terms of upregulation 
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of the chemokine receptor CCR7and downregulation of CCR5, with accompanying 
chemotaxis to CCL19 and loss of sensitivity to CCL5 (RANTES) (Scandella et al., 
2002)(Figure 3.9).  
 
Maturation also induced a change in the cytokines and chemokines that were 
produced by the DC. mDC cultures produced higher levels than iDC of IL-12,  
soluble IL-2 receptor and the chemokine, IL-8. The high levels of IL-12 are 
interesting as this would usually promote T cell differentiation towards a 
Th1response, and thus contrasts with Kalinski and others‟ suggestion that PGE2 
treatment of DC may be Th2 polarising(Kalinski et al., 1998)  It should be noted that 
despite the high levels of IL-12 from these DC there was no clear bias to Th1 
phenotype from the corresponding T cell cultures, with significant levels of both Th1 
and Th2 cytokines being produced. Soluble IL-2 receptor is the extracellular domain 
of the IL-2Rα  shed from IL-2R expressing activated cells including lymphoctyes, 
macrophages and dendritic cells(Obara et al., 1992). It has been shown to be elevated 
in a number of inflammatory diseases such as ankylosing spondylitis (Wendling et al., 
1991) and malignancy; it was not however shown to be altered in the serum of 
patients with idiopathic uveitis (Calder et al., 1999). It is not clear whether it has a 
biological function. The chemokine IL-8 is the ligand for CXCR1 and 2, and is 
chemotactic for neutrophils, basophils and T cells. Elevation of IL-8 production by 
mature DC is significant in attracting T cells in order to present antigen to them (Taub 
et al., 1996; Taub and Oppenheim, 1994). 
  
The fundamental characteristic of dendritic cell maturation is their ability to present 
antigen and induce proliferation of naive T cells. As expected the mDC generated by 
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the inflammatory cytokine cocktail showed increased capacity to induce proliferation 
both of naïve and memory CD4+ T cells in an allogeneic proliferation assay. 
Interestingly although mDC always induced significantly more proliferation than iDC, 
the absolute levels of proliferation varied considerably between donors (Figure 3.9C). 
This is likely to reflect variations in allogenicity between donor pairs. An alternative 
method of measuring DC induction of T cell responses would have been to measure 
recall responses to tetanus toxoid pulsed DC (Duperrier et al., 2000; Pietschmann et 
al., 2000), however this would only be suitable for testing memory rather than naive 
CD4+ T cell responses. The use of CFSE as opposed to 3H-thymidine incorporation 
(Duperrier et al., 2000; Pietschmann et al., 2000) avoids the hazards of radioactivity, 
and enabled us to look at number of divisions and differences in variables such as side 
scatter or FoxP3 levels between generations of dividing cells. 
  
It has been suggested that immature dendritic cells may deviate CD4+ T cells towards 
a regulatory rather than effector phenotype(Reis e Sousa, 2006; Lutz and Schuler, 
2002). Although a number of extracellular markers have been identified, the most 
consistent marker of regulatory CD4+ T cells is the transcription factor FoxP3. Even 
the use of FoxP3 to define a Treg is problematic in a proliferating population, as 
activation per se also leads to an increase in FoxP3 levels.  My studies of combined 
FoxP3/CFSE labelling showed that there are differences in the expression of FoxP3 
expression by naïve CD4+ T cells in iDC vs mDC: T cell co-cultures, with elevated 
expression of FoxP3 being maintained out to day 8 for iDC co-cultures, but returning 
to near baseline for mDC co-cultures; this is the case for both divided and undivided 
cells. Whilst it is interesting to speculate that this may in part reflect iDC induction of 
a regulatory T cell phenotype it is likely that most, if not all, of the FoxP3 elevation 
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reflects the activation state of the T cells. Further elucidation would require 
purification of these FoxP3
hi
 T cells using surrogate markers such as CD25hiCD127lo 
(since FoxP3 staining is intracellular and therefore not possible on live cells) followed 
by a functional test of their ability to suppress a normal T cell response (eg allogeneic, 
recall to tetanus toxoid or by direct stimulation with antiCD3/CD28) .  
 
Comparison of in vitro generated monocyte-derived DC with isolated circulating 
myeloid dendritic cells revealed striking parallels in their responses under serum-free 
conditions to inflammatory stimuli, and in their ability to induce T cell responses. 
Both monocyte-derived DC and myeloid DC showed a broadly similar response to 
maturation cytokines, with  increase in MHC and the costimulatory molecules CD80 
and CD86 (Figure 3.14), and decrease in CCR5(data not shown). Interestingly Piccioli 
reported that BDCA-1+ myeloid DC were relatively unresponsive to TNFα 
alone(Piccioli et al., 2007), so  it is likely that myeloid DC, like monocyte-derived 
DC, require all or most of the cytokines (IL1β, IL6, TNFα) and PGE2. Additionally in 
an allogeneic proliferation assay, monocyte-derived and myeloid DC from the same 
donor generated similar levels of proliferation of naive CD4+ T cells. Whilst 
recognising that the myeloid DC studied here are themselves ex vivo, such parallel 
behaviour is supportive of the usefulness of monocyte-derived DC in modelling the 
function of myeloid DC in vivo. The ability of both DC populations to survive, mature 
and function normally in my serum-free in vitro model also suggests that these 
conditions would be suitable for studying the effects of AqH as I seek to understand 
the behaviour of dendritic cells in the ocular microenvironment. 
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4 DENDRITIC CELL FUNCTION IN THE OCULAR 
MICROENVIRONMENT: THE SUPPRESSIVE ROLE 
OF NON-INFLAMMATORY AQUEOUS HUMOUR 
 
4.1 Introduction 
 
In the ocular microenvironment, DC, macrophages or any other potential antigen 
presenting cells, are exposed to a number of molecules which have been reported to 
have immunomodulatory effects. In vivo and in vitro animal studies have suggested 
that TGFβ2 (Takeuchi et al., 1997; Takeuchi et al., 1998) and αMSH (Taylor et al., 
1992; Taylor et al., 2000) are the dominant immunosuppressive components of AqH, 
with well-documented inhibitory effects on macrophage inflammatory activity and on 
the generation of Th1 responses. Since almost all functional studies have used either 
rabbit AqH (Shen et al., 2007; Taylor et al., 1992; Taylor et al., 1997; Taylor and Yee, 
2003; Taylor et al., 1994b; Cousins et al., 1991a; Nishida and Taylor, 1999; Kaiser et 
al., 1989) or murine AqH(Kaiser et al., 1989; Granstein et al., 1990), it has not been 
clear to what extent these molecules are significant mechanisms of APC regulation in 
man, nor whether other mechanisms such as endogenous glucocorticoids (notably 
cortisol) (Knisely et al., 1994; Rauz et al., 2003) might contribute. In addition  studies 
of AqH components on APC function have tended to focus on the macrophage 
(Takeuchi et al., 1998; Takeuchi et al., 1998) rather than the DC, even though the DC 
is the most potent APC of peripheral tissues.   
 
Our central hypothesis was that the normal resting ocular microenvironment 
maintains a relatively immature DC phenotype. We propose that this contributes to 
immune privilege by reducing their capacity to induce T cell proliferation, and by 
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changing the nature of the T cells produced. We show here that, as seen in animal 
models (Shen et al., 2007), human AqH inhibits DC-induction of naïve T cell 
responses associated with reduced expression of MHC and costimulatory molecules 
on the DC. We observe that the principal inhibitors of DC function in human AqH are 
cortisol and TGFβ2, with cortisol having the dominant effect. 
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4.2 Investigation of the effects of human non-inflammatory AqH on 
monocyte-derived dendritic cell function  
 
Having established an in vitro serum-free model within which to test the effects of the 
ocular microenvironment, we conducted a series of experiments to investigate 
whether non-inflammatory human AqH modulated human dendritic cell (DC) 
function under either resting conditions or in response to a strong cytokine-driven 
inflammatory stimulus previously shown to induce full DC maturation (see Chapter 
3). 
 
4.2.1 Non-inflammatory AqH reduces expression of  MHC and costimulatory 
molecules on immature dendritic cells and prevents normal dendritic cell 
maturation 
 
We wished to determine whether DC surface expression of MHC and key 
costimulatory molecules was affected by the presence of AqH under resting 
conditions or when exposed to a potent cocktail of inflammatory cytokines. 
Monocyte-derived DC were cultured under standard conditions (RPMI/10%HS) as 
described previously. They were then washed and placed in serum-free culture for 
48h in the presence or absence of 50% pooled human AqH, with or without a cocktail 
of inflammatory cytokines (IL-1β, IL-6, TNFα, PGE2). At the end of this period they 
were harvested, labelled and analysed by flow cytometry (Figure 4.1). 
 
Under resting conditions the presence of AqH was associated with significant 
reduction in DC expression of class II MHC and of the costimulatory molecule CD86.  
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In the presence of inflammatory cytokines normal maturation was prevented, with 
downregulation of MHC (class I and class II) and CD86, and failure to upregulate 
CD80 and CD83.  
 
4.2.2 Non-inflammatory AqH alters chemokine production by dendritic cells 
under resting conditions and in response to inflammatory cytokines 
 
Having identified changes in key surface molecules of DC, we wished to determine 
whether AqH modulated DC function, notably in terms of cytokine production, 
migration or induction of T cell responses. Monocyte-derived DC generated under 
standard conditions were placed in serum-free culture for 48h in the presence or 
absence of 50% pooled human AqH, with or without a cocktail of inflammatory 
cytokines (IL-1β, IL-6, TNFα, PGE2) as described previously. Supernatants were then 
harvested and cytokine levels for IL-1β, IL-1RA, IL-2, IL-2R, IL-4, IL-5, IL-6, IL-7, 
IL-8, IL-10, IL-12, IL-13, IL-15, IL-17, TNFα, IFNα, IFNγ, GM-CSF, CCL2 (MCP-
1), CCL3(MIP-1α), CCL4 (MIP-1β), CCL5 (RANTES), CXCL9 (MIG), CXCL10 
(IP-10) and  Eotaxin were measured by multiplex bead immunoassay (Figure 4.2). 
 
Under resting conditions the presence of AqH was associated with significant 
reduction in the levels of the chemokines, CCL3 (MIP-1α) and CCL4 (MIP-1β). In 
response to an inflammatory stimulus (ie to generate mDC), production of IL-12 and 
the chemokine IL-8 increased (as noted previously; Figure 3.8). Addition of non-
inflammatory AqH to these mDC cultures did not significantly affect levels of IL-12 
or IL-8 but did lead to significant reduction in the chemokines CCL4 (MIP-1β) and 
CCL5 (RANTES) (Figure 4.2). Analytes not shown were either not significantly  
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affected by the addition of non-inflammatory AqH (IL-1β, IL-1RA, IL-2, IL-2R, IL-8, 
IL-10, IL-12, CCL-2, CXCL9, CXCL10, Eotaxin) or were at or below the limits of 
detection IL-4, IL-5, IL-7, IL-13, IL-15, IL-17, IFNα, IFNγ, CXCL9, CXCL10, 
Eotaxin (see section 3.3.3). Since IL-1β, IL-6 and TNFα were added to the mDC 
cultures these were excluded from the analysis. 
 
4.2.3 Non-inflammatory AqH does not alter chemokine receptor expression 
and chemotactic function in response to inflammatory cytokines 
 
I wished to determine whether the presence of non-inflammatory AqH affected 
chemokine receptor expression and chemotactic function, both under resting 
conditions and in the presence of a cytokine-driven maturation stimulus, such as 
would normally cause a downregulation of CCR5 and upregulation of CCR7 (see 
chapter 3). 
 
Monocyte-derived DC generated under standard conditions were placed in serum-free 
culture for 48h in the presence or absence of 50% pooled human AqH, with or 
without a cocktail of inflammatory cytokines (IL-1β, IL-6, TNFα, PGE2) as described 
previously. Cells were harvested and either stained for chemokine receptor expression 
and analysed by flow cytometry or entered into a transmigration assay as below. 
Ninety-six well plates with transwell inserts were used to assess DC migration to a 
range of concentrations of either CCL5 (RANTES; ligand for CCR5 expressed on 
iDC) or CCL19 (ligand for CCR7 expressed on mDC). They were then harvested and 
placed in fresh serum-free medium in the top chambers of the 96-well insert, with 
serum-free medium or 1 -100ng/ml chemokine placed in the bottom chamber. After 
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three hours of culture both chambers were harvested and cell number was counted by 
flow cytometry (Figure 4.3).  
 
Non-inflammatory AqH did not affect baseline levels of CCR5 and CCR7 and did not 
prevent the normal upregulation of CCR7 and downregulation of CCR5 observed 
with DC maturation. The upregulated CCR7 was shown to be equally functional both 
for DC matured under normal conditions, and for DC matured in the presence of non-
inflammatory AqH.  
 
4.2.4 Non-inflammatory AqH inhibits the capacity of dendritic cells to induce 
proliferation of allogeneic naive CD4+ T cells  
 
To investigate whether non-inflammatory AqH alters DC capacity to induce T cell 
responses, AqH-treated DC were cultured in an allogeneic proliferation assay. 
Monocyte-derived DC were cultured in serum-free medium for 48h in the presence or 
absence of 50% pooled human AqH, with or without a cocktail of inflammatory 
cytokines (IL-1β, IL-6, TNFα, PGE2) as described previously. These DC were then 
washed and placed in fresh culture medium with CFSE labelled naïve 
CD45RA+CD4+ T cells for 4 days.  As previously, the number of proliferated cells in 
the cultures was calculated from the number of live cells with submaximal CFSE (ie 
gate R2) counted on flow cytometry, with counting beads enabling absolute cell 
numbers to be calculated (Figure 4.4).  
 
AqH-treatment significantly inhibited DC capacity to induce proliferation of naive 
CD4+ T cells, regardless of whether these DC were cultured under resting (iDC) or  
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inflammatory conditions (mDC). As previously noted, mDC were observed to induce 
greater proliferation of naïve CD4+ T cells than iDC (p<0.001), and both iDC and 
mDC induced greater proliferation than unstimulated T cell cultures (both p < 0.001). 
Proliferation of CD4+ naive T cells was found to correlate with CD86 expression of 
DC (Figure 4.5; r = 0.86; p = 0.006)), although there was also a weaker correlation 
with HLA-DR levels. 
 
4.2.5 Cytokine production by naive CD4+ T cells stimulated by AqH-treated 
DC reflects their reduced levels of proliferation 
 
Having noted that AqH treatment of DC reduced the magnitude of the T cell response 
induced, I wished to determine whether the differentiation of T cells was also 
affected, with phenotype being skewed for example to Th1, Th2, Th17 or Treg. Naïve 
CD45RA+CD4+ T cells were cultured for 4 days with or without monocyte-derived 
DC (either iDC or inflammatory cytokine-stimulated mDC). Supernatants were then 
harvested and cytokine levels for IL-2, IL-5, IL-10, IL-12p40/p70, IL-13, IL-17, and 
IFNγ were measured by multiplex bead immunoassay (Figure 4.6A).  
 
In general, cytokine concentrations reflected the levels of proliferation in each culture 
with higher concentrations in T cell co-cultures with mDC rather than iDC. AqH-
treated mDC induced significantly lower levels of IL-2 and IL-13 in DC: T cell 
cocultures than untreated mDC. Concentrations of IL-2, IL-13, IFNγ and TNFα all 
correlated with levels of proliferation (Figure 4.6B). IL-17 was near baseline from all 
cultures and showed no significant effect of AqH treatment. 
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4.3 Investigation of the effects of human non-inflammatory AqH on 
myeloid dendritic cell function  
 
Having established that non-inflammatory AqH significantly altered function and 
inhibited normal maturation in monocyte-derived DC, I wished to identify whether 
AqH induced similar effects on myeloid DC purified directly from peripheral blood.  
 
Myeloid DC were bead-purified from the blood of healthy donors using a two-stage 
magnetic separation as described previously. Myeloid DC were then cultured for 48h 
in serum-free conditions with or without the addition of inflammatory cytokines (IL-
1β, IL-6, TNFα, PGE2). The cells were then harvested and the expression of a range 
of key surface molecules was analysed by flow cytometry (Figure 4.7A,B).  
 
The addition of inflammatory cytokines to myeloid DC culture led to dramatic 
elevation in CD86 expression which was largely prevented by the presence of AqH 
(Figure 4.7). A similar but less dramatic effect was seen with HLA-DR (2004 + 58) 
for iDC, 1968 + 0) for AqH-treated iDC, 2628 + 0) for mDC and 1865 + 48) for AqH-
treated mDC (mean + SD)). 
Myeloid DC were then cultured as before in the presence or absence of 50% pooled 
human AqH, with or without the addition of the inflammatory cytokine cocktail (IL-
1β, IL-6, TNFα, PGE2), and tested for their capacity to induce proliferation of CFSE 
labelled naïve CD4+ T cells using an allogeneic proliferation assay.  
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As had been observed for monocyte-derived DC, treatment with AqH significantly 
inhibited myeloid mDC ability to induce T cell proliferation. A mild non-significant 
inhibitory effect was also seen for myeloid iDC (Figure 4.7 C).  
 
4.4 Investigation of the mechanism by which human aqueous humour 
inhibits dendritic cell function 
 
Having demonstrated that whole human AqH could significantly alter the behaviour 
of human dendritic cells, I wished to determine which components of human AqH 
were chiefly responsible for this effect. Possible candidates suggested by animal 
studies included TGFβ, αMSH and VIP, however our own work amongst others also 
suggested that the endogenous glucocorticoid cortisol might be present at sufficient 
levels to play an inhibitory role (Knisely et al., 1994; Rauz et al., 2003). 
  
4.4.1 Cortisol downregulates CD86 expression by dendritic cells and 
contributes to CD86 downregulation by aqueous humour 
 
Cortisol has previously been measured by radioimmunoassay to be present at levels of 
between 5-50 x10
-9
M in non-inflammatory AqH (Knisely et al., 1994; Rauz et al., 
2003). In order to determine these levels in our own cohort of patients, an 
ultrasensitive ELISA was used to measure cortisol levels in a series of 17 non-
inflammatory AqH samples (non-pooled).  
 
Human AqH was diluted 25-fold prior to testing in a cortisol acetylcholinesterase 
competitive EIA assay (Cayman) as per the manufacturer‟s instructions. As the 
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ELISA is a competitive assay, absorbance values are proportional to concentration of 
competitive bound cortisol tracer (and inversely proportional to concentration of 
cortisol). Standard curves were plotted using a 4-parameter logistic equation fitted to 
the logarithmic transformation of the standard concentrations vs the percentage 
cortisol bound. The concentration of cortisol in AqH was found to range from 755 to 
6402pg/ml with a median (IQR) of 2820 (1650-4297) pg/ml.  
 
In order to determine whether cortisol would affect human dendritic cell function, 
monocyte-derived DC were cultured in the presence of 10
-9
 to 10
-6
M cortisol with or 
without the glucocorticoid receptor antagonist, RU486, with or without the addition of 
the inflammatory cytokine cocktail (IL-1β, IL-6, TNFα, PGE2). CD86 expression, 
which I had previously been determined to be a sensitive marker of overall DC 
function, was measured by flow cytometry. Percentage inhibition of CD86 expression 
was used as the chief measure of the inhibitory effect of AqH or its constituents. In a 
second set of experiments monocyte-derived DC were cultured in the presence of 
medium, 50% AqH or 10
-7
M cortisol, with or without RU486 and with or without the 
addition of the inflammatory cytokine cocktail. 
 
Cortisol treatment of DC caused dose-dependent inhibition of CD86 expression 
(Figure 4.8A).  This was present under both resting conditions (iDC) and in the 
presence of inflammatory cytokines (mDC), although mDC were ten-fold less 
sensitive to the effects of cortisol than iDC.  The addition of RU486 blocked the effect 
of cortisol for cortisol concentrations up to 10
-7
M for iDC and up to 10
-6
M for mDC. 
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AqH-treatment of DC showed, as previously, significant inhibition of CD86 
expression for iDC which was partially reversed by glucocorticoid blockade with 
RU486 (Figure 4.8B). As observed with the addition of exogenous cortisol earlier, 
mDC were less sensitive to the effects of AqH, and, although there was a trend 
towards reversal with RU486, this was not statistically significant. 
 
4.4.2 TGFβ2 but not αMSH or VIP downregulates CD86 expression by 
dendritic cells 
 
TGFβ2 and the neuropeptides αMSH and VIP are known immunomodulatory 
compounds which are present at measurable levels in AqH (see Introduction). I 
therefore wished to establish whether these molecules were contributing to AqH 
inhibition of DC function.  
 
Monocyte-derived DC were cultured in the presence or absence of 0.1 – 100ng/ml 
TGFβ2, αMSH or VIP with or without the addition of the inflammatory cytokine 
cocktail (IL-1β, IL-6, TNFα, PGE2). CD86 expression was measured by flow 
cytometry. TGFβ2 treatment of DC caused dose-dependent inhibition of CD86 
expression (Figure 4.9A).  This was present under both resting conditions (iDC) and 
in the presence of inflammatory cytokines (mDC). iDC were significantly inhibited 
from 10ng/ml; mDC were only sensitive to the effects of TGFβ2 from 100ng/ml.  
αMSH and VIP caused no significant inhibition of CD86 expression in iDC or mDC 
even up to doses of 100ng/ml (Figure 4.9B). Similarly the alternative TGFβ isoforms 
TGFβ1 and TGFβ3 were also not found to have significant inhibitory effects on DC 
expression of CD86 or induction of T cell responses (data not shown). 
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4.4.3 Cortisol and TGFβ2 have additive downregulatory effects on CD86 
expression by dendritic cells 
 
Having established that cortisol and TGFβ2 can independently downregulate CD86 
expression, I wished to establish whether these molecules demonstrated synergistic 
(or at least additive) effects when present together, as would occur in AqH. 
Monocyte-derived DC were cultured in the presence of 10
-9
 to 10
-6
M cortisol in 
combination with 0, 1 or 10ng/ml TGFβ2. The addition of 1ng/ml TGFβ2 caused 
significant additional inhibition at cortisol doses of 10
-7
 and 10
-6
M (Figure 4.10A); the 
same additive effect was also observed at the higher TGFβ2 dose of 10ng/ml (data not 
shown).  
 
In view of the additive effect described above, we hypothesised that the residual 
inhibitory effect of AqH not accounted for by cortisol alone (Figure 4.8) might be due 
to the additive or even synergistic effects of TGFβ2. To establish that I could 
effectively inhibit TGFβ function, I tested the Activin Receptor-Like Kinase (ALK) 
inhibitor SB431542 on TGFβ alone (data not shown) and then in combination with 
RU486 to block a combination of cortisol and TGFβ2 (Figure 4.10B).  
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4.4.4 Cortisol and TGFβ2 jointly contribute to AqH-induced downregulation 
of CD86 on dendritic cells and reduction in their capacity to induce T 
cell proliferation 
 
In order to test my hypothesis that the inhibitory effect of AqH on DC was due to 
cortisol and TGFβ2 in combination, I studied the effects of blocking both these 
molecules in whole non-inflammatory AqH.  
 
Monocyte-derived DC were cultured in the presence or absence of 50% AqH with or 
without the addition of the inflammatory cytokine cocktail (IL-1β, IL-6, TNFα, 
PGE2). Reversal of any AqH effect was tested with combined glucocorticoid and 
TGFβ blockade (RU486 and SB431542). The combination of cortisol (10-7M) and 
TGFβ2 (10ng/ml) was used as a positive control.  CD86 expression was measured by 
flow cytometry, and capacity of DC to induce T cell proliferation was tested in an 
allogeneic proliferation assay. 
 
Combined glucocorticoid and TGFβ blockade with RU486 and SB431542 caused 
significant reversal of AqH-induced CD86 inhibition (Figure 4.11A). As noted earlier 
when studying the effect of cortisol alone this effect was more dramatic for iDC than 
mDC, with mDC being relatively less sensitive to the effects of both the exogenous 
molecules and AqH itself. CD86 was shown earlier to correlate with capacity of DC 
to induce T cell proliferation. In addition to their reversal of the AqH effects on CD86 
expression, combined glucocorticoid and TGFβ blockade led to a significant recovery 
of DC function as demonstrated by their improved induction of T cell proliferation 
(Figure 4.11B). 
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4.5 Discussion 
 
The aim of the series of experiments described in this chapter was to use my in vitro 
model of DC differentiation, maturation and function (described in chapter 3) to 
investigate for the first time the effects of AqH on DC in an entirely human system. I 
have shown that the presence of non-inflammatory AqH induces significant 
suppression of human DC function, with reduction in MHC and costimulatory 
molecule expression, cytokine production, chemotaxis and induction of T cell 
responses. It is of note that AqH inhibition of DC function occurred even in the 
presence of a potent cocktail of inflammatory cytokines that would normally drive DC 
to a highly immunogenic mature DC phenotype(Jonuleit et al., 1997). Thus would 
suggest that in the human eye, DC are constitutively kept in a suppressed state and, 
even in the presence of a strong inflammatory stimulus, full maturation is inhibited.  
 
Although evidence for the anterior chamber of the eye being an immunologically 
privileged niche dates back to the observations of van Dooremaal and Medawar 
((Medawar, 1948); reviewed Niederkorn (Niederkorn, 2006)), direct evidence of the 
modulatory properties of AqH on the cells of the immune system stems from the work 
of Kaiser and colleagues in which they described the inhibitory effects of rodent AqH 
on lymphocyte proliferative responses in vitro. Specifically they found that murine 
and lapine AqH inhibits T cell proliferation to antigens, and lymphocyte responses to 
either polyclonal mitogens or growth factors. They found that AqH-induced 
immunosuppression was not achieved through direct cytotoxicity, and that it was 
distinct from the effects of murine serum (Kaiser et al., 1989). Shortly afterwards 
Cousins and colleagues identified TGFβ2 in lapine and human AqH, and 
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demonstrated that the inhibitory effects of rabbit AqH were at least partially reversed 
by neutralising TGFβ2 (Cousins et al., 1991a). 
 
Indirect evidence of an immunomodulatory role of AqH on ocular antigen presenting 
cells,  was provided by experiments which sought to define the mechanisms 
underlying ACAID. Streilein and colleagues showed in mouse, that iris and ciliary 
body contained bone-marrow derived cells which were mostly F4/80+ (found on 
mature murine macrophages and macrophage-like cells), and demonstrated that 
iris/ciliary body preparation (intact tissue or single cell suspensions) were not 
allostimulatory but in fact inhibited a Mixed Lymphocyte Reaction (Williamson et al., 
1989). Subsequently the same group showed that whilst the induction of ACAID was 
dependent on iris/ciliary body F4/80+ cells, injection of non-ocular F4/80+ cells into 
the anterior chamber and subsequent pulsing with antigen also resulted in the antigen-
specific suppression of DTH reactions characteristic of ACAID (Wilbanks et al., 
1991). Critically they then showed that similar ACAID-inducing characteristics could 
be generated in non-ocular macrophages by exposure to either aqueous humour or to 
culture supernatants from iris and ciliary body cells, and that this also was TGFβ-
dependent (Wilbanks and Streilein, 1992).  
 
The identification of TGFβ2 as the molecule of ocular immune privilege in mouse led 
many in the field to abandon the study of whole AqH in favour of the use of TGFβ 
and in due course the various neuropeptides identified in AqH. Whilst this is perhaps 
not surprising given the challenges of working with whole AqH, it has led to a 
disparity between the extensive literature on the identification and subsequent 
characterisation of various components of AqH, and a rather sparse body of work on 
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the effects of the complex biological fluid itself. As noted earlier, the series of 
experiments described in this chapter attempt to investigate the wide-ranging effects 
of whole human AqH, with particular regard to the role of the dendritic cell and its 
implications for the influence of the ocular microenvironment on antigen presentation.  
 
For the first time in an entirely human system I have shown that the presence of non-
inflammatory AqH maintains an immature DC phenotype, associated with reduction 
in MHC and costimulatory molecule expression and significant suppression of normal 
human DC function in terms of cytokine production, chemotaxis and induction of T 
cell responses. Previous investigations of the effects of whole AqH on antigen 
presenting cells include: the induction of the ability to induce ACAID (mouse AqH on 
non-ocular macrophages cells (Wilbanks and Streilein, 1992), suppression of nitric 
oxide generation by macrophages(Taylor et al., 1998), suppression of HLADR, CD80 
and CD86 and inhibition of a Mixed Lymphocyte Reaction (Mouse BM-derived DC 
with rabbit AqH)(Shen et al., 2007). In addition there are a number of studies which 
did not directly look at the effects of AqH on APC (as they are sometimes reported to 
have done (Stein-Streilein and Watte, 2007)), but which consider the effects of AqH 
or iris/ciliary body supernatants on T cell and APC together. Cousins showed that IL-
2 secretion of the T cell hybridoma (DG11) in response to an I-A
d
-expressing B cell 
lymphoma (A20) was inhibited by up to 20% in the presence of rabbit AqH(Cousins 
et al., 1991a).  Similarly Streilein found that iris-ciliary body supernatants inhibited 
both the same DG11/A20 model used by Cousins, and a murine mixed lymphocyte 
reaction (C3H responder spleen cells with irradiated BALB/c stimulator spleen 
cells)(Streilein and Bradley, 1991).   
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In animal studies the constitutive AqH components implicated in immunosuppression 
are TGFβ2, and αMSH and to a lesser extent VIP, CGRP, somatostatin and cortisol. 
In AqH the concentration of TGFβ2 is 1-10ng/ml with >90% being in latent form, 
bound to the latency associated peptide (LAP)(Taylor, 2007). In the mouse, TGFβ2 
treatment of APC inhibits their production of IL12 (ie deviates them away from a 
TH1 response) and reduces CD40 activation accessory signals(Takeuchi et al., 1997; 
Takeuchi et al., 1998). Additionally TGFβ2 prevents macrophage pro-inflammatory 
functions such as secretion of inflammatory cytokines or generation of reactive 
oxygen species. Interestingly Tsukahara observed that TGFβ treatment of peritoneal 
exudate cells with 5ng/ml of porcine TGFβ2 did not alter expression of CD80 or 
CD86, but that blockade of these two molecules prevented TGFβ2-treated PEC from 
inducing ACAID. TGFβ2 treatment was also noted to divert the PEC to produce IL4 
and IL10 but not IFNγ (Tsukahara et al., 2005). Recently however Shen et al have 
demonstrated that murine bone-marrow derived DC are maintained in an immature 
MHC
lo
 CD80/86
lo
 state by the addition of rabbit aqueous humour, and that this effect 
can be recapitulated by recombinant TGFβ2 or blocked by AqH pre-treatment with 
anti-TGFβ2(Shen et al., 2007).  In my studies I found TGFβ2 to have a weak 
inhibitory effect on DC maturation at levels of >10ng/ml for iDC but only at the 
supraphysiological dose of 100ng/ml for mDC, suggesting that under conditions of 
intraocular inflammation TGFβ2 would no longer be a significant regulator of DC 
function. I did not find the alternative isoforms TGFβ1 and TGFβ3 to have any effect 
on DC expression of CD86 or induction of T cell proliferation. Although neither of 
these isoforms are present at measurable levels in AqH under resting conditions, they 
are potentially relevant to the immunity of the ocular microenvironment as mRNA of 
all three isoforms have been identified in the eye (Pasquale et al., 1993) and 
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interestingly whole AqH induces TGFβ1 production by T cells under serum-free 
conditions.  
 
It is interesting that in my study MSH did not significantly affect human DC 
maturation. This finding is supported by the recent study by Shen(Shen et al., 2007) 
which found that despite their well-documented inhibitory effects on murine 
macrophage function (Taylor, 2005; Taylor et al., 1998) αMSH and CGRP were not 
significantly inhibitory for murine DC. The finding that VIP similarly had no effect at 
physiological levels is perhaps to be expected since its main immunomodulatory 
effects are thought to be directly against T cells(Taylor et al., 1994b). 
 
In contrast, the endogenous glucocorticoid cortisol (hydrocortisone) did have a 
significant suppressive effect on DC maturation, inhibiting both CD86 expression and 
induction of naive CD4+ T cell proliferation. Cortisol has been observed at 
biologically significant levels in human and rodent AqH. Levels in human AqH as 
measured by radioimmunoassay ranging from 1.7 to 18.0 ng/ml equating to 4.8 to 
49.7nmol/l (Rauz et al., 2003) (Weinstein et al., 1991; Rozsival et al., 1981; Knisely 
et al., 1994) . Interestingly the binding protein Cortisol Binding Globulin (CBG) was 
not present at detectable levels (by radioimmunoassay) (Knisely et al., 1994). Thus it 
would appear that the vast majority of cortisol in AqH exists in free form, in contrast 
to the situation in serum where 80-90% is bound to CBG, 4-10% is bound to albumin 
and the remaining 6-10% is free cortisol.  
 
The potential immunoregulatory function of cortisol in AqH has received little 
attention previously, and there are no previous studies on its potential role on APC 
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function in the eye. Knisely noted that cortisol at the levels present in AqH could 
inhibit PHA/IL-1 stimulated thymocyte proliferation, and interestingly that there was 
an additive effect with physiological levels of TGFβ(Knisely et al., 1994). In vitro 
studies of human DC have shown that cortisol and other glucocorticoids may interfere 
with DC differentiation and maturation. The addition of dexamethasone during DC 
differentiation from monocytes reduces Class II MHC, CD80/86 and CD83 
expression with consequent reduction in T cell proliferation in a mixed lymphocyte 
reaction (Piemonti et al., 1999). Freeman observed that the addition of 10
-8
M cortisol 
during DC differentiation from monocytes inhibited DC upregulation of CD83, IL-12 
production and allostimulatory activity in response to a maturation stimulus (TNFα) 
(Freeman et al., 2005).  
 
The consequences of glucocorticoid treatment on DC post-differentiation is more 
complex. Vieira reported that when monocyte-derived DC were cultured in FCS-
supplemented media and stimulated with LPS, treatment with cortisol or clobetasol-
17-propionate inhibited production of IL-12 but did not affect expression of HLA-DR 
or CD80 or their allostimulatory activity (Vieira et al., 1998). In contrast when 
monocyte-derived DC were stimulated with IL-1β and TNFα (similar to my own 
model of DC maturation), the presence of cortisol or clobetasol-17-propionate did 
inhibit upregulation of CD80, CD83 and CD86, with consequent reduced ability to 
simulate naive CD4+ T cells (De Jong et al., 1999). Similarly addition of 
hydrocortisone or the synthetic glucocorticoid dexamethasone to monocyte-derived 
DC activated by nickel sulphate hexahydrate, prevented normal upregulation of 
CD86, and reduced IL-12 and TNFα production (Toebak et al., 2008). These studies 
are supportive of my observations that cortisol at the levels present in AqH can inhibit 
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DC maturation, and that blockade of endogenous glucocorticoids within the AqH 
leads to a significant (albeit partial) reduction in the inhibitory effect of AqH. 
 
It should be noted that there is also evidence that AqH has a number of 
immunosuppressive properties directly on T cells (ie not via its effects on APC). 
These effects include inhibition of Th1 function (Taylor et al., 1992; Cousins et al., 
1991b), induction of T reg function (Taylor et al., 1997) and induction of apoptosis. 
However in this study I wished to specifically investigate the effects of AqH on the 
DC, and so carefully removed AqH from the DC cultures before commencing DC: T 
cell coculture. 
 
Although distinct, the role of AqH within the eye shares some striking similarities to 
the role of the CSF in the brain. In a parallel series of experiments to their induction 
of ACAID with AqH-treated APC, Wilbanks and colleagues showed that CSF 
treatment of PEC also induced ACAID (Wilbanks and Streilein, 1992). DC, both 
myeloid and plasmacytoid, were shown to be present in the CSF of patients with both 
inflammatory and non-inflammatory disease (Pashenkov et al., 2001).  The same 
group then studied the effects of inflammatory and non-inflammatory CSF on 
monocyte-derived DC, and observed that, in contrast to my observations with AqH, 
non-inflammatory CSF did not cause significant downregulation of HLA-DR, CD80 
or CD86 and did not inhibit DC induction of T cell proliferation in an allogeneic 
proliferation assay (Pashenkov et al., 2002). Whilst this may be a real difference 
between CSF and AqH, it may also reflect the disparity between „normal‟ fluids from 
completely healthy volunteers for which sampling usually cannot be justified and the 
„non-inflammatory‟ fluids which are used as a surrogate for normal. In my 
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experiments the „non-inflammatory‟ group have no ocular or significant systemic 
disease other than mild to moderate lens opacity, whilst in Pashenkov‟s CSF series, 
the non-inflammatory group are patients with wide-ranging active „Non-inflammatory 
neurological diseases‟ such as ischaemic stroke, depression and pseudotumor cerebri. 
Given that the range of effect of CSF for the non-inflammatory group was so wide (ie 
from >30% inhibition to >30% increase of an allogeneic proliferation assay 
(Pashenkov et al., 2002)) it would be interesting to know the effect of non-
inflammatory CSF on DC in the context of a more homogeneous „normal‟ population. 
 
Our central hypothesis is that the normal resting ocular microenvironment maintains a 
relatively immature DC phenotype. I propose that this contributes to immune 
privilege by reducing their capacity to induce an adaptive immune response. The 
experiments described in this chapter provide evidence that human AqH inhibits DC-
induction of naïve T cell responses associated with reduced expression of MHC and 
costimulatory molecules on the DC, and that in human AqH the key 
immunoregulators are cortisol and TGFβ2, with cortisol having the dominant effect.  
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5 DENDRITIC CELL FUNCTION IN UVEITIS: 
SUSTAINED SUPPRESSION OF DENDRITIC CELL 
FUNCTION DESPITE IFNγ MEDIATED 
UPREGULATION OF MHC 
 
 
5.1 Introduction 
 
One of the fundamental paradoxes of ocular immunology is the occurrence of 
potentially devastating intraocular inflammation (uveitis) in an immune privileged 
site. There has been considerable debate as to whether uveitis constitutes a failure of 
immune privilege, or whether immune privilege persists but is simply overwhelmed 
((Ohta et al., 2000b; Ohta et al., 2000a; Mo et al., 2003; Mo and Streilein, 2005; Mo 
and Streilein, 2001). 
 
In the body of work described in the previous chapter I presented evidence supporting 
my hypothesis that under normal resting conditions the ocular microenvironment 
maintains DC in a relatively immature state, reducing their capacity to induce an 
adaptive immune response. In contrast I proposed that during uveitis alterations in the 
ocular microenvironment result in uveitic AqH becoming stimulatory to DC function, 
resulting in a loss or at least a diminution of immune privilege. 
 
Although APC populations resembling macrophages and dendritic cells have been 
identified in tissues of the anterior segment in rodents and human cadaveric studies, 
they have not previously been isolated from humans ex vivo. We hypothesised that 
whilst usually resident in the tissue, dendritic cells might be found in the anterior 
chamber during severe intraocular inflammation. We therefore conducted a series of 
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experiments first to test the feasibility of identifying myeloid dendritic cells in the 
AqH, then to characterise them and finally to test the extent to which their phenotype 
could be recapitulated by exposure of monocyte-derived DC to uveitis AqH in vitro.  
In light of the debate on the persistence or otherwise of immune privilege during 
uveitis, we then sought to establish whether the effect of uveitis AqH on DC in vitro 
was primarily regulatory (as observed for non-inflammatory AqH; see chapter 4) or 
stimulatory (as per our hypothesis).  Previous analysis of the cytokine profile of 
uveitis AqH has identified increased levels of a number of pro-inflammatory 
cytokines (such as IL-6 and IFNγ (Curnow et al., 2005; Ooi et al., 2006)). This, 
coupled with a fall in TGFβ levels (Curnow et al., 2005), pointed to the likelihood 
that uveitic AqH would be stimulatory, however there remained the possibility that 
AqH might continue be immunosuppressive due to the persistence of molecules 
present during resting conditions (eg cortisol) or due to the influx or production of 
other molecules  in response to the inflammation. 
 
In summary, the aims of the series of experiments described in this chapter was (1) to 
identify and characterise myeloid dendritic cells in human AqH and (2) to investigate 
whether dendritic cell regulation by the ocular microenvironment persists during 
human uveitis. We show here that myeloid DC can be successfully isolated from the 
uveitic anterior chamber. In addition we refute our hypothesis, finding that, during 
uveitis, AqH continues to be predominantly immunosuppressive as evidenced by the 
phenotype of myeloid DC isolated directly from the uveitic eye. We have shown in 
vitro that this phenotype is a result of the effects of the AqH itself and that the 
consequences of exposure to AqH, even during uveitis, is a functionally immature 
population of DC within the eye. 
Chapter Five Results 168 
5.2 The identification of myeloid dendritic cells in human AqH during 
uveitis with a distinct MHChi CD86lo phenotype 
 
Matched peripheral blood and AqH were taken from patients presenting with uveitis. 
Myeloid DC and CD14+ monocyte/macrophages were identified by flow cytometry 
of both the PBMC fraction and the AqH. Myeloid DC were defined according to 
Forward/Side scatter profile and characteristic expression of BDCA-1(CD1c)+CD19-
CD56-CD14-/low (Figure 5.1). Monocyte and macrophage populations were also 
identified by high expression of CD14 (Figure 5.1). Nineteen patients were recruited, 
sixteen of which had acute anterior uveitis and three of which had panuveitis (Table 
5.1).   
 
Myeloid DC could be identified in the AqH of patients with uveitis representing 0.6 + 
0.7% (mean + SD) of total AqH cells. This compares with the peripheral blood where 
0.3 + 0.6% (mean + SD) of the PBMC fraction were myeloid DC. CD14+ cells 
(monocytes/ macrophages) were more numerous than myeloid DC, being present at a 
3.3 + 3.9% (mean + SD) of AqH cells and at 7.9 + 5.5% (mean + SD) of the PBMC 
fraction. The relative cellular profile for anterior and panuveitis are compared in 
tables 5.2 (for AqH) and 5.3 (for peripheral blood).  
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Anterior Uveitis 
 
 
Panuveitis 
Number of samples 16 
 
3 
Aetiology 14 Idiopathic 
1 Ankylosing spondylitis 
1 Ulcerative colitis 
 
2 Fuchs Heterochromic Uveitis 
1 Vogt-Koyanagi-Harada     
syndrome 
Activity (AC cells) 
(Mean + SD) 
2.4 + 0.2 1.0 + 0.6 
Unilateral vs         
bilateral disease 
15 Unilateral 
1 Bilateral 
 
2 Unilateral 
1 Bilateral 
First episode vs  
recurrent disease 
5 First episodes 
11 Recurrences 
 
3 Recurrences 
Duration of current     
episode (days) *** 
(Mean + SD) 
3.9 + 0.6 17.5 + 3.5 
Treatment 1 Topical glucocorticoid 
15 Untreated 
1Systemic glucocorticoid 
1 Topical glucocorticoid 
1 Untreated 
 
Table 5.1 Clinical profile of Anterior and Panuveitis samples analysed by flow 
cytometry for the presence of myeloid dendritic cells.  
Anterior chamber cellular activity was graded as per Standardization of Uveitis 
Nomenclature 2005 classification criteria(Jabs et al., 2005). Unpaired t-test for 
comparison of anterior and panuveitis for activity and duration (normality of 
distribution tested by Kolmogorov-Smirnov test); *** p < 0.001; all else NS. 
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 Anterior Uveitis Panuveitis 
Total cell count 
(Mean + SD) 
 
3870 + 2645 6185 + 5666 
Neutrophils (%) 
(Mean + SD) 
 
60.6 + 19.8 29.5 + 5.9 
Lymphoctyes (%) ** 
(Mean + SD) 
 
35.1 + 18.8 68.7 + 5.7 
Monocyte/macrophages (%) 
(Mean + SD) 
 
3.7 + 4.2 1.0 + 0.5 
Myeloid DC (%) 
(Mean + SD) 
 
0.6 + 0.7 0.8 + 0.8 
 
Table 5.2 Cellular profile of Anterior and Panuveitis AqH samples analysed by 
flow cytometry for the presence of myeloid dendritic cells 
Monocyte/macrophages defined by CD14+; myeloid DC defined as BDCA-1+CD14-
/lowCD19-CD56-; lymphocytes and neutrophils defined on the basis of forward/side 
scatter and being negative for the above markers.  
Unpaired t-test for comparison of anterior and panuveitis aqueous humour samples for 
cellular composition (normality of distribution tested by Kolmogorov-Smirnov test); 
** p < 0.01; all else NS. 
 
 
 Anterior Uveitis Panuveitis 
Monocyte/macrophages (%) 
(Mean + SD) 
 
8.6 + 5.7 4.3 + 2.4 
Myeloid DC (%) 
(Mean + SD) 
 
0.37 + 0.69 0.14 + 0.06 
 
 
Table 5.3 Cellular profile of Anterior and Panuveitis matched blood samples 
analysed by flow cytometry for the presence of myeloid dendritic cells 
Monocyte/macrophages defined by CD14+; myeloid DC defined as BDCA-1+CD14-
/lowCD19-CD56-.  
Unpaired t-test for comparison of anterior and panuveitis blood samples for cellular 
composition (normality of distribution tested by Kolmogorov-Smirnov test); all NS. 
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For characterisation with regard to expression of key surface molecules, the 
homogeneous group of untreated idiopathic acute anterior uveitis were considered. 
Myeloid DC in the AqH expressed significantly higher levels of Class I and Class II 
MHC, but lower levels of the costimulatory molecule CD86 compared to the matched 
peripheral blood samples (Figure 5.2); they also showed significant elevation in their 
expression of CCR5 but no difference in levels of CD11c (data not shown). CD14+ 
monocyte/macrophages showed similar elevations in MHC (class I and class II) and 
CCR5 but unlike myeloid DC did not show a significant difference in CD86 
expression (Figure 5.3). 
5.3 Investigation of the role of the uveitic microenvironment on 
dendritic cell phenotype in vitro 
 
Having identified that dendritic cells in the uveitic anterior chamber appear to have a 
distinct phenotype, we wished to identify whether this was due to differential 
recruitment of MHChiCD86lo expressing DC or a consequence of the ocular 
microenvironment on normal DC. To investigate the role of the ocular environment 
we first tested the effects of uveitis AqH on the phenotype of monocyte-derived DC in 
vitro, and then sought to identify the molecules present in uveitis AqH that were 
responsible for these changes. 
 
5.3.1 Uveitis AqH can recapitulate an MHCIhi CD86lo phenotype in 
monocyte-derived DC in vitro  
 
Monocyte-derived DC were cultured in serum-free medium for 48h in the presence or 
absence of either 50% uveitic AqH or non-inflammatory AqH. Uveitis AqH was  
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taken from patients with active uveitis and > 1+ anterior chamber cells. Non-
inflammatory AqH was taken from patients attending for routine cataract surgery as 
described previously. At the end of 48h the cells were harvested, labelled and 
analysed by flow cytometry. 
 
Treatment of monocyte-derived DC with uveitis AqH supernatant resulted in 
significant upregulation in class I MHC and downregulation of class II MHC 
(specifically HLA-DR) and the costimulatory molecule CD86 (Figure 5.4). 
Upregulation of class I MHC was greatest when treated with uveitic AqH from 
patients with severe anterior uveitis (3/4+ anterior chamber cells), whereas class II 
MHC and CD86 levels were not affected by severity. CCR7 upregulation did not 
occur (Figure 5.5) and CCR5, rather than being downregulated as observed during 
normal DC maturation (Figure 3.6B) was further upregulated (Figure 5.5). 
  
5.3.2 Uveitis AqH-induced upregulation of MHCI on DC is IFNγ dependent  
 
In order to identify the mechanism by which uveitis AqH induced upregulation of 
class I MHC, we investigated the role of a number of molecules which had previously 
been noted to be elevated in active uveitis, notably IFNγ and IL-6 ((Curnow et al., 
2005; Ooi et al., 2006)); additionally IFNγ is known to be capable of MHC 
upregulation (Steimle et al., 1994). We therefore tested the effects both of the 
recombinant molecule and the consequence of blocking its effects in AqH. Monocyte-
derived DC were cultured in serum-free medium for 48h in the presence or absence of 
(1) 0.1 -100 ng/ml IFNγ with or without an IFNγ blocking antibody or (2) 50% uveitic  
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AqH vs non-inflammatory AqH with or without an IFNγ blocking antibody. At the 
end of 48h the cells were harvested, labelled and analysed by flow cytometry.  
 
Recombinant IFNγ caused a dose-dependent increase in MHC (class I and II) and 
CD86 (Figure 5.6). There was differential sensitivity of molecular expression to IFNγ 
with upregulation of class I MHC occurring from concentrations of IFNγ of 0.1ng/ml, 
HLA-DR from 1ng/ml and CD86 upregulation only being present at the higher 
concentrations of 10 and 100ng/ml. AqH-induction of class I MHC was shown to be 
IFNγ dependent with significant reversal with the addition of an IFNγ blocking 
antibody. As previously observed AqH-treatment downregulated HLA-DR but 
interestingly HLA-DR expression was further reduced in the presence of IFNγ 
blockade suggesting that there is an IFNγ-dependent drive to upregulate HLA-DR (as 
seen with class I MHC) but that this is insufficient to overcome the inhibitory effects 
of other components of AqH. CD86 levels which were reduced in the presence of 
AqH (as previously noted) were unaffected by IFNγ blockade. 
 
In a similar set of experiments investigating the possible contribution of IL-6, the 
effects of uveitis AqH on DC phenotype were (1) not recapitulated by the addition of 
recombinant IL-6 and were not reversed (or augmented) by IL-6 blockade: MFI for 
CD86 was 26.1 (15.5-40.3) with uveitis AqH alone (median (IQR) vs 28.3 (20.1-45.8) 
with matched uveitis AqH and IL-6 blockade (median (IQR); p = 0.56; Wilcoxon 
matched pairs analysis).   
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5.3.3 Cortisol levels are elevated in uveitis AqH, and increase with anterior 
chamber activity 
 
Despite the pro-inflammatory IFNγ-dependent upregulation of class I MHC, the 
predominant effect of uveitis AqH appeared to be inhibitory, with downregulation of 
class II MHC and CD86, as previously noted for non-inflammatory AqH.  In order to 
establish  the mechanism by which this was achieved, we first considered the role of 
the molecules which we had already demonstrated to be important in the 
immunosuppressive function of non-inflammatory AqH, namely cortisol and TGFβ2. 
To investigate the role of cortisol we first established by ELISA whether it was 
present at significant levels during uveitis, before proceeding to attempt to block its 
function in uveitis AqH. Our group had already demonstrated that TGFβ levels in 
AqH fall markedly during uveitis from a median of 353 (range <40 to 497) to a 
median of 86 (<40 to 667) pg/ml (Curnow et al., 2005). Since this is significantly 
below the level at which we have found TGFβ to inhibit DC function (Chapter 4), 
TGFβ was not considered further in this context. 
 
The presence of cortisol in human AqH during uveitis had not previously been 
determined. We therefore used an ultrasensitive ELISA to measure cortisol levels in a 
series of 13 untreated uveitic AqH samples, as described previously. As the ELISA is 
a competitive assay, absorbance values are proportional to concentration of 
competitive bound cortisol tracer (and inversely proportional to concentration of 
cortisol). The standard curve (Figure 5.7A) was plotted using a 4-parameter logistic 
equation fitted to the logarithmic transformation of the standard concentrations vs the 
percentage cortisol bound. The concentration of cortisol in uveitic AqH was found to 
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range from 1884 to 25536 pg/ml, with a median (IQR) of 5468 (3905 – 12300) pg/ml. 
This compares with a median (IQR) of 2820 (1650-4297) pg/ml for non-inflammatory 
AqH (Figure 5.7B). Cortisol level in AqH increased with severity of uveitis as 
measured by anterior chamber activity (Figure 5.7C; linear trend test p < 0.01). 
 
5.3.4 In uveitis, AqH-induced inhibition of CD86 loses glucocorticoid-
dependency which is restored in the presence of therapeutic 
glucocorticoids  
 
Having established (1) that cortisol levels were elevated during active uveitis (Figure 
5.7), (2) that addition of exogenous cortisol at these levels significantly inhibited DC 
expression of CD86 and induction of T cell responses (Chapter 4) and (3) that 
blockade of the glucocorticoid receptor with RU486 reversed the inhibitory properties 
of non-inflammatory AqH (Chapter 4), we hypothesised that the persistence of 
immunosuppression by AqH during uveitis was also likely to be due to endogenous 
cortisol, supplemented by exogenous (ie therapeutic) glucocorticoids in the case of 
„treated‟ samples. We therefore tested the inhibitory effects of uveitis AqH in the 
presence or absence of glucocorticoid blockade, recognising that for treated uveitis 
AqH samples glucocorticoid reversal would be blocking the combined effect of 
endogenous cortisol and exogenous glucocorticoids (such as dexamethasone).  
Monocyte-derived DC were cultured in the presence or absence of non-inflammatory 
or uveitis (untreated or treated) AqH with or without the glucocorticoid receptor 
antagonist, RU486; 10
-7
M cortisol was included as a positive control. After 48h, 
surface expression of HLA-A,B,C, HLA-DR and CD86 was determined by flow 
cytometry (Figure 5.8).  
Chapter Five Results 182 
Fig 5.7 
Chapter Five Results 183 
Fig 5.8 
Chapter Five Results 184 
As noted previously for non-inflammatory AqH, both untreated and treated uveitis 
AqH caused significant reduction in CD86 expression. Glucocorticoid blockade with 
RU486 caused significant reversal of inhibition for treated uveitis AqH (as also seen 
for non-inflammatory AqH), but did not cause significant reversal of the inhibitory 
effect of untreated uveitis AqH. Class I and class II MHC were not affected by the 
addition of RU486.  
 
5.4 Investigation of the role of the uveitic microenvironment on 
dendritic cell function 
 
Having identified that the inflamed ocular microenvironment induced both a 
„stimulatory‟ upregulation of MHC (class I and II in vivo; class I only in vitro) and an 
„inhibitory‟ downregulation of CD86, we wished to investigate the functional 
consequences of this altered phenotype, in particular the possibility of selective 
inhibition of CD4+ vs CD8+ T cell responses, and the consequences of treatment on 
DC function. 
 
5.4.1 Uveitis AqH inhibits DC capacity to induce proliferation of CD4+ and 
CD8+ T cells 
 
Monocyte-derived DC were cultured in serum-free medium for 48h in the presence or 
absence of  50% uveitic AqH vs non-inflammatory AqH. These DC were then washed 
and placed in fresh culture medium with CFSE labelled naïve CD45RA+CD4+ T 
cells, or memory CD45RO+CD4+ T cells or CD8+ T cells for 4 days.  As previously, 
the number of proliferated cells in the cultures was calculated from the number of live 
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cells with submaximal CFSE (ie gate R2) counted on flow cytometry, with counting 
beads enabling absolute cell numbers to be estimated (Figure 4.3).  
 
Uveitis AqH-treatment significantly inhibited DC capacity to induce T cell 
proliferation, whether naive or memory CD4+ or CD8+ (Figure 5.9).  Inhibition with 
uveitis AqH was of a similar magnitude to that seen with non-inflammatory AqH. As 
noted previously for non-inflammatory AqH (Figure 4.5), induction of proliferation 
was found to correlate with CD86 expression of DC (Figure 5.10; r = 0.67; p = 
0.006).  
 
5.4.2 In vivo glucocorticoid treatment does not affect the capacity of uveitic 
AqH to inhibit DC induction of T cell proliferation, but is associated 
with lower IL-10 levels in DC: T cell supernatants 
 
Having noted that uveitis AqH treatment caused similar inhibition of DC function to 
non-inflammatory AqH, we wished to observe whether the inhibitory effects of 
uveitis AqH were affected by the  presence of glucocorticoid treatment. In addition 
we wished to determine whether the differentiation of T cells was also affected, with 
phenotype being skewed for example to Th1, Th2, Th17 or Treg.  
Naïve CD45RA+CD4+ T cells were cultured for 4 days with or without monocyte-
derived dendritic cells in the presence or absence of non-inflammatory AqH, 
untreated uveitis AqH or treated uveitis AqH (ie from patients who had already 
commenced topical glucocorticoid treatment at the time of sampling). Supernatants 
were then harvested and cytokine levels for IL-2, IL-5, IL-10, IL-12p40/p70, IL-13, 
IL-17, IFNγ and TNFα were measured by multiplex bead immunoassay (Figure 5.11).  
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In general, cytokine concentrations reflected the levels of proliferation in each culture. 
Uveitis AqH treatment of DC resulted in lower levels of proliferation regardless of 
whether the AqH was a „treated‟ or „untreated‟ sample, with no significant difference 
between them (Figure 5.11A). Similarly exposure of DC to uveitis AqH, whether 
untreated or  treated, resulted in lower levels of IL-2, IL-10, IL-13, IFNγ and TNFα 
(figure 5.11B); correlation with proliferation was high for all these cytokines (Figure 
5.11C). IL-17 was near baseline from all cultures and showed no significant effect of 
AqH treatment. 
 
5.4.3 In uveitis, AqH inhibition of DC function loses glucocorticoid-
dependency which is restored in the presence of therapeutic 
glucocorticoid 
 
Having established that (1) during uveitis downregulation of CD86 by AqH was no 
longer glucocorticoid-dependent, but that (2) this was restored in treated uveitis AqH, 
we wished to establish whether this was reflected in the glucocorticoid dependency 
(or otherwise) of the AqH inhibition of DC induction of T cell responses.  We 
therefore tested the inhibitory effects of uveitis AqH in the presence or absence of 
glucocorticoid blockade on DC induction of proliferation and T cell cytokine 
production; again it was noted that for treated uveitis AqH samples, the glucocorticoid 
receptor antagonist RU486 would be blocking the combined effect of endogenous 
cortisol and exogenous glucocorticoids (such as dexamethasone).  
 
Monocyte-derived DC were cultured in the presence or absence of non-inflammatory 
or uveitis (untreated or treated) AqH with or without the glucocorticoid receptor  
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antagonist, RU486; 10-7M cortisol was included as a positive control. After 48h, DC 
were then washed and placed in fresh culture medium with CFSE labelled naïve 
CD45RA+CD4+ T cells for 4 days.  The level of proliferation was estimated from the 
number of live cells with submaximal CFSE counted on flow cytometry (Figure 
5.12A).  
As noted previously for non-inflammatory AqH, both untreated and treated uveitis 
AqH caused significant impairment in DC capacity to induce T cell proliferation. 
Glucocorticoid blockade with RU486 caused significant reversal of inhibition for 
treated uveitis AqH (as also seen for non-inflammatory AqH), but did not cause 
significant reversal of the inhibitory effect of untreated uveitis AqH. Although it was 
not possible to directly measure the levels of therapeutic glucocorticoids in these AqH 
samples, it was noted that RU486 reversal of their inhibitory effect was not related to 
the intensity of treatment which they had received prior to sampling (5.12B). 
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5.5 Discussion 
 
The aim of the series of experiments described in this chapter was first to identify and 
characterise myeloid DC from the human anterior chamber, and second to investigate 
whether, with regard to the dendritic cell, immune privilege persists during human 
uveitis. We have shown that myeloid DC can be identified in human AqH during 
active uveitis, that they are MHChiCD86lo and that when this phenotype is 
recapitulated  in vitro by the exposure of monocyte-derived DC to uveitis AqH 
supernatant, the function of these DC is generally inhibited despite the opposing 
effects of inflammatory molecules such as IFNγ.  Furthermore the regulatory effects 
of uveitis AqH prior to treatment appear to be distinct from the cortisol and TGFβ2-
dependent mechanism we demonstrated for non-inflammatory AqH (chapter 4). 
 
The identification and characterisation of a defined BDCA-1+ myeloid DC population 
in human AqH is important in the context of the evolving debate over the identity and 
function of the ocular APC populations. As reviewed earlier (see Introduction) an 
ocular DC-like population was identified in human cadaveric studies, both by Flugel  
who described a population of CD45+ HLA-DR+ dendritiform cells(Flugel et al., 
1992) and by Chang who noted that these dendritiform cells were HLADR+ TLR4+ 
CD68- (ie typical of DC rather than macrophages) but which  also expressed CD14 
(suggestive of immature DC or macrophages)(Chang et al., 2004; Chang et al., 2004).  
Detailed studies in rodents have identified separate populations with both dendritic 
cell and macrophage-like characteristics (reviewed in Introduction). For example in 
the mouse the important F4/80 population responsible for ACAID can be divided into 
a class II MHC (Ia+) subset (typical of DC) and class II MHC (Ia-) subset (typical of 
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macrophage). In our flow cytometric analysis of whole uveitic AqH we have similarly 
been able to identify both a CD14+ monocyte/macrophage population and a separate 
CD14-/low BDCA-1+ myeloid DC population. We found that in the uveitic anterior 
chamber, DC were less abundant than CD14+ monocyte/macrophages; similarly in 
mouse the macrophage population outnumbered the DC population(McMenamin et 
al., 1994). Functionally, however, the role of these DC should not be under-estimated 
as they are far more potent than macrophages in their antigen presentation capacity, 
are unique in their ability to induce naive T cell responses and can fulfil regulatory as 
well as stimulatory roles.  
 
One of the most important findings of this entire thesis is that the regulatory 
properties of AqH observed under resting conditions persist during uveitis. Although 
in the context of our model we have only considered the effects of uveitis AqH on the 
afferent arm of the immune system (specifically DC function), this refutation of our 
hypothesis is very interesting in the context of the wider debate over whether immune 
privilege is maintained or lost during uveitis. We, and others, have analysed the 
cytokines present in human AqH during uveitis, finding increases in IFNγ and IL-6 
and a fall inTGFβ2 suggestive of an anterior chamber switch from a regulatory to an 
inflammatory microenvironment (Curnow et al., 2005; Ooi et al., 2006).  Rodent 
models of uveitis reflect a similar change in profile, and provide some additional 
information as to how these levels change over time during an episode of uveitis. For 
example in the murine model of experimental autoimmune uveitis, Ohta found that at 
onset of disease (day 11 after inoculation of IRBP) there is an increase of AqH IL-6, 
IL-1β and IL-2; that at the peak of disease (day 17) there is a sharp increase in IFNγ 
and TNFα, a fall in IL-6 and IL-1and maintenance of IL-2; and that at disease 
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resolution (day 28) most cytokine levels had returned to baseline, although IL-2 and 
TNFα were still found at low levels(Ohta et al., 2000a).  
 
A number of groups have investigated the functional consequences of these changes 
in the ocular microenvironment in rodents, with different conclusions. Most early 
investigators argued that immune privilege was lost during ocular inflammation (at 
least in the early phase), and that this was primarily due to a rise in IL-6. In the 
experimental autoimmune uveitis (EAU) model outlined above, Ohta observed that 
the ability of the ocular microenvironment to suppress anti-CD3 driven T cell 
proliferation in vitro was lost at the onset of disease (d11; associated with blood 
ocular barrier breakdown and elevated AqH IL-6), and that recovery of this 
suppressive function occurred  at the peak of disease (d17; associated with a fall in 
IL-6 and elevated TGFβ2 (locally produced) and TGFβ-1 (from blood/infiltrating 
leucocytes)) (Ohta et al., 2000a). Neutralisation of IL-6 was associated with 
maintenance of normal AqH suppression at day 11, whereas neutralisation of TGFβ2 
blocked the recovery of this suppressive function(Ohta et al., 2000a). Subsequently 
using the alternative model of endotoxin induced uveitis(EIU) the same group found 
that 6 to 24 hours after systemic LPS injection into the footpads of C3H/HeN mice, 
AqH lost its capacity to suppress in vitro T-cell activation (again associated with an 
increase in AqH IL-6), and that this could be recovered by neutralization of IL-6(Ohta 
et al., 2000b). Finally they noted that the induction of antigen-specific anterior 
chamber–associated immune deviation (ACAID) in normal mice was prevented by 
the addition of IL-6 into the anterior chamber (Ohta et al., 2000b).  
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This model of a loss of immune privilege at the onset of uveitis, and its restoration 
coincident with the onset of recovery seemed reasonably robust, supported as it was 
by convincing evidence in two different animal models. More recently however two 
alternative animal models of uveitis have demonstrated that severe intraocular 
inflammation is compatible with maintenance of immune privilege, a finding which 
we have now demonstrated for the first time in human. In the first of these models, a 
variant of the Endotoxin Induced Uveitis model in which LPS is injected, not 
systemically, but into the vitreous cavity of BALB/c mice, Mo and colleagues found 
that even at the peak of intraocular inflammation (9h; associated with high levels of 
IL-6) these eyes would permit the proliferation of allogeneic tumour cells and support 
ACAID in vivo, and their AqH would still strongly inhibit T cell activation in vitro 
(Mo and Streilein, 2001). In a second model of Mycobacterium tuberculosis adjuvant-
induced uveitis (MTU), intravitreal injection of Mycobacteria tuberculosis adjuvant 
into the eyes of BALB/c mice resulted in an intense anterior uveitis which again 
supported the growth of allogeneic tumour cells, and their AqH again inhibited T cell 
activation in vitro. Interestingly, however, the early phase of disease was associated 
with a temporary failure in the ability of the eye to induce ACAID(Mo and Streilein, 
2005). 
 
Our finding that uveitis AqH continues to be inhibitory to DC function is an important 
addition to the predominantly murine literature regarding the retention or otherwise of  
immune privilege during uveitis. The four animal models described above (see also 
Table 1.9) have important immunological differences to each other, reflected in their 
different profiles of disease severity, time-course and eventual outcome .Whilst none 
are a perfect model for spontaneous disease in humans, between them they reflect 
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something of the puzzling spectrum of human disease.  Mo et al argue that 
maintenance of immune privilege is normal during inflammation, but that (1) a strong 
Th1dominated inflammation can lead to the retention of a DTH response (ie loss of 
ACAID) associated with elevated IL-12 levels  during EAU and the early phase of 
MTU; and  that (2) whilst IL-6 can abrogate TGF-β driven immune privilege in 
systemically immunized models which are characterised by lower grade ocular 
inflammation (ie EAU and systemic EIU), the more extensive blood ocular barrier 
breakdown seen with intraocular immunization (ie local EIU and MTU models) 
results in an influx of plasma proteins which neutralize the effects of IL-6 ((Mo and 
Streilein, 2007)).  It is interesting to note that whilst in humans we have observed 
elevated IL-6 levels in uveitis AqH to be functional in terms of preventing T cell 
apoptosis (via a sIL-6R trans-signalling pathway(Curnow et al., 2004)), we have 
recently shown that IL-6 is auto-regulated by an influx of sgp130, a natural inhibitor 
of IL-6 trans-signalling(Simon et al., 2008). We hypothesise that differences in 
sgp130associated with variable blood-ocular barrier breakdown may account for the 
varying responses to IL-6 seen in the different animal models of uveitis.  
 
With regard to DC function, we had demonstrated in preliminary experiments that  
IL-6 alone did not significantly affect DC function . When used in combination with 
IL-1β, TNFα and PGE2 it caused characteristic changes of maturation such as 
elevation of MHC and costimulatory molecules and allostimulatory function, but that 
these changes could be blocked by the addition of normal AqH (chapter 3); similarly 
blockade of IL-6 in uveitis AqH did not significantly affect DC phenotype. In contrast 
IFNγ was associated with the limited pro-inflammatory activity of uveitis AqH. We 
have previously shown IFNγ levels to increase in uveitis and to correlate with disease 
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activity(Curnow et al., 2005). Here we have demonstrated that recombinant IFNγ 
upregulates class I and class II MHC, and that IFNγ-blockade reduces the uveitis 
AqH-driven upregulation of class I MHC and leads to further downregulation of class 
II MHC. 
 
Our observation of the persistence of the regulatory properties of human AqH during 
uveitis is also intriguing since it appears to be operating by an alternative mechanism 
to the dominant cortisol/TGFβ2 pathway of non-inflammatory AqH. Again this is 
controversial in the animal literature. It would appear that in mouse the predominant 
regulatory molecules are neuropeptides such as αMSH and VIP, with TGFβ playing a 
relatively minor role due to most of it being in the latent state. In the EAU and 
systemic EIU models, levels of active TGFβ1 and TGFβ2 increase and  it appears that 
TGFβ quickly becomes the dominant mechanism of immune privilege (hence 
regulation can be reversed by the addition of IL-6)(Ohta et al., 2000b; Ohta et al., 
2000a).  
 
In contrast, whilst the local EIU and MTU models do not discount a role for TGFβ, 
the lack of IL-6 effect suggests that other factors must be involved. In parallel to the 
animal studies we found that the dominant regulatory mechanism we had identified in 
non-inflammatory human AqH (predominantly cortisol with TGFβ2 contributing) was 
not operational, or at least not dominant, in uveitis AqH, despite the presence of 
increasing levels of cortisol in these samples;  in humans TGFβ levels have been 
shown to fall precipitately in uveitis and hence was discounted as a significant 
contributor in these experiments. We have been unable to determine the novel 
factor(s) that appear in uveitic AqH and contribute to the maintenance of regulation. It 
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is likely that the potential regulatory role of cortisol is maintained (or even enhanced 
given its increasing levels), but that the presence of novel alternative regulatory 
molecules provide for redundancy in the system, resulting in AqH inhibition of DC 
function no longer being reversible by glucocorticoid blockade alone. This seems 
plausible given that we have shown up to ten-fold increases in the level of cortisol 
during uveitis, and have shown in vitro that at these higher concentrations cortisol can 
inhibit DC function even under inflammatory conditions. An alternative explanation 
of the loss of cortisol-dependency is that rather than simply being redundant, the 
cortisol is no longer effective, either due to elevated cortisol binding globulin or due 
to inactivation of cortisol to cortisone by 11β-HSD2 dehydrogenase activity. This 
explanation seems less likely given that we have measured the levels of free cortisol 
(rather than total) and have shown that cortisol at these doses is effective. Furthermore 
with relation to 11β-HSD expression, monocyte-derived dendritic cells and ocular 
tissue predominantly express the oxo-reductase enzyme 11β-HSD1  (which activates 
cortisone to cortisol) rather than the 11β-HSD2 isoform (Freeman et al., 2005; Rauz et 
al., 2001). 
 
The origin and identity of these novel regulatory molecules is uncertain. Possibilities 
include locally produced molecules such as regulatory cytokines (eg TGFβ, IL-10) or 
mediators of resolution (resolvins and other lipid-derived small molecules such as 
lipoxin A4), or serum-borne molecules (such as sgp130  or 1α,25-dihydroxyvitamin D 
(Simon et al., 2008; Hewison et al., 2003)). As alluded to earlier we have already 
established that in humans neither TGFβ nor IL-10 are elevated in most uveitis; in 
fact TGFβ levels fall, and IL-10 is maintained at non-inflammatory levels in all forms 
of uveitis other than Herpes-viral (Curnow et al., 2005). Evidence that the key 
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molecule(s) may be present in the serum come from animal and our own studies 
which have shown that whilst low concentrations of uveitic serum was stimulatory, 
higher concentrations of serum (uveitic or normal) was significantly 
immunosuppressive. Whilst we hypothesise that in the animal models (and in human 
T cell survival) sgp130 regulation of IL-6 trans-signalling may be a key factor, the 
lack of IL-6 effect in our experiments argues against any significant role of AqH 
sgp130 in terms of human DC function.  The recently described „resolvins‟ and 
related lipid-derived molecules are of interest. Although the effects on DC are as yet 
poorly characterised, Lipoxin A4 has been shown to inhibit dendritic cell function in 
mouse by inhibiting IL-12 production, downregulating CCR5 and inhibit migration, 
although they do not comment on surface molecule expression of MHC and 
CD86(Aliberti et al., 2002).  
 
Our observation that treatment of uveitis is associated with restoration of a 
glucocorticoid-dependent mechanism of regulation is fascinating and has clear 
parallels with the recovery of immune privilege in the animal models. Whilst in our 
experiments it was not possible to differentiate between the effects of exogenous and 
endogenous topical steroids, it is interesting that the degree of inhibitory effect and 
subsequent reversal by RU486 was independent of the intensity of glucocorticoid 
therapy suggesting that this is at least partly due to recovery of the normal cortisol 
mechanism of regulation. In any event, the return to glucocorticoid dependency 
implies that the unknown mechanism of immunoregulation operational in uveitis AqH 
prior to treatment, is no longer a significant mechanism once treatment is underway. 
This may reflect restoration of the blood-ocular barrier (untreated and treated groups 
were matched for cellular activity but not for flare) which would result in falling 
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levels of any serum-borne mediator of regulation, or may be a direct effect of the 
treatment (eg glucocorticoid therapy has been associated with a reduction in 
resolvins). We wish to pursue this work by analysing a number of recently described 
bioactive molecules such as resolvins in non-inflammatory and uveitis AqH. 
Additionally by performing time-course studies of the change in cytokine levels (and 
other modulators of inflammation) during an episode of uveitis and correlating this 
with the effects of AqH on DC and related cell types, we hope to refine our 
understanding of the role of DC in the onset, progression, resolution and recurrence of 
human uveitis.  
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6 FINAL DISCUSSION 
6.1 Introduction 
 
During the course of this thesis I have shown that myeloid DC can be isolated from 
the anterior chamber of the human eye during uveitis, that human AqH regulates DC 
function and that even in the presence of the pro-inflammatory milieu of uveitis this 
regulatory function predominates.  I  have also provided evidence that in the normal 
human eye this suppressive function is cortisol and TGFβ2 dependent, but that during 
uveitis novel regulatory mechanisms are introduced, with apparent redundancy of the 
cortisol/TGFβ system.  
 
In the previous chapters I have set these results in the context of two of the great 
debates in ocular immunology: first, the identity of the ocular APC and the location 
and nature of its interaction with the target T cell; second, the maintenance (or 
otherwise) of immune privilege during intraocular inflammation. In this final 
discussion I will consider the broader implications of these findings, first with regard 
to the concept of immune privilege and second with regard to the aetiology, 
pathogenesis and treatment of ocular inflammatory disease.  
 
6.2 Immune privilege: an extreme of normal regulation 
 
Like many homeostatic processes, the immune system is tightly regulated to operate 
within the narrow compass of what is both effective and safe. An inadequate immune 
response leaves the organism vulnerable to surrounding pathogens. A misdirected or 
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excessive response may itself lead to damage to the organism, either due to specific 
anti-self responses or due to collateral damage to healthy tissue as the pathogen is 
cleared. For the immune response to be effective, all parts of the organism must be 
accessible to it. For it to be appropriate, each tissue must have regulatory mechanisms 
(whether specific or generic) to control the magnitude and direction of that response. 
 
The concept of immune privilege as originally described by Medawar was as an 
exception to the normal immune response (Medawar, 1948). „Normal‟ immunity 
could be demonstrated by the usual rejection of foreign grafts except when placed in a 
few „immune privileged‟ sites, such as the eye. Since then, however, the number of 
sites described as being immune privileged has grown. Thus whilst only a limited 
number of tissues exhibit prolonged tolerance of foreign grafts (as per the original 
definition), relative degrees of immune privilege are present in most tissues in order 
(at least in teleological terms) to „tailor‟ the immune system to the requirements of 
that site. In this discussion I argue that the literature points to regulation of the 
immune system as a normal property of all tissues, varying according to the needs of 
that site. In this context „immune privilege‟ per se simply represents the extreme of a 
continuum of normal regulation exhibited by all tissues.  In line with this model, I 
propose that the mechanisms of DC regulation that I have been investigating in the 
AqH may be more generally applicable and are likely to occur in other sites outside of 
the eye. 
 
Although ocular immune privilege is remarkable as a phenomenon, there is nothing 
unique in its component parts. Careful consideration of other tissues demonstrates that 
every mechanism of immune regulation found in the eye may be observed to some 
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extent in other sites. Some, such as complement regulatory proteins to prevent 
inappropriate cascade initiation, are almost ubiquitous. Similarly Fas:Fas ligand 
interactions to induce leukocyte apoptosis, though originally described in the eye, has 
since been recognised in the testis, brain, lung, kidney, liver, pancreas, heart, skin, 
thyroid and blood vessels (reviewed (Green and Ferguson, 2001)). 
Interestingly the regulatory mechanisms surrounding antigen presentation and the 
dendritic cell may be more limited in their distribution. These mechanisms include: 
(1) limited drainage of antigen or APC due to either absent or inefficient lymphatic 
drainage (eye, brain(Yamada et al., 1991), hamster cheek pouch(Barker and 
Billingham, 1971) or due to DC „entrapment‟ (as seen in the feto-placental unit 
(Collins et al., 2009)); (2) immune deviation responses such as ACAID (seen in the 
eye) and similar phenomena (seen in the brain and possibly by the feto-placental 
unit); and (3) central to this thesis, the presence of immunosuppressive molecules 
such as (a) TGFβ (present in the eye, brain, feto-placental unit, tumours, sites of 
inflammation), (b) the neuropeptides αMSH, VIP,  CGRP and somatostatin (present 
in the eye, brain, feto-placental unit)  and (c) steroid hormones such as cortisol (also 
eye, brain (Popp et al., 2009), feto-placental unit (Nolten and Rueckert, 1981)) or 
progesterone (feto-placental unit). 
 
Our finding that human DC may be regulated jointly by cortisol and TGFβ2 (chapter 
4) and that regulation continues even in the presence of inflammation, is thus relevant 
both to the specific situation in the eye, but also more generally to other sites where 
these molecules are present. Whilst the parallels to the CNS and the feto-placental 
unit are most evident, it is possible that cortisol and TGFβ2 contribute to DC 
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regulation in the many other tissues where these molecules may occur constitutively 
or be found under inflammatory conditions. 
 
6.3 Aetiology and pathogenesis of uveitis: common pathways from 
varied insults 
 
The extent to which autoimmunity (ie a self-directed immune response) is an 
inevitable consequence of a highly sensitive amplificatory immune system or whether 
dysregulation only occurs in the context of an external stimulus is still a matter of 
debate(Cooke, 2003; Kivity et al., 2009). In reviewing the aetiology and pathogenesis 
of uveitis we will first consider the extent to which uveitis (or some forms of uveitis) 
may be entirely due to the „spontaneous‟ recognition of unique uveitogenic antigens 
within the eye, before turning to the putative role of infectious agents (both extra-
ocular and intra-ocular) in triggering ocular autoimmunity.  
 
Since the DC is regarded as the key player in the induction of an antigen-specific 
adaptive immune response, it is strongly implicated in the development of the 
autoreactive T cells which are thought to mediate much „idiopathic‟ uveitis. These 
models of the initiation of uveitis are therefore considered within our evolving 
understanding of DC immunology, and in the light of my findings regarding 
modulation of DC function within the ocular microenvironment. Previous discussion 
of the ocular microenvironment (chapters 4 and 5) arising from my findings has been 
primarily limited to the anterior segment of the eye, in recognition that all the 
experimental work described within this thesis is based on AqH, both its contents 
(cellular and molecular) and immunodulatory effects. In this final discussion, I wish 
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to reflect more broadly on the probable role of DC within the aetiology and 
pathogenesis of uveitis, a process which will highlight both the similarities and some 
of the differences between types of uveitis found in both animal models and human 
disease. 
 
6.3.1 Model 1: ‘Spontaneous’ ocular autoimmunity 
 
A number of different ocular antigens have been proposed to be uveitogenic. In 
animal models, immunization with retinal-S antigen and interphotoreceptor retinoid 
binding protein (IRBP), among others, have been shown to induce uveitis. It is 
interesting that in most uveitis models, and many other models of autoimmunity, 
disease only develops when immunisation occurs with an appropriate adjuvant. Such 
models include Experimental Autoimmune Anterior Uveitis ( EAAU; antigen is a 
fragment of type I collagen) which primarily causes an anterior uveitis and 
Experimental Autoimmune Uveitis (EAU; antigen is retinal S-Ag or IRBP) which 
primarily generates a panuveitis ((Bora et al., 2004; Roberge et al., 1993; Lipham et 
al., 1990) and recently reviewed (Kerr et al., 2008)). Extrapolating to the human eye 
would suggest that most „spontaneous‟ human uveitis does in fact require an 
additional infective (or at least inflammatory) stimulus in order for uveitis to develop. 
Given that ocular antigen is, to at least some extent, sequestered (resulting in 
immunological ignorance) this is perhaps to be expected. In passing it should be noted 
that the model Endotoxin Induced Uveitis (EIU) is sometimes described as being 
„adjuvant-free‟ depending as it does on systemic LPS administration to induce a 
hyperacute neutrophilic ocular infiltrate (Rosenbaum et al., 1980). Since this model 
does not induce an antigen-specific adaptive immune response it cannot be regarded 
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as a helpful model of autoimmune uveitis, although it is of interest in providing a 
mechanism by which extraocular exposure to Gram negative bacteria (and their cell 
wall component, LPS) can selectively induce intraocular inflammation (considered 
later). 
 
One naturally occurring animal model of uveitis, recurrent equine uveitis, has been 
proposed as a model of spontaneous human disease (Forrester, 2007; Deeg et al., 
2002). It should be noted however that this form of uveitis appears to be associated 
with environmental exposure, particularly to Leptospira sp.(Faber et al., 2000). 
 
A number of models of „spontaneous uveitis‟ have now been developed. Some of 
these models involve compromising thymic tolerance such as by the reconstitution of 
nude mice with rat embryonic thymus(Ichikawa et al., 1991)or by deletions of the 
autoimmune regulator (AIRE) gene (Anderson et al., 2002). Other proposed models 
involve the insertion into the mouse genome of MHC susceptibility genes such as 
HLA-A29 (associated with bird-shot retinochoroidopathy in humans) or HLA-B27 
(associated with acute anterior uveitis). Interestingly whilst HLA-A29 does lead to a 
spontaneous retinochoroidopathy resembling human disease in up to 80% of 
transgenic mice(Szpak et al., 2001), HLA-B27 transgenic mice do not spontaneously 
develop uveitis (whereas they do develop colitis and spondylarthropathy as discussed 
below).  
 
An alternative strategy is to generate mice which are transgenic for a foreign antigen 
expressed under ocular tissue promoters (such as the rhodopsin promoter) and then 1) 
inoculate with that antigen, 2) adoptively transfer with T cells specific to the foreign 
Chapter Six Final Discussion 207 
antigen or 3) cross with mice transgenic for the TCR to the foreign antigen. Gregerson 
and colleagues observed the effect of differing levels of expression of E. Coli β-
galactosidase in the retina by expressing it under different promoters. They observed 
that mice were refractory to the induction of uveitis by inoculation or adoptive 
transfer except when β-galactosidase was expressed at very high levels (β-gal-hi-
arrestin) and immunization was with a strong adjuvant (CFA and Pertussis) 
(Gregerson and Dou, 2002; Gregerson, 2002; Gregerson et al., 1999); this underlined 
the role of antigen sequestration in the tolerance of ocular antigens.  
 
Conversely the role of central tolerance was demonstrated in two studies of 
„spontaneous‟ uveitis using double transgenic mice. Ham et al used a double 
transgenic model (HEL expressed under the rhodopsin promoter (rho-HEL) with anti-
HEL TCR) to demonstrate that there was central deletion of anti-HEL T cells. 
Interestingly since deletion was partial, a degree of „spontaneous‟ uveitis was seen in 
the double transgenic model which was comparable to that seen with adoptive transfer 
of anti-HEL T cells into a single transgenic (rho-HEL); HEL immunisation with CFA 
into the single transgenic (rho-HEL) mice was not successful in inducing uveitis 
(Ham et al., 2004).  Similarly Zhang et al observed central deletion of anti-HEL T 
cells in a double transgenic model (membrane bound and soluble forms of HEL 
expressed under the α-crystallin promoter with anti-HEL TCR). Again uveitis still 
occurred due to escape of anti-HEL T cells (Zhang et al., 2003). 
 
While these models of spontaneous uveitis are ingenious, they serve rather to 
underline the strength of the immunoregulatory mechanisms which maintain ocular 
tolerance. Inducing uveitis in the absence of an infective or inflammatory trigger (as 
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postulated by this model) is difficult. This is entirely consistent with my finding that 
the ocular microenvironment strongly suppresses DC function in human. This strong 
inhibition of DC by the ocular microenvironment is also supported by data from 
animal models, notably Shen‟s observations that rabbit AqH inhibits mouse DC 
maturation and function (Shen et al., 2007). Spontaneous uveitis due to failure of 
these mechanisms is possible, but is likely to be a rare event in vivo. In summary, my 
data and evidence from the wider literature suggests that it is very unlikely that this 
model of „spontaneous‟ ocular autoimmunity is a frequent cause of non-infective 
uveitis. 
 
6.3.2 Model 2: Extraocular infection triggering ocular autoimmunity 
 
Although external aetiological agents have been proposed for many autoimmune 
diseases, there are relatively few for which there is robust evidence of cause and 
effect. One of the best-described examples of an infection-triggered autoimmune 
disease is reactive arthritis  in which there is strong evidence for the role of Gram 
negative bacteria. In outlining the possible role of extraocular infection in triggering 
ocular autoimmunity, I will first outline the evidence for the role of Gram negative 
bacteria in the development of ReA before considering the evidence for a similar 
mechanism in uveitis. 
 
6.3.2.1 Reactive arthritis as a model for infection-triggered autoimmunity 
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Reactive arthritis (also known as Reiter‟s syndrome) comprises a spectrum of clinical 
features including arthritis, urethritis and conjunctivitis which follows an infectious 
episode, either a genitourinary infection (commonly Chlamydia trachomatis) or 
gastro-intestinal (Salmonella sp., Shigella, Campylobacter jejuni and Yersinia 
enterocolitica). In most cases clinical features start 2-4 weeks post-infection, and 
resolve by 6-12 months post-infection, but around 15% may relapse and develop a 
progressive course. The presence of HLA-B27 is a risk factor for ReA, and is 
particularly common amongst those developing a progressive course or exhibiting 
extra-articular manifiestions (Brewerton et al., 1973b; Rihl et al., 2006a).  
 
In addition to clinical evidence associating prior Gram negative infection with the 
subsequent disease, there is reasonable immunological evidence to suggest cause and 
effect. Chlamydia, Yersinia and Salmonella antigens and Chlamydia bacterial RNA 
(but not cultivatable organisms) have all been identified from synovial tissue or fluid 
in ReA, sometimes years after the initial infection(Rihl et al., 2006b; Gerard et al., 
2000). The role of HLA-B27 in promoting susceptibility is not clear. It is possible that 
when HLA-B27 processes peptides from Gram negative bacteria, it results in an 
MHC-peptide complex which resembles self, and can thus via „ molecular mimicry‟ 
induce an anti-self response. Interestingly HLA-B27 restricted T cell responses are 
observed both to Chlamdyia and Klebsiella antigens and to human aggrecan (a 
proteoglycan found in cartilage). An alternative explanation is that the B27 molecule 
itself is immunogenic. This might be through misfolding (it is noted to have a 
relatively slow folding rate) and accumulation in the endoplasmic reticulum(Turner et 
al., 2005); or through the formation of immunogenic homodimers (Allen et al., 1999);  
or through molecular mimicry (ie resemblance between HLA-B27 and Gram negative 
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bacteria antigens (Chang et al., 2006; Chang et al., 2005; Chang et al., 2004).  Other 
susceptibility genes identified include functional polymorphisms of IL-10 and TNFα.  
6.3.2.2 Uveitis and the role of extraocular infection 
 
In most uveitis, the evidence for an external trigger leading to a dysregulated immune 
response is less clear. For acute anterior uveitis, like ReA, there is a strong association 
with HLA-B27 (50% of those presenting with AAU are HLA-B27+)(Chang et al., 
2005). Furthermore AAU has been reported to develop after both Yersinia and 
Salmonella infection, and specific cellular and humoral immune responses to a 
number of Gram negative bacteria have been identified in AAU patients (reviewed 
Wakefield (Wakefield et al., 1991)). It has been suggested, particularly in light of the 
organisms implicated, that chronic mucosal inflammation may be an important factor 
in disease development(Chang et al., 2005). Interestingly two-thirds of those with 
AAU have been shown to have chronic asymptomatic bowel inflammation on 
ileocolonoscopy(Banares et al., 1995). This finding parallels the observation that 
whilst HLA-B27 transgenic mice develop spondylarthropathy and colitis in the 
presence of commensal gut bacteria, they fail to do so in pathogen free conditions 
(Rath et al., 1996).  
 
The idea that much uveitis is an autoimmune response to an ocular antigen is an 
attractive hypothesis. In the context of AAU it is generally suggested that, as 
proposed for ReA, an ocular-antigen specific immune response arises through 
molecular mimicry to a pathogenic antigen (presented by DC or other professional 
APC). Autoreactivity may be present from the outset, or occur via epitope/antigen 
spreading in which priming to self-antigens released during tissue damage may occur; 
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this arises most commonly in the context of persistent immune response to the 
original antigen such as during chronic infection. It should be noted that, unlike the 
situation in ReA, conclusive identification of intact antigen from Gram negative 
bacteria has not been identified in the target tissue (ie the eye) itself, nor is there clear 
evidence for DC traffic from the eye (Dullforce et al., 2004; Camelo et al., 2003; 
Camelo et al., 2006; Camelo et al., 2004a); indeed my own data suggests that the 
required CCR7 upregulation/CCR5 downregulation is not induced by uveitis AqH. 
This provides further support to the concept that the encounter of APC and antigen 
may have occurred at an extra-ocular site of infection, such as the gastrointestinal or 
genitourinary tract.  
 
6.3.3 Model 3: Intraocular infection triggering ocular autoimmunity 
 
Infective uveitis due to intraocular invasion by pathogen may be caused by a wide 
range of organisms including viruses (eg Herpes simplex family), bacteria (eg 
Mycobacteria tuberculosis, Treponema pallidum), protozoa (eg Toxoplasma gondii), 
nematodes (eg Toxocara canis, Onchocerca volvulus) and fungi (eg Candida albicans, 
Histoplasma capsulatum). It is increasingly evident that much of the pathology of 
these diseases is mediated less by the organism itself and more by the immune 
response to chronic infection or possibly persistent antigen. It is interesting to 
speculate that some of the idiopathic uveitis syndromes such as Fuchs‟ heterochromic 
uveitis (FHU) and Posner-Schlossman syndrome (PSS) may represent a persistent 
immune response to a latent infection or to persistent antigen from a cleared infection. 
Each of these syndromes share clinical features with recognised presentations of viral 
anterior uveitis. In the past chronic infection with Herpes simplex and more recently 
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Rubella have been postulated for FHU (Bonfioli et al., 2005); trabeculitis due to 
Herpes simplex family members are still the leading candidates for PSS (Chee and 
Jap, 2008).  
 
An extension of this hypothesis is that the intraocular infection leads to the generation 
of autoreactive to T cells to an ocular antigen (by molecular mimicry, epitope 
spreading and/or bystander activation) so inducing a purely autoimmune uveitis which 
would continue after clearing of the pathogen. Although speculative, such a 
mechanism could account for the discordance between the reported falling incidence 
of FHU in line with rubella vaccination and the lack of clear evidence of persistent 
rubella pathogen (or even antigen) in ocular tissues/fluid (Birnbaum et al., 2007). 
Similarly in the context of posterior or panuveitis, it has been proposed that 
sarcoidosis (and its related uveitis) reflects a persistent immune response to chronic 
atypical mycobacteria infection; however it is also possible that such an infection 
generates a purely autoimmune syndrome which persists even after successful 
clearing of the mycobacteria.  
 
My data does not support the hypothesis that ocular DC, whether under resting or 
inflammatory conditions, migrate to draining lymph node tissue to induce a naive T 
cell response. As noted earlier my own data suggests that uveitis does not induce the 
normal CCR7 upregulation/CCR5 downregulation required for migration to the 
draining lymph nodes (indeed CCR5 was upregulated). Additionally ocular DC 
expression of the costimulatory molecule CD86 was reduced, and there was 
concomitant diminution of T cell responses (naive and memory; CD4+ and CD8+), 
suggesting that if any DC had trafficked to the draining lymphoid tissue (or if DC 
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encounter memory T cells in the ocular tissue itself) that this is unlikely to result in a 
strong antigen-specific effector immune response. 
 
6.3.4 T cell trafficking to the eye 
 
Although the mechanisms are very ill-defined, it seems increasingly likely that the 
initiating events in most cases of uveitis involve the extra-ocular/systemic priming of 
autoreactive T cells as a by-product of a normal response to pathogen(Forrester, 
2007). Indeed the capacity of a systemic injection of retinal antigen in conjunction 
with adjuvant to induce uveitis (as in EAU), is a clear demonstration that these 
mechanisms can operate. The next unresolved question is: regardless of where T cells 
are primed, how do they encounter antigen in the eye? 
 
6.3.4.1 Extraocular priming and site specific homing 
 
In the context of the model of ocular autoimmunity being triggered by extra-ocular 
mucosal inflammation (discussed earlier), it would follow that priming of naive 
antigen-specific T cells would occur in draining secondary lymphoid tissue. Thus in 
the presence of gastrointestinal inflammation, this would constitute Peyers patches 
and the mesenteric lymph nodes. The majority of T cells primed in this lymphoid 
tissue would home back to the gut due to expression of CCR9 and α4β7-integrin 
(responding to gut-specific CCL25 and mucosal vascular addressin cell-adhesion 
molecule (MADCAM-1) respectively), but such site-specific recirculation is not 
complete, allowing for the possibility that gut-DC primed T cells may circulate (Mora 
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et al., 2003)through other tissues such as the eye (reviewed Adams (Adams and 
Eksteen, 2006)). Mora et al found that the ratio of gut-DC primed T cells to peripheral 
lymph node-DC primed T cells was 17 times higher in the small intestine than the 
blood, but they also showed that these gut-DC primed T cells circulated to a range of 
other tissues including liver, lung and peripheral lymph nodes. Furthermore there is 
evidence that site-specific homing can be reprogrammed by subsequent encounters 
with DC from other tissues as has been demonstrated between skin and gut-DC 
primed T cells (Dudda et al., 2005). Whilst unique homing signals have not been 
identified for ocular tissues, this does at least provide a mechanism by which gut or 
skin-DC primed T cells may be diverted to other peripheral tissues including the eye. 
 
6.3.4.2 Hypothesis 1. Routine T cell trafficking through the non-inflamed eye leads 
to encounter of ocular antigen-specific T cell with cognate Ag/resident APC 
 
It is not clear to what extent there is any circulation of T cells through the eye under 
non-inflamed conditions, although during active uveitis we have found the anterior 
chamber infiltrate to have a high proportion of CD4+T cells which are almost 
exclusively the CD45RO+ memory (rather than CD45RA+ naive) population. Studies 
of non-inflamed CSF have however demonstrated a significant number of  memory 
CD4+ and CD8+ T cells circulating through the CSF which appear to provide a 
degree of „immune surveillance‟ to the adjacent CNS tissues (Hickey, 1999). 
Although this runs somewhat counter to its status as an immunologically-ignored 
antigen-sequestered organ, it seems likely that the eye may experience a similar 
degree of routine lymphocyte trafficking. Such trafficking would then permit the 
encounter of recirculating memory CD4+ or CD8+ T cell with APC in the eye 
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allowing reactivation of the antigen-specific T cell by either resident dendritic cell or 
macrophage, activation of macrophages by Th1 effector cells or direct cytotoxic 
function of effector CD8+ T cells. Interestingly Prendergast et al suggest that 
activated T cells are not restricted by the blood-ocular barrier. They observed that 
activated T cells, whether antigen specific (a retinal S-Ag specific T cell line) or non-
specific (concanavalin-A stimulated T cells), accessed the retina within 24h and that 
this preceded any visible signs of inflammation (Prendergast et al., 1998). 
 
An alternative explanation for this model comes from the findings of Xu et al who 
showed that adoptive transfer of non-Ag-specific activated T cells (concanavalin-A 
stimulated) into the normal mouse can themselves cause a transient local breakdown 
in the blood ocular barrier with passage of activated T cells across the endothelium. 
This mechanism, which is dependent on ICAM-1 upregulation on the endothelium 
and its interaction with LFA-1 on the T cell (Xu et al., 2003), provides an explanation 
by which activated autoreactive T cells may encounter cognate antigen within the eye 
in the absence of pre-existing ocular inflammation. 
 
A central feature of this hypothesis is it places the interaction of effector T cell and its 
cognate Ag-bearing APC (or Ag-bearing parenchymal cell) within the eye before 
there has been any local inflammation or breakdown in the blood-ocular barrier. In the 
context of this model, my findings that DC function is generally inhibited in the 
presence of non-inflammatory AqH (see chapter 4), would suggest that most 
encounters with circulating ocular-antigen specific T cells will not result in an 
effective (auto)immune response. Indeed, as discussed previously, the encounter may 
result in T cell anergy or even regulatory function, although I have not been able to 
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investigate this conclusively within this thesis. In the light of my findings, it seems 
unlikely that this non-specific routine circulation of T cells through the eye under 
resting conditions is the dominant mechanism by which uveitis-associated ocular-Ag 
specific T cell recruitment to the eye occurs. 
 
6.3.4.3 Hypothesis 2. Non-specific systemic inflammation leads to generalised 
endothelial activation and blood-ocular-barrier breakdown enabling 
encounter of ocular antigen-specific T cell with cognate Ag/resident APC 
 
The blood-ocular barrier and limited lymphatic drainage reduces leukocyte trafficking 
to and from the eye, resulting in a degree of immunological ignorance. It is therefore 
argued that any primed ocular antigen-specific T cells may simply never encounter 
antigen that is sequestered exclusively in the eye. A systemic inflammatory response, 
such as occurs during a generalized viral infection (eg influenza), leads to systemic 
release of IL-1β, IL-6 and TNFα. Release of these cytokines results in generalised 
activation of endothelial barriers, and may also affect the blood-ocular barrier. This in 
turn would lead to recruitment of memory T cells to the site of inflammation; it has 
also been suggested that under extreme inflammation naive T cells may also circulate 
through.  
 
Support for this hypothesis comes from the data of Xu et al who, in contrast to the 
conclusions of Prendergast et al (discussed earlier), suggest that activated T cells 
cannot routinely cross the uninflamed blood-ocular barrier. Using a scanning laser 
ophthalmoscope to track labelled leucocytes, they observed that under normal 
circumstances the high shear stress of the retinal vessels and lack of appropriate 
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adhesion molecules, precluded lymphocyte rolling, sticking and egress. When EAU 
was induced, they observed that early on in the disease (d9) reduction in shear stress, 
and upregulation of ICAM-1, P- and E-selectin on the endothelium permitted IRBP 
Ag-primed cells to leave the vessels and infiltrate the retina. Interestingly at the peak 
of disease (d16), naive cells also were able to infiltrate the retina(Xu et al., 2004). The 
numbers of these naive cells identified in retinal tissue were significantly fewer than 
the Ag-primed cells at all time points which may, in addition to the observed 
reduction in recruitment, reflect differential retention (or selective apoptosis). 
 
One molecule which may be released systemically and which has been shown to 
cause blood-ocular barrier breakdown is LPS. In EIU, injection of LPS alone (either 
systemic or intravitreal) leads to an anterior uveitis characterized by severe blood-
ocular barrier breakdown and neutrophilic infiltrate. The selective sensitivity of iris 
and ciliary body to LPS is interesting, and is possibly mediated via TLR-4 which has 
been shown to be expressed on APC in these tissues(Chang et al., 2004). The 
sensitivity of the blood-ocular barrier to LPS is important both in terms of the possible 
link between extraocular mucosal infection and anterior uveitis and more generally in 
demonstrating how a systemic stimulus can cause selective blood-ocular barrier 
breakdown. 
 
A central feature of this hypothesis is that the effector T cell does not enter the eye 
until inflammation (albeit generalised) is already present. The encounter of 
autoreactive T cell with cognate antigen as presented by antigen presenting cells (or 
on parenchymal cells) would thus occur in the context of inflammatory cytokines such 
as IL-1, IL-6 and TNFα. Given that AqH continues to inhibit DC function even in the 
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presence of inflammation, whether actual uveitis (chapter 5) or exogenous cytokines 
(chapter 4), it is likely that antigen presentation within the eye (at least by DC) does 
not result in a strong effector response, either for naive or for memory T cells. 
 
6.4 The natural history of uveitis and the role of treatment 
 
One of the unresolved issues of this thesis (and of our understanding of human uveitis 
in general) concerns how the immune response evolves during the clinical course of 
uveitis. To further characterise the uveitic immune response would require 
longitudinal AqH samples from a cohort of patients. Ideally one would take samples 
at onset and regularly throughout any acute episode (for first episodes and 
recurrences) or through any exacerbation of chronic disease, as is possible in animal 
models.  Although such regular exposure to an invasive technique would not be 
justified in humans, ethical approval has been granted to take up to three serial AqH 
samples in appropriately consented patients. Although serial sampling was not carried 
out as part of this series of experiments, such longitudinal information regarding the 
ocular infiltrate and microenvironment could be extremely valuable. Specifically it 
should  provide further insight into: the impact of treatment (note the advantage that 
one is comparing within the same patient cf between patients in this thesis); signals of 
resolution vs persistence; and the immunological difference between a first episode 
and recurrence (and possibly what determines recurrences). 
 
 In the context of this thesis it is interesting to speculate as to whether a rapidly 
resolving uveitis represents non-specific breakdown in the blood-ocular barrier (such 
as associated with LPS) but without DC priming of ocular antigen specific T cells, 
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whereas persistent (and possibly recurrent) disease represents a true autoimmune 
phenomenon mediated by DC (either ocular or extraocular). One way in which this 
might be tested would be to investigate the Ag-specificity of the T cells present in the 
AqH during episodes of uveitis, and look for restriction to ocular antigens occurring 
over time during a single recurrence and from first episode to subsequent recurrences. 
 
Patients frequently inform ophthalmologists that they have had previous episodes of 
uveitis that resolved spontaneously.  It would be interesting to know how spontaneous 
resolution differs from „treatment-assisted‟ resolution, but since one could not with-
hold treatment from any patient with active uveitis it is difficult to see how this could 
be tested. It is possible however that progress may be made by observing the 
differences in resolution between patients on different forms of therapy. 
 
6.5 Treatments for uveitis: do ocular APC have a role? 
 
Regulation of inflammation in the eye may potentially be achieved by the use of two 
different DC-based strategies: first, treatment directed at the ocular DC population; 
and second, treatment with in vitro generated „tolerogenic‟ DC populations. We will 
consider each of these in turn. 
 
The dominant finding of this thesis is that the ocular microenvironment is suppressive 
to normal DC function, and continues to be so even in the presence of uveitis. It 
should be noted, however, that despite this suppression, these  DC are still capable of 
inducing some degree of T cell proliferation, with progeny expressing both Th1 and 
Th2 cytokines. It is therefore interesting to speculate that pharmacological ablation of 
Chapter Six Final Discussion 220 
DC function or deviation towards a tolerogenic DC phenotype might lead to further 
reduction in the effector T cell response and/or an increase in the regulatory T cell 
response within the eye. This would translate into more rapid resolution of clinical 
inflammation, and, more speculatively, might also reduce disease recurrence. Such 
potential pharmacological agents include molecules to which the eye is already 
exposed such as glucocorticoids and TGFβ.  
 
As discussed previously (Chapter 4) endogenous glucocorticoid (cortisol) and TGFβ2 
are already present within the eye at physiologically significant levels. It is interesting 
that the first-line treatment of uveitis (therapeutic glucocorticoids such as 
dexamethasone) has, among its protean effects, a profound dose-dependent 
suppression of DC expression of CD86 and associated loss in induction of T cell 
responses (chapter 5). Additionally Woltman et al have shown that stimulation of 
naive or memory T cells by dexamethasone treated of human monocyte-derived DC 
results in T cells that are anergic and have mild regulatory properties (Woltman et al., 
2000; Woltman et al., 2006) .  
 
The suppressive role of TGFβ induced tolerogenic APC has been demonstrated in a 
number of murine models of inflammation, including the suppression of EAU by 
TGFβ2-treated IRBP-pulsed PEC, the delayed onset and reduction in severity of 
Experimental Autoimmune Encephalomyelitis (EAE) by TGFβ2-treated Myelin Basic 
Protein (MBP)-pulsed PEC, and the reduction in severity of a model of autoimmune 
pulmonary fibrosis induced by hapten 2,4,6-trinitrobenzene-sensitized T effector cells 
by the addition of TGFβ2-treated hapten-pulsed APC. As discussed previously (see 
chapter 4), TGFβ2 in normal AqH appears to have an inhibitory role on DC, although 
Chapter Six Final Discussion 221 
it has been suggested that this effect is reduced by the high proportion of the molecule 
in latent form. It is interesting to speculate whether exogenous treatment with TGFβ2 
or even in vivo activation of the molecule could further promote toloerogenicity in the 
ocular DC. 
 
In a review written in 2001, de Smet noted that „the functional characteristics of 
ocular DC have yet to be determined, particularly in the setting of acute 
inflammation‟ and that „modulation of DC function ... may prove to be an effective 
therapeutic approach in years to come‟ (de Smet and Chan, 2001). Since then in vitro 
generated tolerogenic DC have been used to induce suppression in a wide variety of 
animal models and, to a much more limited extent, in human. Strategies include the 
use of immature DC, or DC treated with IL-10 (with or without TGFβ), 
dexamethasone, 1,25(OH)2 Vitamin D3, PGE2, VIP, cyclosporin A, rapamycin and 
mycofenolate mofetil(Thomson and Robbins, 2008). 
 
In mouse such tolerogenic DC have been successful in prolonging allograft survival, 
in protecting from disease in models of colitis, arthritis, asthma and endotoxaemia and 
in reducing DTH response. In human healthy volunteers, immature DC pulsed with 
influenza matrix protein and keyhole limpet haemocyanin led to selective inhibition 
of MP-specific CD8+ T cell function, and generation of IL-10 producing MP-specific 
cells (Gad et al., 2004).  
 
Tolerogenic DC trials for human autoimmune disease are currently underway: these 
include one trial for diabetes mellitus using DC pulsed with antisense 
oligodeoxyribonucleotides to CD40, CD80 and CD86 and two trials for rheumatoid 
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arthritis using DC, one with DC pulsed with citrullinated peptides and one with non-
pulsed DC treated with dexamethasone and vitamin D3 (reviewed (Thomson and 
Robbins, 2008)). Although there are many practical challenges to the use of 
tolerogenic DC in the clinic, progress may be rapid due to the extensive experience 
gained from vaccination protocols for immunogenic DC use in cancer (reviewed 
(Palucka et al., 2008)). Whilst it is unlikely that DC vaccination is ever first-line 
therapy for mild disease, it remains an exciting possibility that, in refractory uveitis, 
tolerogenic DC (perhaps generated by endogenous ocular molecules or their 
analogues) may finally enable targeted resolution of the adaptive immune system in 
the eye. 
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8 APPENDIX 
 
8.1 Patient Information Sheet 
See pages I to V. 
8.2 Patient Consent Form 
See page VI. 
8.3 Study letter to GP 
 
See page VII. 
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Birmingham and Midland Eye Centre 
Dudley Road 
Birmingham 
B18 7QH 
Tel: 0121 554 3801 
www.cityhospital.org.uk 
 
Immune mechanisms in the ocular microenvironment 
 
You are being invited to take part in a research study. Before you decide it is 
important for you to understand why the research is being done and what it will 
involve.  Please take time to read the following information carefully. Talk to others 
about the study if you wish.  
 Part 1 tells you the purpose of this study and what will happen to you if you take 
part.   
 Part 2 gives you more detailed information about the conduct of the study.  
Ask us if there is anything that is not clear or if you would like more information.  
Take time to decide whether or not you wish to take part. 
 
PART 1. 
What is the purpose of the study? 
 
We are studying how the fluid inside the front of the eye (known as aqueous humour) 
is involved in a range of diseases that can cause the eye to become inflamed. We 
wish to look at a number of cells and molecules in the aqueous humour of people 
who have eye inflammation and compare these with people who do not have eye 
inflammation. By studying these differences we hope it will give us new information 
about how the inflammation is caused. In the longer term this information may lead to 
the development of better treatments for these conditions. 
 
Why have I been chosen? 
 
You have been invited to participate in this study because you have a condition that 
has caused your eye to become inflamed.  
  
Do I have to take part? 
 
No.  It is up to you to decide whether or not to take part.  If you do, you will be given 
this information sheet to keep and be asked to sign a consent form. You are still free 
to withdraw at any time and without giving a reason.  A decision to withdraw at any 
time, or a decision not to take part, will not affect the standard of care you receive.  
 
What will happen to me if I take part? 
 
If you decide to take part, we will take a very small sample of the fluid (aqueous 
humour) from the front of your eye. This is done in the Out-Patient Clinic or Casualty 
Department. First we use a few anaesthetic drops to numb your eye and then some 
antiseptic drops to clean the eye. With you sitting on our slit-lamp microscope (this is 
the machine we always use to look at your eyes) we introduce a very fine needle 
through the outside edge of the window of the eye to take a tiny sample of fluid 
(about the size of a drop of water) from the front of the eye. As the procedure is 
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undertaken under local anaesthesia there should be no pain but there might be a 
sensation of a slight pulling feeling for a few seconds as the sample is taken. 
We often perform this test in people who we think an infection has caused their eye 
inflammation. Only a doctor highly experienced in this technique and a member of 
Professor Murray‟s team will take the sample. 
 
We also wish to take a blood sample (about six teaspoonfuls) so we can compare the 
cells and molecules in it with your aqueous humour sample. 
 
Overall, it should take about 30 minutes to have the aqueous humour and blood 
samples taken. 
 
In most people we will only take the aqueous humour and blood samples once. 
Some people can get more than one attack of eye inflammation and if it does comes 
back we may ask to take the samples again. We will not ask to take samples more 
than a total of three times.   
 
What do I have to do? 
 
During the procedure you should keep as still as possible and follow any instructions 
from the doctor, for example to look in a particular direction.  
 
After the procedure we ask you to use some antibiotic drops for a few days. You will 
also need to use the treatment prescribed for your eye inflammation, and attend your 
follow-up clinic appointment as directed by the doctor who has seen you. 
You do not have to make any extra visits because you have had a sample of 
aqueous humour taken from the eye. 
 
What is being tested? 
 
After the procedure we examine your fluid (aqueous humour) and blood sample in 
the laboratory to look at a number of cells and molecules that might be responsible 
for the eye becoming inflamed. 
 
What are the potential side effects of the procedure? 
 
Complications are unusual from taking aqueous humour samples. Theoretical risks 
include the fluid from the front of the eye leaking out of the wound, reduced eye 
pressure, infection getting into the eye, clouding of the focusing lens, and bleeding 
into the front of the eye. We have performed hundreds of these procedures and have 
never had any of these complications. 
 
Complications from having a blood sample taken are rare, other than the brief 
discomfort of the needle. Some people may get some bruising of the skin around 
where the sample was taken.  
 
What are the other possible disadvantages and risks of taking part? 
 
Your appointment may take a few minutes longer than usual, but all other treatment 
and follow-up arrangements are unchanged. 
 
What are the possible benefits of taking part? 
 
We cannot promise that our research will help you directly but we hope that it will 
help us understand why some people get eye inflammation and that this may lead to 
improvements in treatment for these conditions. 
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What happens when the research study stops? 
 
Your direct involvement in this study only lasts for the time taken to take the aqueous 
humour and blood samples. Sometimes the samples may be kept for several years 
before the research is completed. At this point the samples will be carefully disposed 
of.   
  
What if there is a problem? 
 
Any complaint about the way you have been dealt with during the study or any 
possible harm you might suffer will be addressed. The details are included in Part 2. 
 
If you have any complaints please contact the Chief Investigator, Prof Philip I. Murray 
on 0121 507 6851. If you wish to contact someone independent please contact the 
Patient Advice and Liaison Services on 0121 507 4396. 
 
Will my taking part in the study be kept confidential?  
 
Yes.  All the information about your participation in this study will be kept confidential.  
The details are included in Part 2. 
 
Contact Details: 
 
For further information about the study or should you have any concerns about your 
involvement please contact either: 
 
Chief Investigator: Principal Investigator: 
Prof Philip I. Murray 
Academic Unit of Ophthalmology 
Birmingham & Midland Eye Centre 
Sandwell & West Birmingham NHS Trust 
Dudley Rd 
Birmingham  
B18 7QU 
Miss Saaeha Rauz 
Academic Unit of Ophthalmology 
Birmingham & Midland Eye Centre 
Sandwell & West Birmingham NHS Trust 
Dudley Rd 
Birmingham  
B18 7QU 
Tel: 0121 507 6851 Tel: 0121 507 6849 
Fax: 0121 507 6853 Fax: 0121 507 6853 
Email: P.I.Murray@bham.ac.uk Email: S.Rauz@bham.ac.uk 
 
 
This completes Part 1 of the Information Sheet. 
 
If the information in Part 1 has interested you and you are considering participation, 
please continue to read the additional information in Part 2 before making any 
decision. 
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Part 2  
 
What will happen if I don’t want to carry on with the study? 
 
You can withdraw from the study at any point, even after we have taken your 
samples. If you withdraw from the study, and you wish us to destroy your samples, 
we will do so but we would need to use the data collected up to your withdrawal.  
 
What if there is a problem? 
 
Complaints: If you have a concern about any aspect of this study, you should 
ask to speak with the researchers who will do their best to answer your 
questions (0121 507 6851).  If you remain unhappy and wish to complain 
formally, you can do this through the NHS Complaints Procedure.  Details can 
be obtained from the hospital. 
 
Harm:  In the event that something does go wrong and you are harmed during 
the research study there are no special compensation arrangements.  If you 
are harmed and this is due to someone‟s negligence then you may have 
grounds for a legal action for compensation against Sandwell & West 
Birmingham Hospitals NHS Trust, but you may have to pay your legal costs. 
The normal National Health Service complaints mechanisms will still be 
available to you (if appropriate). 
 
Will my taking part in this study be kept confidential? 
 
All information which is collected about you during the course of the research will be 
kept strictly confidential.  This information will be gathered by one of the clinical 
members of staff either directly from you at the time you enrol in the study or from 
your clinical notes at a later date. This information is anonymised, and only clinical 
members of staff involved directly with this research will have access to any 
identifiable data. Any information about you which leaves the hospital will have your 
name and address removed so that you cannot be recognised from it 
 
Our procedures for handling, processing, storage and destruction of your data are 
compliant with the Data Protection Act 1998. You have the right to view the data we 
have on record about you and to correct any errors. 
 
With your permission we would like to inform your GP that you have participated in 
this study. We will inform the GP that you have had a sample of aqueous humour 
and blood taken today but that this does not affect your treatment or follow-up 
arrangements. 
 
What will happen to any samples I give? 
 
The samples are stored in a secure environment on the Birmingham & Midland Eye 
Centre Site and are only removed to the Academic Unit of Ophthalmology Laboratory 
(University of Birmingham site) when they need to be analysed. Only members of 
Professor Murray‟s research team will have access to the samples. The samples will 
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eventually be destroyed in a safe manner following clinical waste protocol. All these 
conditions are compliant with the MRC guidance „Human Tissue and Biological 
Samples for Use in Research‟ and the Human Tissue Act 2004 
 
 
Will any genetic tests be done?   
 
No 
 
What will happen to the results of the research study? 
 
It is intended that the results of the research will be presented at scientific meetings, 
and published in relevant clinical and academic journals. We also feed these results 
back to participants through patient support groups and information in clinic. You will 
not be identified in any report or publication. 
 
Who is organising and funding the research?   
 
The Academic Unit of Ophthalmology of the University of Birmingham is organising 
this study. Our funding is derived from several ocular charities including the 
Birmingham Eye Foundation. Your doctor will be not be paid for including you in this 
study, and you will not receive any payment for participating in the study. 
 
Who has reviewed the study?  
 
This study was given a favourable ethical opinion for conduct in the NHS by the 
Dudley Local Research Ethics Committee. 
 
Patient Information Leaflet: Immune Mechanisms in the Ocular Microenvironment 
31.08.06 version 1.1 
 
And finally … 
 
You will be given a copy of the information sheet and a signed consent form. Thank 
you for taking the time to read this sheet and considering involvement in this 
research study. 
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Birmingham and Midland Eye Centre 
Dudley Road 
Birmingham 
Centre Number: BMEC               B18 7QH 
Study Number: UKCRN 4654         Tel: 0121 554 3801 
Patient Identification Number for this trial:            www.cityhospital.org.uk 
 
 
CONSENT FORM: Immune mechanisms in the ocular microenvironment 
 
Name of Chief Investigator: Professor Philip I. Murray 
Name of Principal Investigator: Miss Saaeha Rauz 
                                                Please initial box 
 
1. I confirm that I have read and understand the information sheet dated 31.08.06      
(version 1.1) for the above study. I have had the opportunity to consider the 
information, ask questions and have had these answered satisfactorily. 
 
2. I understand that my participation is voluntary and that I am free to withdraw at 
any time, without giving any reason, without my medical care or legal rights 
being affected. 
 
3.   I understand that relevant sections of any of my medical notes and data 
collected during the study, may be looked at by responsible individuals from 
regulatory authorities or from the NHS Trust, where it is relevant to my taking  
part in this research.  I give permission for these individuals to have access to 
my records.                             
                                                                                                             
4. I agree to my GP being informed of my participation in the study. 
 
 
5.   I agree to take part in the above study.    
 
 
 
 
________________________ ________________ ____________________ 
Name of Patient Date Signature 
 
 
 
_________________________ ________________ ____________________ 
Name of Person taking consent Date Signature 
(if different from researcher) 
 
 
 
_________________________ ________________ ____________________ 
Researcher Date  Signature 
 
 
When completed,  1 for patient;  1 for researcher site file;  1 (original) to be kept in medical notes 
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Birmingham and Midland Eye Centre 
Dudley Road 
Birmingham 
B18 7QH 
Tel: 0121 554 3801 
www.cityhospital.org.uk 
 
 
Centre Number:BMEC  
Study Number: UKCRN4654 
 
 
Title of Project: Immune mechanisms in the ocular microenvironment 
 
Name of Chief Investigator: Professor Philip I. Murray 
Name of Principal Investigator: Miss Saaeha Rauz 
  
 
 
Dear Doctor, 
 
This is to inform you that your patient: 
 
 
 
 
 
 
 
 
 
 
      
has today participated in our study on “Immune Mechanisms in the Ocular 
Microenvironment”. Their involvement included having samples of aqueous humour and 
peripheral blood taken. Neither of these procedures should affect their clinical care in any 
way. A separate letter will be sent to you regarding their clinical condition. 
 
Yours faithfully, 
 
 
 
 
 
Philip I. Murray PhD FRCP FRCS FRCOphth 
Professor of Ophthalmology 
 
                                        
 
 
 
 
Insert Addressograph here 
CHAPTER 3 
The development of an in-vitro model 
to study dendritic cell function in the 
ocular microenvironment
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Figure 3.1 Differentiation of dendritic cells from monocytes is inhibited in the 
absence of serum, with a lower yield and altered surface profile.
Bead purified CD14+ monocytes were cultured for 6d in the presence of 10% 
human serum or a serum-free alternative (1% BSA, ITS+3 or ITS+3/Non-essential 
amino-acids/Sodium pyruvate). (A) Forward scatter vs Side scatter and CD86  
expression for representative cultures in human serum vs serum-free (here ITS+3). 
(B) Yield and (C) MFI of HLA-DR, CD80 and CD86 for mean + SD of triplicate 
cultures; representative of three separate experiments. 
One-way ANOVA  with Bonferroni post-hoc test for each column vs human serum 
* p < 0.05; ** p < 0.01; *** p < 0.001; NS = not significant
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Figure 3.2 Differentiation of dendritic cells from monocytes is affected by 
serum type, with reciprocal changes in CD80 and CD86.
Bead purified CD14+ monocytes were cultured for 6d in the presence of 10% 
human serum or fetal calf serum (FCS), which was either standard or heat 
inactivated. (A) Yield and (B) MFI of HLA-DR, CD80 and CD86 for mean + SD 
of triplicate cultures; representative of three separate experiments.
One-way ANOVA  with Bonferroni post-hoc test for selected columns shown;      
* p < 0.05; ** p < 0.01; *** p < 0.001; NS = not significant.
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Figure 3.3 Fetal calf serum (FCS) induction of CD80 is prevented by the 
presence of human serum (HS), whilst FCS inhibits normal CD86 
upregulation by HS.
Bead purified CD14+ monocytes were cultured for 6d in the presence of (A) 0-
10% human serum or fetal calf serum or (B) both sera. MFI of CD80 and CD86 
for mean + SD of triplicate cultures; representative of two separate experiments. 
One-way ANOVA  with Bonferroni post-hoc test for matched concentrations 
shown;      * p < 0.05; ** p < 0.01; *** p < 0.001; NS = not significant.
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Figure 3.4 Dendritic cell differentiation in human serum is not affected by 
whether the serum is autologous or standard pooled AB male serum.
Bead purified CD14+ monocytes were cultured for 6d in the presence of 10% 
human serum (HS; standard pooled male AB+ vs autologous). MFI of HLA-DR, 
CD80 and CD86 for mean +SD of triplicate cultures; representative of three 
experiments. Student’s t-test (unpaired); NS = not significant.
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Figure 3.5 Serum-free conditions are compatible with dendritic cell 
maturation in response to inflammatory cytokines but are associated with 
lower yields.
Monocyte-derived dendritic cells were cultured for 48h with or without 
inflammatory cytokines (IL1β, IL6, TNFα, PGE2 to generate mature mDC vs 
immature iDC) in the presence or absence of serum. Histograms for (A) yield (B) 
MHC and key costimulatory molecules for mean + SD MFI of triplicate cultures; 
representative of three separate experiments. 
One-way ANOVA  with Bonferroni post-hoc test for selected columns shown; 
* p < 0.05; ** p < 0.01; *** p < 0.001; NS = not significant.
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Figure 3.6 Inflammatory cytokines under serum-free conditions induce 
changes in key surface molecules characteristic of dendritic cell maturation
Monocyte-derived dendritic cells were cultured for 48h in the presence or absence 
of a cocktail of inflammatory cytokines (IL1β, IL6, TNFα, PGE2). Flow cytometry 
plots and mean +SD MFI of triplicate cultures for (A) MHC (B) selected 
chemokine receptors and (C) key costimulatory molecules;  representative of three 
separate experiments.
Student’s t-test (unpaired); * p < 0.05; NS = not significant. 
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Figure 3.7 Changes in chemokine receptors induced by inflammatory 
cytokines under serum-free conditions affect transmigration in response to 
CCL5 (RANTES) and CCL19.
Monocyte-derived dendritic cells were cultured for 48h in the presence or absence 
of a cocktail of inflammatory cytokines (IL1β, IL6, TNFα, PGE2). Migration to 
chemokine was assayed in a 96-well transwell plates with (A) flow cytometric 
counting of both chambers after 3h incubation to estimate (B) percentage 
transmigration. Representative of three separate experiments. Region R1 
corresponds to live cells; R35 to counting beads.
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Figure 3.8 Cytokine production induced by inflammatory cytokines under 
serum-free conditions is selectively upregulated
Monocyte-derived dendritic cells were cultured for 48h in serum-free conditions 
with or without inflammatory cytokines (IL1β, IL6, TNFα, PGE2). Culture 
supernatants were analysed by multiplex bead immunoassay. Mean + SEM 
concentrations for triplicate cultures; representative of four separate experiments. 
Student’s t-test * p < 0.05; ** p < 0.01; *** p < 0.001; NS = not significant.
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Figure 3.9 Dendritic cell maturation under serum-free conditions is 
compatible with highly stimulatory DC in an allogeneic proliferation model
CFSE labelled naive CD4+ T cells were cultured for 4 days in the presence or 
absence of monocyte-derived dendritic cells (either untreated (iDC) or pre-treated 
with inflammatory cytokines (mDC)). (A) Flow cytometric detection of CFSE 
levels in counted cells enables estimation of (B) number of divided cells with 
mean + SD of triplicate cultures shown. (A) and (B) are representative of ten 
separate experiments as shown in (C).
One-way ANOVA  with Bonferroni post-hoc test for selected columns (B) and 
Wilcoxon matched pairs test (C). * p < 0.05; ** p < 0.01; *** p < 0.001; NS = not 
significant.
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Figure 3.10 Dendritic cells matured under serum-free conditions are highly 
stimulatory to both naive and memory CD4+ T cells in an allogeneic 
proliferation model
CFSE labelled naive or memory CD4+ T cells were cultured for 4 days in the 
presence or absence of monocyte-derived dendritic cells (either untreated (iDC) or 
pre-treated with inflammatory cytokines (mDC)) (A) Flow cytometric detection of 
CFSE levels (B) number of divided cells with mean + SD of triplicate cultures 
shown. (A) and (B) are representative of three separate experiments.
One-way ANOVA  with Bonferroni post-hoc test for selected columns shown; 
* p < 0.05; ** p < 0.01; *** p < 0.001; NS = not significant.
P
ro
li
fe
ra
ti
o
n
(n
 o
f 
d
iv
id
e
d
 c
e
ll
s
)
NS
*** ***
***
iDC mDC T cell only
S
S
S
S
CFSE CFSE CFSE
A
B
iDC             mDC       T cells
only    
Naive CD4+
Memory CD4+
+     - +     - +     -
- +         - +         - +
NS
*** ***
N
a
iv
e
 C
D
4
+
M
e
m
o
ry
 C
D
4
+
Chapter Three Results 113
Figure 3.11 Dendritic cells cultured in serum-free conditions do not 
selectively skew T cell differentiation as measured by T cell cytokine 
production
CFSE labelled naive or memory CD4+ T cells were cultured for 4 days in the 
presence or absence of monocyte-derived dendritic cells (either untreated (iDC) or 
pre-treated with inflammatory cytokines (mDC)), and cytokine concentration in 
culture supernatants measured by multiplex bead immunoassay. Mean + SEM 
concentrations for four separate experiments shown. 
One-way ANOVA  with Bonferroni post-hoc test for selected columns shown; 
* p < 0.05; ** p < 0.01; *** p < 0.001; NS = not significant.
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Figure 3.12 Activation by dendritic cells induces FoxP3 elevation in naive 
CD4+ T cells which peaks at day 4, but is only present in a minority by day 8.  
CFSE labelled naive CD4+ T cells were cultured for 4 days in the presence or 
absence of monocyte-derived dendritic cells (either untreated (iDC) or pre-treated 
with inflammatory cytokines (mDC)) and stained for intracellular FoxP3 
expression. 
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Figure 3.13 FoxP3 expression in dendritic cell-activated naive CD4+ T cells is 
sustained at higher levels when stimulated by immature rather than mature 
dendritic cells
CFSE labelled naive CD4+ T cells were cultured for 8 days in the presence or 
absence of monocyte-derived dendritic cells (either untreated (iDC) or pre-treated 
with inflammatory cytokines (mDC)) and stained for intracellular FoxP3 
expression. (A) CFSE vs FoxP3 expression. R11 represents undivided cells with 
high FoxP3 expression; R10 and R12 represent divided cells; R16 represents 
FoxP3 bright divided cells. (B) MFI or percentage expression for mean +SD 
triplicate cultures; representative of three separate experiments. 
Student’s t-test (unpaired); * p < 0.05; ** p < 0.01; NS = not significant.
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Figure 3.14 Myeloid dendritic cells upregulate MHC and costimulatory 
molecules in serum-free conditions in response to an inflammatory stimulus
Bead-purified myeloid dendritic cells (MyDC) were cultured for 48h in the 
presence or absence of a cocktail of inflammatory cytokines (IL1β, IL6, TNFα, 
PGE2). (A)  Forward scatter vs side scatter, (B) surface expression (C) mean +SD 
MFI for MHC and other key surface molecules for triplicate cultures; 
representative of three separate experiments. 
One-way ANOVA  with Bonferroni post-hoc test for selected columns shown; 
* p < 0.05; ** p < 0.01; *** p < 0.001; NS = not significant.
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Figure 3.15 Myeloid DC treated with inflammatory cytokines induce higher 
levels of proliferation of naive CD4+ T cells, indicative of DC maturation
CFSE labelled naive CD4+ T cells were cultured for 4 days in the presence or 
absence of monocyte-derived DC or bead-purified myeloid DC (either untreated 
(iDC) or pre-treated with inflammatory cytokines (mDC)). (A) Flow cytometric 
detection of CFSE levels (B) number of divided cells with mean + SD of triplicate 
cultures shown. (A) and (B) are representative of three separate experiments. 
One-way ANOVA  with Bonferroni post-hoc test for selected columns shown; 
* p < 0.05; ** p < 0.01; NS = not significant
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CHAPTER 4 
Dendritic cell function in the ocular 
microenvironment: the suppressive 
role of non-inflammatory aqueous 
humour
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Figure 4.1 Non-inflammatory AqH reduces expression of MHC and CD86 on 
immature  monocyte-derived dendritic cells and prevents upregulation of 
MHC and costimulatory molecules in response to inflammatory cytokines.
Monocyte-derived DC were cultured for 48h in the presence or absence of 
inflammatory cytokines (IL-1β, IL-6, TNFα and PGE2) with or without 50% AqH. 
(A) Flow cytometry histograms and (B) MFI  of HLA-ABC, HLA-DR, CD80, 
CD83 and CD86 for mean + SD of triplicate cultures; representative of six 
separate experiments.
One-way ANOVA  with Bonferroni post-hoc test for selected columns shown;      
* p < 0.05; ** p < 0.01; *** p < 0.001; NS = not significant.
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Figure 4.2 Non-inflammatory AqH reduces production of  selected 
chemokines by monocyte-derived dendritic cells. 
Monocyte-derived DC were cultured for 48h in the presence or absence of 
inflammatory cytokines (IL-1β, IL-6, TNFα and PGE2) with or without 50% 
AqH.  Supernatants were harvested after 48h and analysed by multiplex-bead 
immunoassay. Mean + SD  concentrations from triplicate cultures; 
representative of four separate experiments.
One-way ANOVA with Bonferroni multiple group comparison for differences in 
cytokines; * p < 0.05; ** p < 0.01; *** p < 0.001.
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Figure 4.3 Non-inflammatory AqH does not alter chemokine receptor 
expression and function in response to inflammatory cytokines
Monocyte-derived DC were cultured for 48h in the presence or absence of 
inflammatory cytokines (IL-1β, IL-6, TNFα and PGE2 to generate mature mDC 
vs immature iDC) with or without 50% AqH.  (A) MFI of chemokine receptor 
levels analysed by flow cytometry, (B) migration to CCL19 assessed in a 96-
well transmigration chapter and (C) correlation of CCR7 expression and ability 
to transmigrate to CCL19; representative of (A) four or (B) two separate 
experiments.  
One-way ANOVA  with Bonferroni post-hoc test for selected columns (A) and 
Pearson r with p value shown (B); NS = not significant.
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Figure 4.4 Non-inflammatory AqH inhibits the capacity of dendritic cells to 
induce proliferation of allogeneic naïve CD4+ T cells.
CFSE-labelled allogeneic naïve CD4+ T cells were cultured for 4 days with 
immature or mature monocyte-derived DC which had been pre-treated with 
medium or 50% AqH.  (A) CFSE  vs side scatter (SS) for live cells and (B) 
number of divided cells for mean + SD of triplicate cultures; representative of six 
separate experiments. (C) Relative proliferation induced by AqH treatment for 
iDC and mDC; mean + SEM of six experiments.
One-way ANOVA with Bonferroni multiple group comparison; * p < 0.05; ** p < 
0.01; *** p < 0.001
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Figure 4.5 Reduction in dendritic cell CD86 expression by non-inflammatory 
AqH  correlates with inhibition of their capacity to induce proliferation of 
allogeneic naïve CD4+ T cells. 
Monocyte-derived DC were cultured in the presence or absence of 50% non-
inflammatory AqH as described previously. CD86 expression (MFI) by DC vs 
number of divided T cells shown for immature DC and AqH treated immature DC; 
representative of six separate experiments. 
Pearson r = 0.860, p = 0.006. Normality of distribution demonstrated by 
Kolmogorov-Smirnov test. 
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r = 0.86
p = 0.0058
Figure 4.6 CD4+ naïve T cells stimulated by human AqH treated dendritic 
cells (DC) show generalised reduction in cytokine production correlating with 
reduced T cell proliferation and with no significant skewing of T cell 
phenotype. Multiplex-bead immunoassay of supernatants of DC:T cell co-
cultures harvested after 4d of culture showing (A) cytokine concentrations (mean 
+ SD of triplicate values) and (B) correlation of cytokine levels with T cell 
proliferation. Representative of four separate experiments. 
One-way ANOVA  with Bonferroni post-hoc test for selected columns shown 
(parametric distribution within groups); Spearman r for correlation (since non-
parametric when groups combined); * p < 0.05; ** p < 0.01; *** p < 0.001; NS = 
not significant.
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Figure 4.7  Non-inflammatory AqH treatment of myeloid dendritic cells 
causes downregulation of CD86 and reduced capacity to induce naïve CD4+ T 
cell proliferation under inflammatory conditions
Bead-purified myeloid dendritic cells were cultured in medium (iDC) or 
inflammatory cytokines (mDC) with or without the addition of non-inflammatory 
human AqH. Myeloid DC expression of CD86 with (A) representative flow 
cytometric histograms and (B) MFI, and (C) induction of naïve CD4+ T cell 
proliferation; Mean + SD for triplicate wells; representative of three separate 
experiments.
One-way ANOVA  with Bonferroni post-hoc test for selected columns shown;      
* p < 0.05; ** p < 0.01; *** p < 0.001; NS = not significant.
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Figure 4.8  Cortisol causes dose-dependent reduction in CD86 expression by 
dendritic cells, and contributes to CD86 inhibition by AqH
(A) Monocyte-derived DC were cultured in the presence of 10-9 – 10-6M  cortisol 
with or without the glucocorticoid receptor antagonist, RU486. Mean percentage 
inhibition of CD86  + SEM for three separate experiments shown. (B) DC were 
cultured in the presence or absence of 50% non-inflammatory AqH with or 
without RU486. Cortisol (10-7M) was used as a positive control. Mean percentage 
inhibition of CD86 (+ SD) for triplicate cultures; representative of three separate 
experiments shown. 
One-way ANOVA  with Bonferroni post-hoc test for selected concentrations/ 
columns shown; * p < 0.05; ** p < 0.01; *** p < 0.001; NS = not significant.
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Figure 4.9  TGFβ2 but not αMSH or VIP cause dose-dependent reduction in 
CD86 expression for immature and mature DC. 
(A) Monocyte-derived DC were cultured in the presence of (A) 0.1 – 100ng/ml 
TGFβ2 or (B) 0.1-100ng/ml αMSH or VIP.  Mean percentage inhibition of CD86 
+ SEM for three separate experiments shown. 
One-way ANOVA  with Bonferroni post-hoc test for selected concentrations 
shown; * p < 0.05; ** p < 0.01; *** p < 0.001; NS = not significant.
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Figure 4.10  Cortisol and TGFβ2 have additive inhibitory effects on dendritic 
cell expression of CD86. 
(A) Monocyte-derived DC were cultured in the presence of 10-9 – 10-6M  cortisol 
with or without the addition of 1 or 10 ng/ml TGFβ2. Mean percentage inhibition 
of CD86 + SD for triplicate cultures; representative of three separate experiments. 
One-way ANOVA  with Bonferroni post-hoc test comparing cortisol treatment 
with or without TGFβ2 at multiple cortisol concentrations; * p < 0.05; otherwise 
not significant. 
(B) Monocyte-derived DC were cultured in the presence or absence of cortisol 
(10-7M) and TGFβ2 (10 ng/ml) with or without the glucocorticoid inhibitor 
RU486 and/or the ALK kinase inhibitor SB431542 (which inhibits TGFβ
function). One-way ANOVA  with Bonferroni post-hoc test comparing the effects 
of RU486 and SB431542 with baseline inhibition by cortisol and TGFβ2; * p < 
0.05; otherwise not significant.
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Figure 4.11  Cortisol and TGFβ2 jointly contribute to CD86 inhibition by 
non-inflammatory AqH
Monocyte-derived DC were cultured in the presence or absence of 50% non-
inflammatory AqH with or without the glucocorticoid inhibitor RU486 and the 
ALK kinase inhibitor SB431542. Cortisol (10-7M) and TGFβ2 (10ng/ml) were 
used as a positive control. (A) Mean percentage inhibition of CD86 + SD and (B)  
mean percentage inhibition of induction of proliferation of allogeneic naïve CD4+ 
T cells + SD for triplicate cultures; representative of three separate experiments. 
One-way ANOVA  with Bonferroni post-hoc test for selected columns shown;      
* p < 0.05; ** p < 0.01; *** p < 0.001; NS = not significant.
B
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CHAPTER 5 
Dendritic cell function in uveitis: 
sustained suppression of dendritic cell 
function despite IFNγ mediated 
upregulation of MHC
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Figure 5.1 BDCA1+ myeloid DC and CD14+ monocyte/macrophages can be 
identified in human aqueous humour during uveitis
Myeloid DC were identified in the peripheral blood and aqueous humour of 
patients with active anterior uveitis. Gating strategy  demonstrating identification 
of CD14+ monocyte/macrophage vs BDCA1+ myeloid DC (CD14-/low 
predominant subset).
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Figure 5.2 Myeloid DC can be identified in AqH during acute anterior uveitis 
and have a distinct MHChi CD86lo phenotype
Myeloid DC were identified in the peripheral blood and aqueous humour of 
patients with active anterior uveitis (A) Representative histograms and (B) MFI of 
MHC and CD86 from matched PBMC and AqH of six or more patients.
Wilcoxon matched pairs analysis; * p < 0.05; ** p < 0.01; *** p < 0.001; NS = not 
significant
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Figure 5.3 CD14+ monocyte/macrophages identified in AqH are MHChi, but 
levels of CD86 are not affected
CD14+ monocyte/macrophages were identified in the peripheral blood and 
aqueous humour of patients with active anterior uveitis (A) Representative 
histograms and (B) MFI of MHC and CD86 from matched PBMC and AqH of ten 
or more patients; 
Wilcoxon matched pairs analysis;* p < 0.05; ** p < 0.01; *** p < 0.001; NS = not 
significant
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Figure 5.4 Treatment of naïve monocyte-derived DC with uveitis AqH 
supernatant in vitro induces a similar MHCIhi CD86lo profile to that seen in 
UvAqH myeloid DC. 
Monocyte-derived DC were cultured for 48h in the presence or absence of 50%  
uveitic or non-inflammatory AqH. (A) Representative histograms and (B) MFI of 
MHC and CD86 for nine uveitis AqH and six non-inflammatory AqH; 
representative of three separate experiments; for medium alone the mean + SD of 
MFI for  triplicate cultures are given; mild = 1+/2+, severe 3+/4+ cells in the 
anterior chamber (see text). 
Kruskal-Wallis with Dunn’s post-hoc test for multiple comparisons; * p < 0.05; ** 
p < 0.01; *** p < 0.001; NS = not significant
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Figure 5.5 Treatment of naïve monocyte-derived DC with uveitis AqH 
supernatant in vitro induces upregulation of CCR5 and no significant change 
in CCR7 expression.
Monocyte-derived DC were cultured for 48h in the presence or absence of 50%  
uveitic or non-inflammatory AqH. (MFI for CCR5 and CCR7 for representative of 
three separate experiments; for medium alone the mean + SD of MFI for  
triplicate cultures are given; mild = 1+/2+, severe 3+/4+ cells in the anterior 
chamber (see text). 
Kruskal-Wallis with Dunn’s post-hoc test for selected columns shown; * p < 0.05; 
** p < 0.01; *** p < 0.001; NS = not significant
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Figure 5.6 Increasing IFNγ levels in AqH during uveitis promote upregulation 
of MHC correlating with disease severity, but is insufficient to overcome 
AqH-induced regulation of HLADR or CD86 
Monocyte-derived DC were cultured in the presence or absence of (A) 0.1-
100ngml-1 IFNγ or (B) 50% uveitis AqH  (UvAqH) with or without an IFNγ 
blocking antibody. (A) and (B) are each representative of three separate 
experiments;  mean + SD of MFI for  triplicate cultures are given except for 
individual AqH samples. 
Wilcoxon matched pairs analysis; * p < 0.05; NS = not significant.
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Figure 5.7 Cortisol levels are elevated in uveitis AqH vs non-inflammatory 
AqH
Cortisol levels in non-inflammatory  (CAqH) and uveitic AqH  (untreated; 
UvAqH) were measured by super-sensitive ELISA. (A) Standard curve (B) 
Cortisol levels in non-inflammatory AqH vs uveitis AqH and (C) Cortisol levels 
according to cellular activity of AqH sample.  
Mann-Whitney U test (B)  and Linear trend test  for all four columns (C); ** p < 
0.01
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Figure 5.8 In uveitis, AqH induced downregulation of CD86 expression on DC 
is no longer dependent on endogenous glucocorticoids. 
Monocyte-derived DC were cultured in the presence or absence of 50%  non-
inflammatory (CAqH) or uveitis AqH (UvAqH) with or without the glucocorticoid 
blocker, RU486; cortisol or dexamethasone (Dex) were used as positive controls. 
Mean + SD of MFI for  triplicate cultures are given except for individual AqH 
samples. Wilcoxon matched pairs analysis; * p < 0.05; NS = not significant.
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Figure 5.9 Uveitis AqH inhibits DC capacity to induce T cell proliferation for 
CD4+ and CD8 + T cells
CFSE-labelled allogeneic naïve CD4+ T cells were cultured for 4 days with 
monocyte-derived DC which had been pre-treated with medium or 50% AqH 
(non-inflammatory (CAqH) or uveitic (UvAqH)).  (A) CFSE  vs side scatter (SS) 
for live cells and (B) number of divided cells;  representative of three separate 
experiments with the mean + SD of triplicate cultures for medium alone. 
One-way ANOVA with Bonferroni post-hoc test for for multiple comparisons 
(normality of data demonstrated by Kolmogorov-Smirnov test); * p < 0.05; ** p < 
0.01; *** p< 0.001; NS = not significant
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Figure 5.10 Uveitis AqH inhibition of DC capacity to induce T cell 
proliferation for naïve CD4+ T cells  correlates with downregulation of CD86 
CFSE-labelled allogeneic naïve CD4+ T cells were cultured with pre-treated 
monocyte-derived DC as described previously.  Proliferation (number of divided 
cells) vs CD86 expression; representative of three separate experiments. 
Pearson r = 0.670, p = 0.006 for uveitis AqH-treated DC. Control AqH-treated DC 
shown for comparison (r = 0.860, p = 0.006; see also Figure 4.5). Normality of 
distribution demonstrated by Kolmogorov-Smirnov test. 
Uveitis AqH  
r = 0.670
p = 0.006
Control AqH
Uveitis AqH
Medium
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Figure 5.11 Uveitis AqH  is suppressive for DC function  regardless of 
glucocorticoid treatment and without skewing T cell phenotype, but 
treatment does cause additional suppression of IL-10 production
CFSE-labelled allogeneic naïve CD4+ T cells were cultured with pre-treated 
monocyte-derived DC as described previously. Supernatants were harvested after 
4d and analysed by multiplex-bead immunoassay.  (A) Proliferation (number of 
divided cells) or (B) cytokine concentration  or (C) correlation of proliferation vs 
cytokine concentration shown; representative of three separate experiments with 
the mean + SD of triplicate cultures for medium alone. 
Kruskal-Wallis with Dunn’s post-hoc test for multiple comparisons (B); * p < 
0.05; all other differences non-significant. Spearman r for correlation (C).
Chapter Five Results 189
A B C
*P
e
rc
e
n
ta
g
e
 p
ro
li
fe
ra
ti
o
n
 (
%
)
A
Figure 5.12 In uveitis, AqH inhibition of DC function loses cortisol 
dependency which is restored in the presence of therapeutic glucocorticoids, 
but is not related to the intensity of therapy.
CFSE-labelled allogeneic naïve CD4+ T cells were cultured for 4 days with 
monocyte-derived DC which had been pre-treated with medium or 50% AqH 
(non-inflammatory or uveitic)  with or without the glucocorticoid blocker, RU486; 
cortisol or dexamethasone (Dex) were used as positive controls. (A) Mean + SD 
of MFI for  triplicate cultures are given except for individual AqH samples. (B) 
Reversal of inhibition by RU486 versus intensity of glucocorticoid therapy. (A) 
and (B) are representative of two separate experiments
Wilcoxon matched pairs analysis (A) and Kruskal-Wallis with Dunn’s post-hoc 
test for multiple comparisons(B); * p < 0.05; NS = not significant.
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